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ABSTRACT 
 
Obesity is closely linked to the development of nonalcoholic fatty liver disease 
(NAFLD). The prevalence of obesity is increasing in the United States, and the most 
recent 2017-2018 National Health and Nutrition Examination Survey recorded 42.4% of 
adults are obese. Cytochrome P450s (CYPs) play a primary role in phase I detoxification 
pathways, which in humans, includes over 90% of phase I-dependent metabolism of 
clinically used drugs, especially within CYP families 1-3. These enzymes also metabolize 
a vast number of environmental pollutants including industrial and agricultural 
chemicals, as well as endogenous compounds such as steroids, bile acids, and fatty acids. 
Hepatic CYP activity has been associated with fatty liver and the main regulator of 
CYP2B, the constitutive androstane receptor (CAR), has been identified as an anti-
obesity transcription factor as its activation improved hepatic glucose and fatty acid 
metabolism in leptin-deficient mice. Thus, indicating a role for CAR in recognizing and 
Cyp2b in metabolizing hepatic lipids. Initial studies determined male Cyp2b-null mice 
are diet-induced obese with increased liver triglycerides. Cyp2b-null male mice fed a 
normal diet also showed hepatic gene expression and phospholipid profiles similar to 
wild-type mice fed a high fat diet (HFD), indicating progression to NAFLD even in the 
absence of a high-fat diet. Based on these results, we hypothesized that Cyp2bs are 
crucial in the hepatic metabolism and elimination of unsaturated fatty acids and continued 
to study the role of Cyp2b in the progression to nonalcoholic steatohepatitis (NASH) 
using our Cyp2b-null mouse model. Unexpectedly, the lack of Cyp2b in female mice was 
moderately protective from diet-induced NASH, while male Cyp2b-null mice were more 
 iii 
susceptible to NAFLD, with few significant changes in NASH development. Therefore, 
murine Cyp2b enzymes are anti-obesogenic in males; however, there are some important 
interspecies differences between mouse and human CYPs. Therefore, PUFA metabolites 
of human CYP2B6 were identified from CYP2B6 containing baculosomes by LC-
MS/MS. Results indicate human CYP2B6 primarily metabolizes PUFAs in the 9- and 13- 
positions with a preference for -linolenic acid in vitro. To increase relevance to 
humans, we produced a humanized CYP2B6 transgenic mouse and tested whether 
CYP2B6 could reverse diet-induced obesity when compared to Cyp2b-null mice. 
CYP2B6 partially reverses diet-induced obesity observed in Cyp2b-null mice, but with 
unexpected sexually dimorphic effects on obesity in females and fatty liver disease in 
males. Metabolic disease was also associated with oxylipin profiles and gene expression. 
Surprisingly, linoleic acid and arachidonic acid – based oxylipins were primarily altered 
in vivo; probably due to higher concentrations of these PUFAs in the mouse diet. 
Differential gene expression revealed changes in gene ontology terms associated with 
circadian rhythm, protein processing and lipid metabolism in humanized CYP2B6 
transgenic mice. In conclusion, the changes in expression or inhibition of CYP2B6 may 
perturb lipid homeostasis, utilization, and metabolism and lead to adverse outcomes, 
primarily in males. 
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CHAPTER ONE 
 
INTRODUCTION 
 
 
 The purpose of this study was to investigate the potential for chemical inhibition 
of the detoxification enzyme cytochrome P450 2B (CYP2B), and the subsequent effects 
on fatty acid metabolism, obesity, and nonalcoholic fatty liver disease. Previous research 
found hepatic cytochrome P450 oxidoreductase-null mice, lacking all hepatic CYP 
activity, develop fatty liver disease with increased amounts of polyunsaturated fatty acids 
(PUFAs) in the liver, and induction of Cyp2b10 via activation of the constitutive 
androstane receptor (CAR) (Finn, Henderson, Scott, & Wolf, 2009). In addition, an 
RNAi-mediated Cyp2b-knockdown mouse model previously generated in our lab to 
study the function of Cyp2b in vivo (B. Damiri, Holle, Yu, & Baldwin, 2012), found male 
Cyp2b-knockdown mice showed increased weight and adiposity with age, and had 
difficulty clearing lipids in their liver (Basma Damiri & Baldwin, 2018). In order to 
provide a more stable drop in hepatic Cyp2b levels in the mouse, a Cyp2b9/10/13-null 
(Cyp2b-null) mouse model was also produced in our lab by eliminating a cluster of 
Cyp2b genes on chromosome 7 using Crispr/Cas9. This model was used to further 
investigate the role of Cyp2b in hepatic lipid metabolism. Initial studies determined male 
Cyp2b-null mice are diet-induced obese and develop weak nonalcoholic fatty liver 
disease (NAFLD) (Data by R. Kumar; (Heintz, Kumar, Rutledge, & Baldwin, 2019). 
Based on these results, we hypothesized that Cyp2bs are crucial in the hepatic 
metabolism and elimination of unsaturated fatty acids and continued to study the role of 
Cyp2b in the progression to nonalcoholic steatohepatitis (NASH). Lastly, CYP2B6 
2 
containing baculosomes and a newly generated humanized-CYP2B6-Tg mouse model 
were used to determine the metabolic role of human CYP2B6 in vitro and in vivo, 
respectively.  
 
1.1. Obesity and progression to nonalcoholic fatty liver disease (NAFLD) 
Obesity is a chronic disease, defined as an abnormal or excessive accumulation of 
fat that may impair health (Bray & Ryan, 2000). The prevalence of obesity in adults aged 
20 and over is increasing in the United States, from 30.5% in 1999-2000 to 42.4% in the 
most recent 2017-2018 National Health and Nutrition Examination Survey (Hales, 
Carroll, Fryar, & Ogden, 2020). Obesity occurs when energy intake exceeds energy 
expenditure over an extended time, and is confounded by lifestyle changes (Church & 
Martin, 2018), food environment (Hall, 2018), genetics (Levian, Ruiz, & Yang, 2014), 
and environmental and behavioral factors (Keith et al., 2006). Some of these 
environmental factors include exposure to environmental toxicants that perturb metabolic 
homeostasis leading to obesity (Hoffman, Petriello, & Hennig, 2017). Individuals with 
obesity often further develop diseases such as hypertension, type II diabetes, 
cardiovascular diseases, and certain types of cancer (Must et al., 1999). 
NAFLD is closely linked to obesity (Pallayova & Taheri, 2014) and is the result 
of the hepatic manifestation of the metabolic syndrome (Marchesini et al., 2001). 
Abdominal obesity, hyperglycemia, insulin resistance, hypertension and atherogenic 
dyslipidemia make up the cluster of risk factors that form metabolic syndrome 
(Gallagher, LeRoith, & Karnieli, 2008). The hepatic intracellular accumulation of lipids 
3 
in fatty liver disease can develop into NASH as inflammation, injury and fibrosis 
progresses (Singh et al., 2015).  
Nuclear receptors are master regulators of metabolic homeostasis, that activate or 
inhibit key metabolic processes and transcription factors in response to dietary intake or 
environmental stressors. Several nuclear receptors are implicated in obesity or NAFLD. 
These receptors often work by forming heterodimers with the retinoid X receptor (RXR) 
before binding to promoter regions of target genes (Swanson et al., 2013). The hepatic 
lipid regulator, peroxisome proliferator-activated receptor alpha (PPARα), is protective 
from fatty liver and NASH, as PPARα-null mice fed a high fat diet (HFD) developed 
oxidative stress, steatosis and inflammation (Abdelmegeed et al., 2011). Additionally, the 
hepatoprotective effects of bile acids are farnesoid X receptor (FXR)-dependent (Kunne 
et al., 2014), and as FXR activity decreases with age, fatty liver increases in mice (Xiong 
et al., 2014). The xenobiotic receptors, pregnane X receptor (PXR) and constitutive 
androstane receptor (CAR) also have endobiotic roles in glucose and lipid metabolism 
and the development of metabolic diseases (Gao & Xie, 2010); however, their functions 
oppose one another, as PXR causes obesity (Spruiell et al., 2014) while CAR is 
protective from obesity (Dong et al., 2009).  
 Furthermore, the Organization for Economic Cooperative Development (OECD) 
identified obesity and diabetes as one of three areas of toxicological concern in addition 
to autism spectral disorders and testicular dysgenesis (LeBlanc et al., 2012). Xenobiotic 
activation of the neonatal estrogen receptor, PPARγ:RXR receptor complex, and 
glucocorticoid receptor all stimulate weight gain (via adipocyte differentiation) and 
4 
associated metabolic conditions (Dallman et al., 2004; Grun & Blumberg, 2006; 
Newbold, Padilla-Banks, & Jefferson, 2009). Chemicals established as “obesogens” bind 
and activate these receptors, perturbing lipid homeostasis and causing obesity (Grun et 
al., 2006). 
 
1.2. Polyunsaturated fatty acid (PUFA) metabolism 
During inflammation, PUFAs found in hepatic membrane phospholipids are 
cleaved by phospholipase A2 (Quach, Arnold, & Cummings, 2014). These available 
PUFAs are then oxidized by cyclooxygenase (COX), lipoxygenase (LOX), or 
cytochrome P450 (CYP) pathways to form physiologically significant metabolites. The 
COX pathway primarily leads to the formation of pain and inflammation mediators, such 
as prostanoids and resolvins. Consequently, the COX pathway is a therapeutic target of 
several anti-inflammatory drugs. The LOX pathway produces proinflammatory 
leukotrienes and hydroxyl fatty acids which have an important role in inflammatory 
diseases such as asthma (Funk, 2001; Wiktorowska-Owczarek, Berezinska, & Nowak, 
2015). Individual CYP enzymes differ in their PUFA substrate specificities in addition to 
positional- and stereo-selectivity. The CYP4A and CYP4F subfamilies mainly function 
as PUFA hydroxylases (Fer et al., 2008), while CYP2C and CYP2J are well studied 
PUFA epoxygenases (Zhang, Kodani, & Hammock, 2014). Additionally, CYPs including 
CYP1A, CYP1B, CYP2B, CYP2C, CYP2D, CYP2J, CYP3A, CYP4A, and CYP4F have 
all demonstrated PUFA metabolism (Hankinson, 2016; Palacharla et al., 2017; Zeldin, 
2001; Zhang et al., 2014). CYP lipid metabolites are important mediators of 
5 
inflammation and metabolic disease, as fatty acid epoxide metabolites have anti-
inflammatory, cardioprotective, and vasodilative effects (Zeldin, 2001; Zhang et al., 
2014). Conversely, the bioactivity of lipid metabolites produced via CYP hydroxylation 
are not as well known, with the exception of arachidonic acid metabolite 20-
hydroxyeicosatetraenoic acid (HETE), which is synthesized by the CYP4 family and 
plays an important role in vascular inflammation and injury (Hoopes, Garcia, Edin, 
Schwartzman, & Zeldin, 2015).   
 
1.3. Cytochrome P450s (CYPs) 
In addition to PUFAs such as arachidonic acid (Zhang et al., 2014) and linoleic 
acid (Finn et al., 2009), CYPs also metabolize other endobiotics including steroids and 
bile acids (Finn et al., 2009; Nebert & Russell, 2002; Wang & Tompkins, 2008). CYPs 
play a primary role in phase I detoxification pathways, which in humans, includes over 
90% of phase I-dependent metabolism of clinically used drugs (Purnapatre, Khattar, & 
Saini, 2008), especially CYP families 1-3 (Hernandez, Mota, & Baldwin, 2009). These 
enzymes also metabolize a vast number of environmental xenobiotics including industrial 
and agricultural chemicals (Hernandez, Mota, & Baldwin, 2009). There are 57 CYP 
genes in humans, organized into 18 families and 42 subfamilies (Nelson & Nebert, 2011), 
and 102 murine CYP genes, with 18 families and 43 subfamilies (Nelson et al., 2004). 
CYP expression is regulated by nuclear receptors including CAR, pregnane X receptor 
(PXR), aryl hydrocarbon receptor (AhR), and peroxisome proliferator activated receptor-
alpha (PPARα). Examples of important CYPs and their respective receptors are as 
6 
follows: Ahr predominantly regulates the CYP1A subfamily (Qiang, 2001), CAR and 
PXR regulate both CYP2B and CYP3A, with CAR primarily inducing CYP2B and PXR 
inducing CYP3A (Hernandez, Mota, & Baldwin, 2009), and PPARα regulates CYP4A 
(Cheng & Klaassen, 2008; Kroetz, Yook, Costet, Bianchi, & Pineau, 1998). Other CYP 
subfamilies not listed such as CYP1B, CYP2A, and CYP2C are also regulated by these 
receptors (Chen et al., 2012; Hernandez, Mota, & Baldwin, 2009; Wortham, Czerwinski, 
He, Parkinson, & Wan, 2007).  
 
1.4. Constitutive androstane receptor (CAR) 
CAR is a member of the “adopted” orphan nuclear receptor subfamily, as it shares 
many of the structural features found in the nuclear receptor family but is activated by 
numerous xeno- and endobiotic chemicals (Chang & Waxman, 2006; Evans, 2005; 
Kretschmer & Baldwin, 2005). This nuclear receptor regulates phase I-III enzymes and 
transporters that are imperative for detoxification and elimination of environmental 
toxicants, steroids, and bile acids. Detoxification genes induced by CAR include phase I 
detoxification CYPs (e.g. CYP2B and CYP3A) (P. Wei, Zhang, Egan-Hafley, Liang, & 
Moore, 2000), phase II sulfotransferases (Saini et al., 2004) and uridine diphospho-
glucuronosyltransferases (Sugatani et al., 2001), and phase III transporters such as 
multidrug resistance proteins (Assem et al., 2004) and multidrug resistance associated 
proteins (Kast et al., 2002). Direct ligand binding to CAR, such as by 1,4-bis[2-(3,5-
dichloropyridyloxy)]benzene (TCPOBOP) in the cytoplasm causes cytoplasmic retention 
proteins including heat shock protein 90 (hsp90) and cytoplasmic CAR retention protein 
7 
(CCRP) to release (Kobayashi, Sueyoshi, Inoue, Moore, & Negishi, 2003; Yoshinari, 
Kobayashi, Moore, Kawamoto, & Negishi, 2003), allowing for subsequent translocation 
of CAR to the nucleus and heterodimerization with RXR. This complex then binds to 
direct repeats-4 (DR-4) and inverted repeats-6 (IR-6) in the phenobarbital response 
element module (PBREM) of the CYP2B promoter, and recruits histone acetylases and 
co-activators to activate transcription and induce target genes (Sueyoshi & Negishi, 
2001). Phenobarbital and other chemicals can also indirectly activate CAR through 
formation of reactive oxygen species or other stressors that cause a phosphorylation 
cascade resulting in a conformational change and translocation of CAR into the nucleus 
(Blattler, Rencurel, Kaufmann, & Meyer, 2007; Shindo, Numazawa, & Yoshida, 2007). 
Recent studies investigating the regulation of CYPs by CAR indicate that CAR is 
involved in regulating the metabolism of fats. Dong et al. (Dong et al., 2009) found that 
the activation of CAR by TCPOBOP in leptin-deficient (ob/ob) mice improved glucose 
metabolism, suppressed lipogenesis and induced β-oxidation, whereas these antidiabetic 
effects were lost in double mutant ob/ob CAR-/- mice. Additional studies have also 
shown the role of CAR in recognizing endogenous compounds and stressors as seen by 
CAR’s involvement with fatty acid metabolism (Finn et al., 2009), caloric restriction 
(Maglich et al., 2004), obesity (Maglich, Lobe, & Moore, 2009), and bile acid 
homeostasis (Saini et al., 2004). Finn et al (Finn et al., 2009) demonstrated that a loss of 
hepatic CYP activity in the hepatic P450 oxidoreductase (POR)-null mouse model led to 
hepatic steatosis and the induction of Cyp2b primarily through the activation of CAR, 
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thus indicating a major role for CAR in recognizing hepatic lipids and Cyp2b in 
metabolizing lipids.  
 
1.5. CYP2B 
In the liver, CAR regulates both human and murine CYP2B genes (Finn et al., 
2009; Hernandez, Mota, & Baldwin, 2009; Hoek-van den Hil et al., 2014). Cyp2b9, 
Cyp2b10, and Cyp2b13 make up the hepatic Cyp2b genes in mice, and CYP2B6 is the 
main hepatic CYP2B isoform in humans. While all three murine hepatic Cyp2b members 
are constitutively regulated by CAR (Kumar et al., 2017; Mota, Hernandez, & Baldwin, 
2010), Cyp2b10 is the member that is highly induced by exposure to xenobiotic 
chemicals (Cheng & Klaassen, 2008; Hernandez, Mota, Huang, Moore, & Baldwin, 
2009). Previously, the CYP2B subfamily was thought to have a negligible role in drug 
metabolism, but due to more sensitive and specific detection methods, the number of 
endobiotic and xenobiotic substrates of CYP2B6 is increasing; in addition to the 
interindividual variability in expression of CYP2B6 (Wang & Tompkins, 2008). CYP2B6 
is primarily expressed in the liver and constitutes 2-10% of the total hepatic CYP content 
(Wang & Tompkins, 2008). This enzyme has many substrates, including over 60 clinical 
drugs such as artemisinin, propofol, ketamine, ifosfamide, nevirapine, efavirenz, 
mephobarbital, bupropion, and tamoxifen (Mo et al., 2009). Many important 
environmental toxicants are also metabolized by CYP2B6 including chlorpyrifos (Tang et 
al., 2001), carbaryl (Hodgson & Rose, 2007), parathion (Foxenberg, McGarrigle, Knaak, 
Kostyniak, & Olson, 2007), triclosan (Wu et al., 2017), perfluorocarboxylic acids (Abe et 
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al., 2017), as well as insect repellant N,N-diethyl-m-toluamide (DEET) (Hodgson & 
Rose, 2007). Additionally, endogenous compounds such as estrone, testosterone, 
arachidonic acid, and lauric acid are also metabolized by this enzyme (Mo et al., 2009).  
Unlike the centrilobular distribution of other major hepatic CYPs such as 
CYP3A4 and CYP2E1, CYP2B6 is widely expressed throughout hepatic lobules across 
zone 1 and 3 in parenchymal cells (Murray et al., 1990). CYP2B6 is also expressed in 
several extrahepatic tissues including the kidney, brain, intestine, endometrium, 
bronchoalveolar macrophages, peripheral blood lymphocytes and skin (Ding & 
Kaminsky, 2003). As mentioned earlier, CYP2B6 expression is closely regulated and 
activated by CAR upon ligand binding (P. Wei et al., 2000). In addition, this enzyme can 
be regulated directly by PXR (Goodwin, Moore, Stoltz, McKee, & Kliewer, 2001) and 
indirectly by the glucocorticoid receptor (Dvorak et al., 2003). 
The hepatic murine Cyp2b members, Cyp2b9 and Cyp2b13 are highly sexually 
dimorphic (Hernandez, Mota, Huang, et al., 2009; Renaud, Cui, Khan, & Klaassen, 2011; 
Wiwi, Gupte, & Waxman, 2004), and CAR regulation of several genes including 
Cyp2b10 is also sexually dimorphic (Ledda-Columbano et al., 2003). Signal transducer 
and activator of transcription 5b (Stat5b) mediates growth hormone (GH)-dependent 
sexually dimorphic gene expression in the male liver (Clodfelter et al., 2006). The male 
GH secretion profile suppresses the GH-STAT5b pathway (Holloway et al., 2007; 
Sakuma et al., 2004); however in females, through the regulation of HNF4α, CAR, and 
FoxA2, this pathway is responsible for the female predominant expression of Cyp2b 
(Hashita et al., 2008; Hernandez, Mota, Huang, et al., 2009; Wiwi et al., 2004). These 
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gender differences are also seen in human CYP2B6, as it is also predominantly expressed 
in females although to a much lesser extent (Lamba et al., 2003). 
Several studies implicate Cyp2b’s role in hepatic fatty acid metabolism. Foxa2 is 
activated by fasting and fatty acids, and induces transcription of β-oxidation, ketogenesis, 
and glycolysis genes in mice, including Cyp2b9 (Hashita et al., 2008; Wolfrum, Asilmaz, 
Luca, Friedman, & Stoffel, 2004). Additionally, Cyp2b is induced via CAR activation 
due to increased hepatic fatty acids in POR-null mice (Finn et al., 2009). Furthermore, 
two recent studies demonstrate that Cyp2b9 exhibited the highest increased expression 
following a HFD in mice (Hoek-van den Hil et al., 2015; Leung, Trac, Du, Natarajan, & 
Schones, 2016). Previous research in our lab using RNAi-mediated Cyp2b-knockdown 
mice found older males had increased weight, adiposity, and difficulty eliminating 
PUFA-rich corn oil (Basma Damiri & Baldwin, 2018). This research suggests mice 
lacking hepatic Cyp2b members are highly susceptible to obesity and accumulate lipids 
in their liver. 
 
1.6. Mouse models 
House mice, Mus musculus, have long served as models of human biology and 
disease due to their genetic and physiological similarities to humans (Morse, 2007). As a 
model organism, the mouse genome is very similar to the human genome (99%), and the 
animal’s small size and relatively short lifecycle makes it a cost-efficient model. 
C57Bl/6J mice are the most extensively used inbred strain, as a result, their genetic 
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similarities and differences to humans are well-studied and are employed in a wide 
variety of biomedical research areas, including diabetes and obesity (Bryant, 2011).  
To investigate the role of Cyp2b in diet-induced obesity and NASH, our lab 
developed a novel triple knockout mouse model lacking the hepatic Cyp2b members, 
Cyp2b9, Cyp2b10 and Cyp2b13 using CRISPR/Cas9 technology on C57Bl/6J 
background (Kumar et al., 2017). These three Cyp2b genes are found in a cluster on 
murine chromosome seven. Three short guide RNAs (sgRNA) were co-injected to 
mediate out of frame modifications within each gene, ultimately producing a large 287 kb 
deletion between the sgRNA Cyp2b10 and Cyp2b9 target sites. Five genes apart from 
this Cyp2b cluster are Cyp2b19 and Cyp2b23 which are still retained in this mouse 
model. Cyp2b19 is expressed in fetal mouse keratinocytes (Keeney et al., 1998), while 
Cyp2b23 is only expressed in adolescent mice (from birth until 20 days old) (Peng et al., 
2012); therefore, neither of these Cyp2b genes make a significant contribution to hepatic 
Cyp2b expression. 
In order to study the role of human CYP2B6 in diet-induced obesity and PUFA 
metabolism in vivo, our lab also generated a humanized-CYP2B6-transgenic (Tg) mouse 
model. CYP2A13/CYP2B6/CYP2F1-Tg mice from Dr. Xinxin Ding’s laboratory 
containing a bacterial artificial chromosome (BAC) of 210 kb from human chr19 (Y. Wei 
et al., 2012) were bred to Cyp2b-null mice from our laboratory (Kumar et al., 2017) to 
produce humanized-CYP2B6-Tg (hCYP2B6-Tg) mice lacking the hepatic murine Cyp2b 
members. These mice also express CYP2A13, which is primarily expressed in the nasal 
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mucosa and lung and CYP2F1, which is primarily expressed in the lung (Y. Wei et al., 
2012). 
 
1.7. Specific aims 
CYP2B6 makes up 2-10% of the total hepatic CYP content (Wang & Tompkins, 
2008) and metabolizes both xeno- and endobiotic compounds including clinical drugs 
(Zanger & Klein, 2013), environmental toxicants (Hernandez, Mota, & Baldwin, 2009; 
Hodgson & Rose, 2007), fatty acids (Palacharla et al., 2017), steroids, and bile acids (Mo 
et al., 2009). In vitro data indicates that PUFAs such as arachidonic acid and linoleic acid 
are metabolized by Cyp2b (Finn et al., 2009; Mo et al., 2009; Palacharla et al., 2017). In 
addition, our lab previously determined that mice lacking hepatic Cyp2b members are 
highly susceptible to obesity and accumulate lipids in their liver (Basma Damiri & 
Baldwin, 2018). We hypothesize that Cyp2bs play an important role in hepatic 
metabolism and the elimination of unsaturated fatty acids. We will continue to study the 
role of Cyp2b in fatty acid metabolism and in the development of NAFLD and the 
progression to NASH using our previously developed Cyp2b-null mouse model (Kumar 
et al., 2017). A humanized-CYP2B6-transgenic mouse model will also be produced to 
determine the role of human CYP2B6 in obesity and the metabolism of fatty acids in 
vivo. 
 
Aim 1: Identify differentially expressed genes involved in energy and fatty acid 
metabolism in high fat diet (HFD)-fed Cyp2b-null mice compared to WT mice.  
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Aim 1a: RNA sequencing (RNAseq) will be used to detect changes in global hepatic gene 
expression and to test whether Cyp2b-null mice fed either a normal diet (ND) or 
high-fat diet (HFD) have perturbed regulation of genes involved in fatty acid 
metabolism, gluconeogenesis, lipogenesis, insulin signaling, and inflammation. 
 
Aim 2: Test whether a lack of Cyp2b worsens or remediates the pathological effects 
of non-alcoholic steatohepatitis (NASH).  
Aim 2a: Cyp2b-null and WT mice will be fed a ND or choline-deficient, L-amino acid 
defined, high fat diet (CDAHFD) for 8 weeks. Mouse weight, tissue weights, lipid 
serum panel, fasting serum glucose, glucose tolerance, and pathological staining 
for steatosis and fibrosis will be measured for each treatment.  
 
Aim 2b: RNAseq will be used to determine changes in genes involved in regulating fatty 
acid metabolism, inflammation, and liver fibrosis development in Cyp2b-null 
mice compared to WT mice. Differentially expressed genes identified by RNAseq 
will be confirmed by qPCR. 
 
Aim 2c: Changes in serum and liver biomarkers of fatty liver, fibrosis, inflammation, and 
stress will also be measured for each treatment group.  
 
Aim 3: Determine changes in the hepatic phospholipid profile of healthy, obese, and 
old Cyp2b-null male mice. 
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Aim 3a: Phospholipid species will be identified and quantified from the livers of male 
Cyp2b-null and WT young (4.5 mo) ND and HFD-fed mice and old (9 mo) mice 
by LC-MS/MS. Changes in lipid species content will be compared between 
genotypes within and across treatment groups. 
 
Aim 3b: Changes in serum and liver lipids and biomarkers will be determined between 
healthy, diet-induced obese, and old Cyp2b-null and WT mice. Correlations 
between treatment groups, Cyp2b-null mice, adverse physiological effects, serum 
lipids, and lipid profiles will be assessed by Principal Component Analysis 
(PCA).  
 
Aim 4: Investigate the role of human CYP2B6 in PUFA metabolism in vitro and in 
vivo.  
Aim 4a: Endogenous inhibitors of CYP2B6 will be determined using CYP2B6 containing 
baculosomes.  
 
Aim 4b: Metabolites of PUFAs produced by CYP2B6 will be identified and quantified 
following incubation with control and CYP2B6 containing baculosomes using 
LC-MS/MS.  
 
Aim 4c: A humanized-CYP2B6-transgenic (hCYP2B6-Tg) mouse model will be created 
by crossing the C57Bl/6J background, Cyp2b-null mouse model with a human 
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CYP2A13/2B6/2F1-Tg mouse model. The purpose of the humanized model is to 
reduce uncertainty when estimating effects in humans.  
 
Aim 4d: Cyp2b-null and hCYP2B6-Tg female and male mice will be fed a high-fat diet 
for 16 weeks. Mouse weight, tissue weights, lipid serum panel, fasting serum 
glucose, glucose tolerance, and pathological staining for steatosis will be 
measured for each treatment group. 
 
Aim 4e: Serum and liver PUFA metabolites will be identified and quantified by LC-
MS/MS from HFD-fed Cyp2b-null and hCYP2B6-Tg mice. 
 
Aim 4f: RNAseq will be used to determine changes in global hepatic gene expression in 
mice with human CYP2B6 compared to mice lacking all hepatic Cyp2b members 
under HFD conditions and to test whether genes involved in fatty acid 
metabolism, lipogenesis, and insulin signaling are differentially expressed in 
hCYP2B6-Tg mice.  
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2.0 Abstract 
Obesity is an endemic problem in the United States and elsewhere, and data indicate 
that in addition to overconsumption, exposure to specific chemicals enhances obesity. 
CYP2B metabolizes multiple endo- and xenobiotics, and recent data suggests that 
repression of Cyp2b activity increases dyslipidemia and age-onset obesity, especially in 
males. To investigate the role played by Cyp2b in lipid homeostasis and obesity, we 
treated wildtype and Cyp2b-null mice with a normal (ND) or 60% high-fat diet (HFD) for 
10 weeks and determined metabolic and molecular changes. Male HFD-fed Cyp2b-null 
mice weigh 15% more than HFD-fed wildtype mice, primarily due to an increase in white 
adipose tissue (WAT); however, Cyp2b-null female mice did not demonstrate greater 
body mass or WAT. Serum parameters indicate increased ketosis, leptin and cholesterol 
in HFD-fed Cyp2b-null male mice compared to HFD-fed wildtype mice. Liver 
triglycerides and liver:serum triglyceride ratios were higher than their similarly treated 
wildtype counterparts in Cyp2b-null male mice, indicating a role for Cyp2b in fatty acid 
metabolism regardless of diet. Furthermore, RNAseq demonstrates that hepatic gene 
expression in ND-fed Cyp2b-null male mice is similar to HFD-fed WT male mice, 
suggestive of fatty liver disease progression and a role for Cyp2b in lipid homeostasis. 
Females did not show as demonstrative changes in liver health, and significantly fewer 
changes in gene expression, as well as gene expression associated with liver disease. 
Overall our data indicates that the repression or inhibition of CYP2B may exacerbate 
metabolic disorders and cause obesity by perturbing fatty acid metabolism, especially in 
males. 
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2.1 Introduction 
According to the National Center for Health Statistics (NCHS) more than 40% of 
adults and 18.5% youth are obese in United States as of 2015-2016 (Hales, Carroll, Fryar, 
& Ogden, 2017). Factors that cause obesity include poor diet, changes in lifestyle, 
genetics, and the environment (Choquet & Meyre, 2011; Grun & Blumberg, 2009; 
Romieu et al., 2017). The primary problem is excess food coupled with inactivity. 
However, data indicates there are other anthropogenic factors, including environmental 
toxicants that exacerbate obesity by modulating the use and allocation of nutrient 
resources leading to increased white adipose tissue and obesity (Grun & Blumberg, 2009; 
Hatch, Nelson, Stahlhut, & Webster, 2010; Sharp, 2009; Wahlang et al., 2013). The terms 
“obesogen” or “metabolic disruptor” (Grun & Blumberg, 2009; Hatch et al., 2010; 
Wahlang et al., 2013) refer to a new subclass of endocrine disruptors that perturb 
metabolic signaling, energy, and lipid homeostasis (LeBlanc et al., 2012; Riu et al., 
2011). In turn, the Organization for Economic Cooperation and Development (OECD) 
considers metabolic disorders one of three critical areas in toxicology in addition to 
testicular dysgenesis and autism spectral disorders (LeBlanc et al., 2012).  
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Chemical exposures shown to cause obesity include perinatal exposure to 
bisphenol A that increases lipogenic gene expression and hepatic steatosis in male mice 
(Marmugi et al., 2012). Tributyltin activation of PPARγ-RXR induces obesity primarily 
through increased adipocyte differentiation (Chamorro-García et al., 2013; le Maire et al., 
2009), and TCDD activation of AhR induces obesity and steatosis through increased 
uptake of fatty acids (Angrish, Mets, Jones, & Zacharewski, 2012; Chang, Chen, Su, & 
Lee, 2016; Lee et al., 2010). Inactivation of the xenobiotic receptor, the constitutive 
androstane receptor (CAR), and activation of the pregnane X-receptor (PXR) are also 
associated with obesity (Dong et al., 2009; K Spruiell et al., 2014; K. Spruiell et al., 
2014). Perturbations in hepatic Cytochrome P450 (CYP) activity were recently associated 
with lipid accumulation (Robert D. Finn, Henderson, Scott, & Wolf, 2009; Hoek-van den 
Hil et al., 2015; Hoek-van den Hil et al., 2014; Wang, Chamberlain, Vassieva, 
Henderson, & Wolf, 2005; Zong, Armoni, Harel, Karnieli, & Pessin, 2012) and the 
inhibition of all hepatic CYP activity was associated with increased hepatic lipid 
accumulation (Robert D. Finn et al., 2009). In constrast, knockouts of Cy2e1 and Cyp3a 
members were associated with reduced lipid accumulation and weight gain (only in 
females in Cyp3a-null mice) (R. Kumar, Litoff, Boswell, & Baldwin, 2018; Zong et al., 
2012).  
CYPs, primarily in families 1-3, metabolize pharmaceuticals (Zanger & Schwab, 
2013), environmental pollutants (Foxenberg, McGarrigle, Knaak, Kostyniak, & Olson, 
2007) and endobiotics such as fatty acids (Arnold et al., 2010), bile acids and steroids (D 
J Waxman, 1988). Several CYP1-3 members are crucial in fatty acid metabolism. For 
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example, CYP3A4 metabolizes arachidonic acid to 13-hydroxyeicosatrienoic acid 
(HETE), 10-HETE and 7-HETE (Bylund, Kunz, Valmsen, & Oliw, 1998), and 
anandamide to several metabolites including 5,6-epoxyeicosatrienoic acid ethanolamide, 
with high affinity for the cannabinoid-2 (CB-2) receptor (Pratt-Hyatt, Zhang, Snider, & 
Hollenberg, 2010). CYP2J2 metabolizes arachidonic acid to epoxyecosatrienoic acid 
(EET) in cardiomyocytes (Wu, Moomaw, Tomer, Falck, & Zeldin, 1996), and some 
Cyp2b members metabolize arachidonic acid with high affinity (Capdevila et al., 1990; 
Keeney et al., 1998). For example, Cyp2b19 expressed in mouse keratinocytes, 
epoxygenate arachidonic acid to 11,12- and 14,15-EET that play a vital role in 
cornification of epidermal cells (Du et al., 2005; Ladd, Du, Capdevila, Mernaugh, & 
Keeney, 2003).  
Several recent studies implicate Cyp2b in obesity. For example, Cyp2b members 
are inducible by anti-obesity transcription factors (CAR; FoxA2) (Hashita et al., 2008; 
Hernandez, Mota, & Baldwin, 2009; Wei, Zhang, Egan-Hafley, Liang, & Moore, 2000). 
CAR is a key regulator of Cyp2b, including Cyp2b9 and Cyp2b10 (J. P. Hernandez, L. C. 
Mota, W. Huang, D. D. Moore, & W. S. Baldwin, 2009; Mota, Hernandez, & Baldwin, 
2010; Oshida et al., 2015), and CAR activation by TCPOBOP ameliorates obesity, 
diabetic activity and fatty liver disease in ob/ob mice, but not ob/ob mice null for CAR 
(Dong et al., 2009). FoxA2, which is activated by fasting and fatty acids and inhibited by 
insulin, is a potent inducer of Cyp2b9 (Bochkis et al., 2008; Hashita et al., 2008; 
Wolfrum, Asilmaz, Luca, Friedman, & Stoffel, 2004). FoxA2-null mice are age-
dependent obese (Bochkis, Shin, & Kaestner, 2013). Thus, Cyp2b expression is induced 
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by CAR and Foxa2 during nutritional or metabolic stress, potentially as a protective 
mechanism from NAFLD. Furthermore, cytochrome P450 oxidoreductase (HRN-null) 
conditional knockout mice that lack all liver CYP activity, activate CAR and induce 
Cyp2b mRNA during treatment with polyunsaturated fatty acid (PUFA)-rich sunflower 
oil (Robert D. Finn et al., 2009). Similarly, treatment with soybean oil (rich in 51% 
linoleic acid) resulted in weight gain, increased white adipose tissue and glucose 
intolerance in association with a significant increase in Cyp2b9 and 13 (Deol et al., 
2015). Cyp2b9 is also the most highly induced gene in a couple of diet-induced obesity 
studies (Hoek-van den Hil et al., 2015; Leung, Trac, Du, Natarajan, & Schones, 2016). 
Last, observations in our laboratory following production of a Cyp2b RNAi-based 
knockdown mouse model on a FVB strain background (B. Damiri, Holle, Yu, & 
Baldwin, 2012) show increases in body weight and adiposity with age and a reduced 
propensity to eliminate PUFA-rich corn oil (B Damiri & Baldwin, 2018). Taken together, 
the Cyp2b enzymes are responsive to high-fat diets and associated with obesity. 
Therefore, we predict that lack of Cyp2b either by gene knockout (as described here) or 
repression by inhibitors coupled with a high-fat diet will perturb lipid metabolism, 
increase body weight and lead to the development of obesity.  
Murine Cyp2b members are expressed in several tissues (B. Damiri et al., 2012). 
For example, Cyp2b19 is primarily expressed in the skin and involved in keratinocyte 
development (Du et al., 2005; Keeney et al., 1998). Cyp2b23 is primarily expressed in 
neonate liver (L. Peng et al., 2012), Cyp2b13 is primarily expressed in adult liver (L. 
Peng et al., 2012), Cyp2b10 is primarily expressed in adult liver and highly inducible (J. 
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P. Hernandez, L. C. Mota, & W. S. Baldwin, 2009; L. Peng et al., 2012), and Cyp2b9 is 
expressed in several tissues including liver, brain, and to a lesser degree kidney and lungs 
(Hersman & Bumpus, 2014; L. Peng et al., 2012). In addition, both Cyp2b9 and Cyp2b13 
are highly female predominant due to sexually dimorphic regulation by HNF4 and 
growth hormone (R Kumar et al., 2017; Wiwi, Gupte, & Waxman, 2004)}(J. P. 
Hernandez, L. C. Mota, W. Huang, et al., 2009; D J  Waxman, Pampori, Ram, Agrawal, 
& Shapiro, 1991). 
We used our newly developed Cyp2b9/10/13-null (Cyp2b-null) mice missing the 
primarily hepatic Cyp2b members, Cyp2b9, Cyp2b10 and Cyp2b13 to demonstrate the 
significance of Cyp2b on diet-induced obesity and hepatic lipid metabolism. We treated 
Cyp2b-null mice with a 60% high-fat diet for 10-weeks, and examined their susceptibility 
to diet-induced obesity compared to wild-type (WT) mice. Physiological changes such as 
body weight, organ weight, glucose tolerance, serum lipids, and specific metabolic 
hormones were examined. In addition, RNAseq was performed to determine differential 
gene expression and investigate which gene ontologies and pathways were perturbed. Our 
data demonstrates a role for perturbations in Cyp2b activity in obesity and lipid 
metabolism.  
  
2.2 Materials and Methods 
2.2.1 High-fat diet treatment of Cyp2b-null mice 
All mice studies followed National Institute of Health guidelines for humane use 
of research animals and were pre-approved by Clemson University’s Institutional Animal 
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Care and Use Committee (IACUC). Cyp2b-null mice were developed using Crispr/Cas9 
technology on C57Bl6/J (B6) background mice as described earlier (R Kumar et al., 
2017). Briefly, the liver predominant Cyp2b genes, Cyp2b10, Cyp2b13 and Cyp2b9 
present as tandem repeat sequences on chromosome seven and were targeted individually 
using small guide RNA sequences (sgRNA). This led to the deletion of 287 kb lacking 
these three primarily hepatic Cyp2b genes (Suppl. Material 2.1; S2.1). Homozygous 
knock-out mice were verified using primers published previously (R Kumar et al., 2017).  
Wildtype C57BL/6J were purchased from The Jackson Laboratory at 3 weeks of 
age (Bar Harbor, ME, USA), and acclimated for 6-weeks prior to the dietary treatments. 
Nine-ten week old male and female mice (n=9) from WT and Cyp2b-null mice were 
divided into normal diet (ND; 2018S-Envigo Teklad Diet, Madison, WI) and high-fat diet 
(HFD; Envigo, TD.06414 Adjusted calorie diet) groups. ND provided 3.1 Kcal/g with 
18% of kilocalories from fat, 24% protein, and 58% carbohydrate. HFD provided 5.1 
Kcal/g with 60.3% of kilocalories from fat (37% saturated, 47% monounsaturated, 16% 
polyunsaturated fat), 18.4% protein, and 21.3% carbohydrates.  
Feed consumption was measured every other day and mice were weighed every 
week to determine their weight gain. At the end of the study, mice were anesthetized, 
blood was collected by heart puncture, and mice euthanized by carbon dioxide 
asphyxiation (B Damiri & Baldwin, 2018). Organs such as liver, kidney, inguinal and 
renal white adipose tissue, and brain were excised and weighed. Livers were dissected 
into five fractions and snap frozen in liquid nitrogen for microsome preparation and RNA 
extraction. Frozen liver fractions were stored at -80oC. A portion of the liver was stored 
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in 10% formalin (Fisher, Fair Lawn NJ USA) for histopathological analyses. A timeline 
of experimental procedures performed on the mice is provided (S2.2). 
 
2.2.2 RNA sequencing (RNAseq) 
Liver samples were stored in RNAlater stabilization solution (Invitrogen) at -
80°C. RNA was extracted from mouse livers using an RNeasy Plus Universal kit 
(Qiagen) per the manufacturer’s instructions and quantified on a NanoDrop 8000 
Spectrophotometer. An Agilent 2100 Bioanalyzer was used to assess the RNA integrity 
number (RIN). Samples with a RIN > 8 were determined to be of high quality and used 
for next generation sequencing. Libraries were prepared with the TruSeq Total RNA 
Library Prep kit. Samples were sequenced to an average sequencing depth of 20,000,000 
read pairs with a 2 x 125 paired-end module using an Illumina HiSeq2500 for males and 
a 2 x 150 paired-end module using a NovaSeq 6000 for females. Quality metrics were 
checked using FastQC on all samples sequenced, and Trimmomatic was used to trim low 
quality bases. Trimmed reads were aligned to the Mus musculus reference genome 
(GCF_000001635.25_GRCm38.p5) using GSNAP, and 99.7% of the trimmed reads 
aligned. Subread feature counts software found reads that aligned with known genes. 
Raw read counts and EdgeR were used to determine differential gene expression (Huber 
et al., 2015). Genes in which the lowest replicate number of samples have less than one 
count per million of expression were ascertained to be low coverage genes and were 
filtered out of the analysis. Samples were then normalized to the scale of their library 
sizes. Genes were considered differentially expressed if their adjusted p-value and false 
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discovery rate were less than 0.05 and 0.1 respectively as performed previously (Park & 
Mori, 2010). Series GSE120761 containing the RNAseq data has been uploaded to GEO.  
Heatmap hierarchical cluster analysis by Euclidiean distance using Ward’s 
method was performed with Heatmap.2 in R (http://www.r-project.org/). Venn diagrams 
were created using Venn Diagram Plotter (omics.pnl.gov). GOSeq, a GO term 
enrichment analysis program was used to adjust for gene length and expression bias 
(Young, Wakefield, Smyth, & Oshlack, 2010). Significantly (p < 0.05) enriched GO 
terms were visualized in Revigo, which reduces enriched term redundancy and displays 
the remaining enriched GO terms in a scatterplot (Supek, Bo snjak, Skunca, & Smuc, 
2011). Differentially expressed genes were annotated using InterPro (R D Finn et al., 
2017), and genes with a log2FC > 1.0 were entered into KEGG Mapper 
(http://www.genome.jp/kegg/) to determine and visualize biochemical pathways 
perturbed by a HFD or a lack of Cyp2b enzymes (Kanehisa, Furumichi, Tanabe, Sato, & 
Morishima, 2017). 
 
2.2.3 Histopathological analysis  
Following necropsy, a clean slice of liver was placed in 10% formalin (Fisher). 
Hematoxylin and Eosin (H&E) staining was performed at Colorado Histoprep (Fort 
Collins, CO USA) and Oil Red O staining was performed with frozen samples at Baylor 
College of Medicine’s Comparative Pathology Laboratory (Houston, TX USA) using 
standard protocols (Acevedo et al., 2005; Dong et al., 2009). Histopathological scoring 
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was performed blind by a veterinary pathologist at Colorado Histoprep (Fort Collins, CO 
USA). 
 
2.2.4 Serum lipid panel  
Blood samples were collected by heart puncture and incubated at room 
temperature for 30 min followed by centrifugation at 6000 rpm for 10 minutes. Serum 
samples were transferred into fresh tubes and 100μl aliquots were shipped on dry ice to 
Baylor College of Medicine’s Comparative Pathology Laboratory (Houston, TX) for 
determination of nonfasting serum cholesterol, triglycerides, alanine aminotransferase 
(ALT), high density lipoprotein (HDL), low density lipoprotein (LDL), and very low 
density lipoprotein (VLDL) with a Beckman-Coulter AU480 analyzer and the appropriate 
Beckman-Coulter biochemical kits according to the manufacturer’s instructions.  
 
2.2.5 Serum concentrations of free fatty acids, -hydroxybutyrate and liver triglycerides 
Serum free fatty acids (FFA) and -hydroxybutyrate (B-OHB) concentrations 
were determined using fluorescent and colorimetric kits, respectively, from Cayman 
Chemical Co (Ann Arbor, MI). Liver triglyceride concentrations were quantified 
following organic extraction (R. Kumar et al., 2018) with a colorimetric kit (Cayman 
Chemical).  
 
2.2.6 Tests of Statistical Significance  
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Data are presented as mean + SEM (n = 9) except serum lipids (n = 5). Statistical 
analysis was performed by one-way ANOVA followed by Fisher’s LSD as the post-hoc 
test when comparing more than two groups. Student’s t-tests were used when comparing 
two groups. Statistical analysis was performed using Graphpad Prism version 6 (La Jolla, 
CA USA). A p-value < 0.05 was considered statistically significant.  
 
2.3 Results   
2.3.1 High-fat diet increases body and white adipose tissue weight 
HFD-fed Cyp2b-null male mice weighed significantly more than HFD-fed WT 
male mice (Fig. 2.1A). The weight of HFD-fed Cyp2b-null male mice was significantly 
greater than HFD-fed WT mice after only 4-weeks and these mice stayed heavier for the 
rest of the study period (Fig. 2.1A). Much of this weight gain is from increased white 
adipose tissue, which increased 55% more in HFD-fed Cyp2b-null mice than HFD-fed 
WT mice (Table 2.1A). Cyp2b-null mice had similar caloric intake compared to their 
WT counterparts when examined by diet (HFD or ND) (S2.3). Therefore, alterations in 
dietary intake do not explain increased weight gain in Cyp2b-null mice.  
Cyp2b-null and WT female mice fed a HFD gained significantly more weight and 
had higher white adipose tissue mass compared to mice fed a ND. However, the Cyp2b-
null genotype had no significant effect on body weight gain or WAT mass in females 
(Fig. 2.1B; Table 2.1B). Overall, the loss of Cyp2b9, Cyp2b10, and Cyp2b13 led to diet-
induced obesity in male, but not female mice.  
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Fig. 2.1:  Changes in body weight during the 10-weeks of dietary treatments. Body 
weight of A) male and B) female, WT, and Cyp2b-null mice were monitored during the 
10-week feeding study. Male but not female Cyp2b-null mice show increased weight 
during HFD treatments. Data are represented as mean + SEM. Statistical significance was 
determined by one-way ANOVA followed by Fisher’s LSD as the post-hoc test (n= 8-9). 
An ‘a’ indicates WT-ND are different than Cyp2b-null-ND, ‘b’ indicates WT-ND are 
different than WT-HFD, ‘c’ indicates Cyp2b-null-ND are different than Cyp2b-null-
HFD, ‘d’ indicates WT-HFD are different than Cyp2b-null-HFD.  
 
 
 
Table 2.1: Organ weights determined in WT and Cyp2b9/10/13-null mice after 10-
weeks of dietary treatment in male (A) and female (B) mice. 
A 
 
 
Mouse model Body weight WAT Liver Kidney Brain 
WT-ND M 26.48+0.57 0.51+0.06 1.23+0.03 0.34+0.01 0.48+0.03 
WT-HFD M 30.43+0.92b** 1.96+0.22b*** 1.06+0.04b* 0.37+0.01 0.44+0.00 
Cyp2b-null ND M 25.75+0.39 0.69+0.06 1.08+0.03a* 0.31+0.01 0.46+0.01 
Cyp2b-null HFD M 34.12+0.88c***d* 3.04+0.19c***d*** 1.08+0.04 0.37+0.02c** 0.43+0.01 
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B 
Data represented as mean (g) +/- SEM (n = 8/9). Statistical significance determined by 
one-way ANOVA followed by Fisher’s LSD as the post-hoc test.  
‘a’ indicates WT ND different than Cyp2b9/10/13-null ND   
‘b’ indicates WT ND different than WT HFD 
‘c’ indicates Cyp2b9/10/13-null ND different than Cyp2b9/10/13-null HFD  
‘d’ indicates WT HFD different than Cyp2b9/10/13-null HFD,  
No asterisk indicates a p-value < 0.05, * indicates a p-value < 0.01,** indicates a p-value 
< 0.0001 and *** indicates a p-value < 0.00001. 
 
2.3.2 Increased hepatic triglycerides in Cyp2b-null mice  
Total liver triglycerides increased 2.3X in the ND-fed Cyp2b-null male mice 
compared to ND-fed WT males (Fig. 2.2A). HFD exacerbated liver triglyceride 
concentrations; however, there was no significant difference between HFD-fed Cyp2b-
null male mice and HFD-fed WT male mice (Fig. 2.2A). HFD-fed female mice showed 
significant increases in liver triglycerides compared to ND-fed mice; however, genotype 
did not significantly alter liver triglycerides in females (Fig. 2.2B). Despite increased 
liver triglycerides in both HFD-fed groups and ND-fed Cyp2b-null males, liver weight 
was decreased in all of these groups compared to ND-fed WT mice for unknown reasons 
(Table 2.1A). Histopathological analysis indicated mild morphological changes 
indicative of fat deposition in male ND-fed Cyp2b-null, HFD-fed WT, and HFD-fed 
Cyp2b-null mice either by H&E or Oil Red O. H&E staining showed mild vacuolization 
in some HFD-fed male mice of both genotypes with slightly greater vacuolization in 
some HFD-fed Cyp2b-null mice than HFD-fed WT mice, but no significant changes 
Mouse model Body weight WAT Liver Kidney Brain 
WT-ND F 20.47+0.44 0.36+0.06 0.87+0.03 0.26+0.01 0.44+0.00 
WT-HFD F 23.17+0.87b* 0.95+0.15b* 0.84+0.03 0.26+0.01 0.45+0.00 
Cyp2b-null ND F 20.29+0.22 0.33+0.03 0.83+0.02 0.25+0.01 0.45+0.00 
Cyp2b-null HFD F 24.15+0.93c** 1.22+0.24c** 0.87+0.04 0.28+0.01c 0.45+0.01 
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within the female mice (Fig. 2.2C-D). Oil Red O staining was absent or weak in male 
and female ND treatments with minimal staining in ND-fed Cyp2b-null males, which 
corroborates the total liver triglyceride data. HFD-fed Cyp2b-null male mice showed 
mildly greater Oil Red O staining than HFD-fed WT mice (Fig. 2.2E). Female mice only 
showed mild staining following a HFD with no difference between genotypes (Fig. 
2.2F). Overall, the data suggests that liver triglycerides are slightly higher in Cyp2b-null 
male mice than correspondingly treated WT male mice.  
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Fig. 2.2: Liver triglyceride concentrations are significantly increased in Cyp2b-null 
mice. Liver triglycerides were extracted and determined as described in the Materials and 
Methods using commercial kits. Data are presented as mean + SEM for males (A) and 
females (B). Statistical significance was determined by one-way ANOVA followed by 
Fisher’s LSD as the post-hoc test (n= 8-9). * indicates a  p-value < 0.05, *** indicates p-
value < 0.001 and **** indicates p-value < 0.0001. An ‘a’ indicates WT-ND are different 
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than Cyp2b-null-ND, ‘b’ indicates WT-ND are different than WT-HFD, ‘c’ indicates 
Cyp2b-null-ND are different than Cyp2b-null-HFD, ‘d’ indicates WT-HFD different than 
Cyp2b-null-HFD. H&E staining was performed in male (C) and female (D) mice with 
increases in vacuolization in HFD-fed males. Oil Red O staining was also performed in 
male (E) and female (F) mice and indicate weak liver lipid staining in all ND treatments 
and greater triglyceride staining in HFD-fed Cyp2b-null males relative to their HFD-fed 
WT counterparts. 
 
2.3.3 Serum lipids were perturbed in Cyp2b-null mice 
Serum triglyceride levels were significantly decreased in Cyp2b-null male mice 
compared to WT mice following ND (28%) or HFD (25%) treatments (Table 2.2), in 
contrast to increased liver triglyceride concentrations (Fig. 2.2). The ratio of liver:serum 
triglycerides was 3X greater in ND-fed Cyp2b-null males than ND-fed WT males, 4X 
greater in HFD-fed WT males than ND-fed WT males, and 1.54X greater in HFD-fed 
Cyp2b-null males than HFD-fed WT males (Fig. 2.3), demonstrating that a Cyp2b-null 
genotype or a HFD increased the retention of liver triglycerides, and the Cyp2b-null 
genotype enhanced liver triglyceride retention induced by a HFD. This indicates either 
decreased metabolism and distribution of hepatic lipids or increased uptake of lipids into 
the liver.  
Table 2.2: Serum lipid levels in Cyp2b9/10/13-null compared to WT mice treated with 
normal diet (ND) or high fat diet (HFD) in male (A) and female (B) mice. 
A
 
 
 Lipid panel WT ND M WT HFD M Cyp2b-null ND M Cyp2b-null HFD M 
ALT 17.00 + 1.48 15.00 + 0.55 17.80 + 0.97 14.00 + 1.00 
-OHB 0.188 + 0.015 0.162 + 0.022 0.120 + 0.015 0.365 + 0.087c***d** 
Cholesterol 103.80 + 1.63 170.4 + 7.00b** 118.60 + 6.27a* 182.75 + 3.61c**d 
Fatty acids 833.7 + 97.3 740.2 + 93.0 739.3 + 36.6 751.4 + 43.2 
HDL 97.00 + 2.21 150.76 + 6.24b** 114.02 + 4.45a* 168.60 + 4.94c**d* 
LDL 10.98 + 0.58 26.34 + 2.46b* 16.34 + 1.09 30.20 +/- 1.57c 
Triglycerides 80.40 + 7.88 69.60 + 3.96b 58.00 + 5.93a** 52.25 + 3.15d* 
VLDL 16.04 +1.59 13.94 + 0.80 11.56 + 1.19a 10.45 + 0.61 
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B
 
Data represented as mean +/- SEM (n = 5). All units expressed as mg/dl except β-OHB 
(mM), fatty acids (μM) and ALT (U/L). Statistical significance was determined by one-
way ANOVA followed by Fisher’s LSD as the post-hoc test.  
‘a’ indicates WT ND different than Cyp2b9/10/13-null ND.  
‘b’ indicates WT ND different than WT HFD 
‘c’ indicates Cyp2b9/10/13-null ND different than Cyp2b9/10/13-null HFD.  
‘d’ indicates WT HFD different than Cyp2b9/10/13-null HFD,  
No asterisk indicates a p-value < 0.05 and * indicates a p-value < 0.01, ** indicates a p-
value of < 0.0001. 
 
 Lipid panel WT ND F  WT HFD F   Cyp2b-null ND F  Cyp2b-null ND F 
ALT 20.20 + 1.69 37.20 + 8.49 17.80 + 0.80 17.80 + 0.80 
-OHB 0.325 + 0.076 0.360 + 0.061 0.328 + 0.098 0.268 + 0.046 
Cholesterol 76.40 + 3.70 98.00 + 12.63 77.40 + 1.94 77.40 + 1.94 
Fatty acids 374.0 + 8.19 380.4 + 27.2 343.9 + 20.5 366.5 + 30.6 
HDL 72.48 + 4.09 54.18 + 22.92 77.36 + 2.57 77.36 + 2.57 
LDL 8.68 + 1.82 8.58 + 3.24 10.20 + 1.46 10.20 + 1.46 
Triglycerides 80.80 + 17.74 78.40 + 18.58 57.40 + 12.70 57.40 + 12.70 
VLDL 16.16 + 3.53 11.46 + 2.52 15.68 + 3.75 20.48 + 3.55 
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Fig. 2.3:  Liver triglyceride:serum triglyceride (A), liver triglyceride:serum free 
fatty acid (B), and serum free fatty acid:serum b-hydroxybutyrate (C) ratios in ND 
and HFD-fed mice. Data are presented as mean + SEM. Statistical significance was 
determined by one-way ANOVA followed by Fisher’s LSD as the post-hoc test (n= 8-9). 
* indicates a  p-value < 0.05, *** indicates p-value < 0.001 and **** indicates p-value < 
0.0001. An ‘a’ indicates WT-ND are different than Cyp2b-null-ND, ‘b’ indicates WT-ND 
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are different than WT-HFD, ‘c’ indicates Cyp2b-null-ND are different than Cyp2b-null-
HFD, ‘d’ indicates WT-HFD different than Cyp2b-null-HFD. 
 
Female mice showed a similar decrease (29%) to males in serum triglycerides in 
ND-fed Cyp2b-null mice compared to ND-fed WT mice (Table 2.2); however, this was 
not statistically significant. In contrast to males, HFD-fed Cyp2b-null female mice 
showed a 31% increase in serum triglycerides compared to HFD-fed WT mice. Changes 
in liver and serum triglycerides were proportional in females, which is different than 
males, and this was further demonstrated by the liver:serum triglyceride ratios that were 
not different between WT and Cyp2b-null female mice (Fig. 2.3A).  
In contrast to serum triglycerides, free fatty acids (FFA) were not perturbed 
significantly across groups (Table 2.2). This relative stability ensured that serum 
TAG:serum FFA ratios were not altered across groups (data not shown). However, the 
relative stability of FFA provides another example of the differences in liver triglyceride 
to serum lipid ratios across treatment groups as both males and females show large 
increases in liver TAG:serum FFA ratio with females showing greater relative increases 
in HFD-fed Cyp2b-null mice (Fig. 2.3B).  
Serum cholesterol and HDL increased 14% and 18%, respectively, in ND-fed 
Cyp2b-null male mice compared to ND-fed WT male mice. Serum cholesterol and HDL 
increased 8% and 12%, respectively, in HFD-fed Cyp2b-null male mice compared to 
HFD-fed WT male mice (Table 2.2A); thus Cyp2b-null male mice consistently present 
higher cholesterol concentrations. For example, HFD-fed Cyp2b-null male mice had 2X 
higher cholesterol than HFD-fed male WT mice, indicating a significant role Cyp2b in 
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serum cholesterol concentrations. Despite lower weight gain and white adipose tissue 
mass, females showed greater changes in serum cholesterol and HDL concentrations. 
Most changes were associated with a combination of diet and the loss of Cyp2b (Table 
2.2B). There were no significant changes in LDL or VLDL serum levels; only in HDL 
serum concentrations. In addition, ALT, a biomarker of liver damage, was increased only 
in Cyp2b-null females fed a HFD, indicating that these mice suffered some liver damage 
such as apoptosis or necrosis in addition to the abnormally high serum cholesterol. It is 
interesting that the HFD-fed Cyp2b-null female mice are not showing greater obesity 
than HFD-fed WT mice, but several other parameters are perturbed.  
β-hydroxybutyate (B-OHB) is generated by the liver from fatty acids during 
prolonged exercise or starvation to meet energy requirements and compensate for lower 
carbohydrate levels. B-OHB can be utilized as an energy source by active tissues such as 
brain and muscles. HFD-fed Cyp2b-null males showed a 2.3-fold increase in B-OHB 
levels compared to HFD-fed WT males and a 3-fold increase compared to ND-fed 
Cyp2b-null males (Table 2.2A). The increase in B-OHB also fueled the decrease in the 
serum FFA/B-OHB ratio observed in HFD-fed Cyp2b-null male mice as serum fatty acid 
levels were relatively stable between groups, but ketones were increased by the 
combination of genotype and a HFD (Fig. 2.3C). Serum triglyceride/B-OHB ratio 
followed the same pattern (data not shown).    
 
2.3.4 ND-fed Cyp2b-null mice have similar gene expression profiles compared to HFD-
fed WT mice  
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RNAseq was performed on male and female liver samples to compare and test 
why only male Cyp2b-null mice showed both significant weight gain and significantly 
increased hepatic lipids (Fig. 2.1, 2.2). Analysis of global gene expression using 
hierarchical clustering demonstrates that male samples cluster into two different groups: 
one cluster consisting of WT-ND mice, and the other cluster consisting of Cyp2b-null 
ND and WT-HFD mice grouped among each other with Cyp2b-null HFD mice in their 
own subgroup. The clustering of HFD-fed WT mice and ND-fed Cyp2b-null male mice 
into the same clade (Fig. 2.4A) suggests similar changes in gene expression. Venn 
diagrams (Fig. 2.4B) confirm that within the liver the Cyp2b-null genotype with no 
change in diet causes comparable transcriptional effects to that of WT mice fed a HFD. 
Cyp2b-null ND and WT HFD mice share the same 217 significantly (p < 0.05) up-
regulated genes and 111 down-regulated when compared to WT ND mice as the control. 
These two experimental groups share over 40% of each group’s total number of 
differentially expressed genes, indicating that the Cyp2b-null genotype causes effects 
similar to that of a HFD-treatment potentially due to increased liver triglycerides in the 
ND-fed Cyp2b-null male mice (Fig. 2.2). 
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Fig. 2.4: Cyp2b-null male mice fed a ND display a similar gene expression profile to 
WT mice fed a HFD. RNAseq was performed on liver samples from WT and Cyp2b-
null mice fed either a ND or HFD. (A) Heat map showing log2-transformed, Z-score 
scaled RNA-Seq expression of 500 genes with the highest variance between treatment 
groups. Red and blue color intensity indicate gene up- or down-regulation, respectively. 
Dendrogram clustering on the x-axis indicates sample similarity, whereas dendrogram 
clustering on the y-axis groups genes by expression profile across samples. (B) Venn 
diagrams of shared up- and down-regulated differentially expressed genes (p<0.05) 
between Cyp2b-null ND-fed and WT HFD-fed mice compared to WT ND mice. (C) GO 
term enrichment analysis summary using Revigo (Supek et al., 2011) for significantly up-
regulated genes in Cyp2b-null ND mice compared to WT ND mice. The scatterplot 
contains enriched GO terms from the biological process class that remain after term 
redundancy is reduced and are displayed in a two-dimensional space where semantically 
similar GO terms are positioned closer together within the plot. Each circle represents an 
enriched GO term; the cooler the color of a term, the more significantly (p < 0.05) 
associated that term is with the group of genes being studied. Circle size indicates the 
frequency of the GO term in the underlying GO database, i.e. circles of more general 
terms are larger. 
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Female samples clustered in a different fashion than males. ND-fed WT and 
Cyp2b-null mice clustered together and separately from most of the HFD-fed mice (Fig. 
2.5A) instead of ND-fed Cyp2b-null mice clustering with HFD-fed WT mice as seen in 
male groups (Fig. 2.4B). There is little gene expression overlap between ND-fed Cyp2b-
null and HFD-fed WT female mice (Fig. 2.5B), in part because there are very few 
differentially expressed genes in HFD-fed WT female mice compared to ND-fed WT 
female mice (only 7; S2.4) and a significant drop in differentially expressed genes 
between ND-fed WT and ND-fed Cyp2b-null female mice compared to males (Fig. 2.5B, 
S2.4-S2.7). For example, in ND-fed groups, 506 genes were induced in Cyp2b-null male 
mice, but only 65 in Cyp2b-null female mice when compared to ND-fed WT mice with 
15 genes overlapping between males and females. 264 genes were down-regulated in 
Cyp2b-null male mice, but only 73 were down-regulated in females with 19 overlapping 
(S2.6, S2.8). Most of the differences in hierarchical clustering are due to diet in females 
(S2.4). This demonstrates the lack of response to the Cyp2b knockout and HFD in female 
mice compared to male mice (Fig. 2.5; S2.4-S2.6), similar to our physiological data.  
50 
 
Fig. 2.5: Cyp2b-null female mice demonstrate relatively fewer gene expression 
changes. RNAseq was performed on liver samples from WT and Cyp2b-null mice fed 
either a ND or HFD. (A) Heat map showing log2-transformed, Z-score scaled RNA-Seq 
expression of 500 genes with the highest variance between treatment groups. Red and 
blue color intensity indicate gene up- or down-regulation, respectively. Dendrogram 
clustering on the x-axis indicates sample similarity, whereas dendrogram clustering on 
the y-axis groups genes by expression profile across samples. (B) Venn diagrams of 
shared up- and down-regulated differentially expressed genes (p<0.05) between Cyp2b-
null ND-fed and WT HFD-fed mice compared to WT ND mice.  
 
Interestingly, the most highly induced gene by the HFD in WT male mice was 
Cyp2b9 (S2.4). Previous diet-induced obesity (DIO) studies have also shown Cyp2b9 to 
be the most highly induced gene (Leung et al., 2016; McGregor et al., 2013). Among the 
list of shared genes by Cyp2b-null ND and WT HFD male mice, up-regulated genes with 
the highest logFC in both groups include Cyp2a4 (logFC: Cyp2b-null ND 6.99, WT HFD 
1.53), Cyp2b9 (LogFC: Cyp2b-null ND 3.60, WT HFD 6.65), and NADH-ubiquinone 
oxidoreductase chain 3 (ND3) (logFC: Cyp2b-null ND 3.33, WT HFD 3.67) (S2.5). 
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Cyp2b9 is probably highly induced in Cyp2b-null mice as a compensatory mechanism as 
the latter half of the Cyp2b9 gene was not eliminated by Crispr/Cas9 and is therefore 
most likely under control of the CAR promoter found at the front of the Cyp2b gene 
cluster (S2.1)(R Kumar et al., 2017). A Western blot confirmed that no Cyp2b’s were 
induced and instead deleted in the Cyp2b-null mice as expected (S2.9). Genes down-
regulated in males and females when comparing the various treatments are also available 
in Supplementary Material (S2.4-S2.7) under a separate tab.  
Significantly (p < 0.05) enriched up-regulated gene ontology (GO) terms for male 
ND-fed Cyp2b-null mice in comparison to ND-fed WT mice were visualized in Revigo 
(Fig. 2.4C). Within the biological process class, ND-fed Cyp2b-null mice have enriched 
terms such as regulation of lipid transport, lipid localization, unsaturated fatty acid 
metabolism, eicosanoid metabolism, cell-cell signaling, circadian rhythms, and 
establishment or maintenance of cell polarity. Many of these terms are associated with 
NAFLD and perturbations in lipid metabolism (Berlanga, Guiu-Jurado, Porras, & 
Auguet, 2014; Leung et al., 2016; Sookoian & Pirola, 2013). Down-regulated GO terms 
for this group were mainly associated with protein stability and folding (S2.10), possibly 
indicating endoplasmic reticulum stress via lipotoxicity from intermediate lipid 
metabolites or perturbations in the endoplasmic reticulum due to the loss of CYPs 
(Mantzaris, Tsianos, & Galaris, 2011). There were no significantly enriched GO terms 
when comparing ND-fed Cyp2b-null and ND-fed WT mice in females (S2.10). 
There are not as many differentially expressed genes when comparing HFD-fed 
Cyp2b-null to HFD-fed WT mice in males or females (S2.7). In males, there are several 
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genes involved in triglyceride accumulation and lipid metabolism, including circadian 
genes associated with liver lipid metabolism, which is expected given the greater obesity 
and liver triglycerides in the HFD-fed Cyp2b-null mice than the HFD-fed WT mice. In 
addition, genes involved in tissue growth and repair and cytoskeletal remodeling are 
perturbed that when combined with excess serum leptin suggests that HFD-fed Cyp2b-
null mice are more susceptible to tissue damage or in the early stages or fibrosis 
(Battaller & Brenner, 2005; Pace, Corrado, Missero, & Byers, 2003; Sanchez-Antolín et 
al., 2015). In females, estrogen and thyroid metabolism, steroid hormone biosynthesis, 
endoplasmic reticulum protein processing, and pancreatic secretion were primarily 
perturbed, and only a few of these are directly linked to obesity, energy metabolism, and 
none of the multigene pathways perturbed are linked to fibrosis.  
There were 646 KEGG pathway perturbations caused by a lack of Cyp2b 
(comparing WT-ND to Cyp2b-null-ND) in male mice, but only 190 in female mice 
(Table 2.3). KEGG pathway analysis for both up- and down-regulated differentially 
expressed genes in ND-fed Cyp2b-null ND compared to ND-fed WT mice (log2FC > 1.0) 
revealed 42 metabolic genes with altered expression in males, but only 14 in females. 
Pathways perturbed include PI3K-Akt signaling, protein processing in the endoplasmic 
reticulum, retinol metabolism, arachidonic acid metabolism, insulin resistance, 
glycerolipid metabolism, and fatty acid elongation within the endoplasmic reticulum 
(S2.11; Table 2.3). Many of these pathways are also crucial in fatty acid metabolism and 
the development of NAFLD (Berlanga et al., 2014; Naa et al., 2018). The greater 
transcriptional (numbers of genes and pathways) effects perturbed in ND-fed Cyp2b-null 
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and HFD-fed WT male mice compared to female mice provides a clue as to why males 
are more susceptible, and females more resistant, to obesity (Table 2.4, 2.5). 
Table 2.3: Comparison of the number of up- and down-regulated genes within 
specific KEGG pathways of male and female Cyp2b-null ND-fed mice. 
  
 
KEGG Pathway 
Male Cyp2b-null ND 
vs WT ND 
Female Cyp2b-null ND 
vs WT ND 
PI3K-Akt signaling 11 5 
Protein processing in 
endoplasmic reticulum 
10 4 
Retinol metabolism 7 2 
MAPK signaling 7 3 
Glycerophospholipid 
metabolism 7 2 
Apoptosis 6 4 
Drug metabolism 6 1 
Thyroid hormone signaling 6 1 
Insulin resistance/signaling 5 4 
PUFA metabolism 5 1 
Circadian rhythm 4 3 
NAFLD 4 1 
Calcium signaling 3 1 
FoxO signaling 2 3 
Cholesterol metabolism 1 3 
Sphingolipid metabolism 1 2 
Total Perturbations 646 190 
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Table 2.4: Comparison of the number of up- and down-regulated genes within 
specific KEGG pathways.
 
 
 
 
 
 
 
KEGG Pathway 
Cyp2b-null ND vs 
WT ND 
WT HFD vs  
WT ND 
Cyp2b-null HFD 
vs WT HFD 
PI3K-Akt signaling  11 12 2 
Protein processing in 
endoplasmic reticulum 
10 1 0 
Retinol metabolism 7 13 1 
MAPK signaling 7 12 1 
Glycerophospholipid 
metabolism 
7 1 1 
Hepatocellular carcinoma 6 11 1 
Drug metabolism 6 9 0 
Thyroid hormone signaling 6 5 1 
Apoptosis 6 1 0 
PUFA metabolism 5 10 3 
Insulin signaling/resistance 5 3 2 
Circadian rhythm 4 2 3 
NAFLD  4 2 0 
Phospholipase D signaling 4 0 0 
Glutathione metabolism 2 12 0 
Cholesterol metabolism 1 4 2 
Total Perturbations 646 620 75 
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Table 2.5: Comparison of the number of up- and down-regulated genes in female 
mice within specific KEGG pathways. 
 
 
 
2.4 Discussion 
Male, but not female Cyp2b-null mice are diet-induced obese. Male Cyp2b-null 
mice fed a HFD gained 15% more body weight than male WT mice fed a HFD primarily 
due to a 55% increase in WAT mass. Diet-induced obesity and genotype-specific diet-
induced obesity are more difficult to measure in B6 female mice than male mice because 
the female mice are much less susceptible to obesity and diabetes than male mice (or 
human females) (Hong, Stubbins, Smith, Harvey, & Nunez, 2009; Wade, Gray, & 
KEGG Pathway 
Cyp2b-null ND vs 
WT ND 
WT HFD vs  
WT ND 
Cyp2b-null HFD 
vs WT HFD 
PI3K-Akt signaling 5 0 0 
Protein processing in 
endoplasmic reticulum 
4 0 6 
Insulin resistance/signaling 4 0 0 
Apoptosis 4 0 0 
FoxO signaling 3 0 0 
Circadian rhythm 3 0 0 
Cholesterol metabolism 3 1 0 
MAPK signaling  3 0 1 
Sphingolipid metabolism 2 0 0 
Glycerophospholipid 
metabolism 
2 0 0 
Retinol metabolism 2 0 1 
Calcium signaling 1 0 2 
Drug metabolism 1 1 0 
NAFLD  1 0 0 
Total Perturbations 190 13 49 
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Bartness, 1985). Previous observations indicated that Cyp2b-KD mice developed age-
onset obesity in males with a significant lesser effect in females. However, this work was 
an observation from aging mice (age-onset obesity); not a tightly planned experiment 
examining diet-induced obesity (B Damiri & Baldwin, 2018). Furthermore, the loss of 
Cyp2b, through either RNAi or Crispr/Cas9 (B. Damiri et al., 2012; R Kumar et al., 
2017), causes obesity independent of strain as it occurs in FVB (Cyp2b-KD) and B6 
(Cyp2b-null) mice. Overall, the loss of the primarily hepatic Cyp2b members increases 
WAT that in turn leads to obesity in males and suggests that inhibition of these enzymes 
by environmental chemicals or pharmaceuticals may have similar consequences.  
Liver triglyceride concentrations were significantly increased in ND-fed Cyp2b-
null mice compared to their WT male counterparts. Increases in liver triglycerides were 
accompanied by decreases in serum triglycerides in ND- and HFD-fed Cyp2b-null mice. 
In turn, both liver:serum triglyceride ratios and liver TAG:serum FFA ratios were greatly 
perturbed, and this includes comparisons between HFD-fed WT and HFD-fed Cyp2b-null 
mice. which indicates a crucial role for Cyp2b in liver triglyceride levels or distribution. 
Overall, triglyceride distribution was greatly perturbed in ND-fed Cyp2b-null mice, 
HFD-fed WT mice, and even more so in HFD-fed Cyp2b-null mice.  
It is noteworthy that ND-fed Cyp2b-null male mice retain triglycerides in their 
liver and display a similar gene expression profile to the HFD-fed WT male mice, 
indicating similar early stage liver disease and compensatory changes due to increased 
lipids. A survey of the key biomarker genes altered in ND-fed Cyp2b-null mice such as 
Cyps and transporters suggests activation of transcription factors such as Foxa2, LXR, 
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FXRb, and potentially Rev-Erb, RAR, ROR and CAR/PXR in males (Bochkis et al., 
2008; Hashita et al., 2008; J. P. Hernandez, L. C. Mota, & W. S. Baldwin, 2009; Sakai, 
Fukushima, Yamamoto, & Ikeuchi, 2017; Thatcher & Isoherranen, 2009; Urquhart, 
Tirona, & Kim, 2007). All of these transcription factors response to changes in lipid 
distribution or energy allocation. Hierarchical clustering, direct comparisons by Venn 
diagrams, shared GO terms, and similarly perturbed KEGG pathways all present 
evidence that ND-fed Cyp2b-null male mice have similar gene expression changes to 
HFD-fed WT mice. For example, both HFD-fed WT and ND-fed Cyp2b-null male mice 
show enriched terms for lipid transport, lipid localization, unsaturated fatty acid 
metabolism, and eicosanoid metabolism, clearly indicating perturbations in lipid 
utilization and metabolism. However, it should be noted that there are also some 
differences based on KEGG pathway analysis. For example, ND-fed Cyp2b-null male 
mice show perturbations in glycerolipid metabolism, apoptosis, and endoplasmic 
reticulum protein processing that are not manifested in WT-HFD mice; whereas WT-
HFD mice show perturbed hepatocellular carcinoma and glutathione metabolism that is 
not manifested in Cyp2b-null-ND mice. Cyp2b induction by CAR is partially responsible 
for subsequent CAR-initiated Nrf2 activation (Rooney, Oshida, Kumar, Baldwin, & 
Corton, 2019), and therefore Cyp2b-null mice may not activate protective mechanisms 
from oxidative stress such as glutathione metabolism as well as WT mice. It is also 
interesting that the apoptotic and hepatocellular carcinoma responses are reversed, 
suggesting Cyp2b-null mice may be less susceptible to cancer even with the increase in 
liver triglycerides. Overall, the similarities in differential gene expression outweigh the 
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differences, and provide data associating the loss of hepatic Cyp2b members to liver 
triglycerides and obesity in males.  
This was not the case in females. Significantly fewer genes were altered in 
females, especially following a HFD and in turn ND-fed Cyp2b-null females did not 
cluster with HFD-fed WT females. Female mice are generally considered partially 
resistant to obesity except post-menopausal (Hong et al., 2009; K Spruiell et al., 2014). 
This resistance was also observed during this study and demonstrates that Cyp2b 
enzymes such as Cyp2b9 and Cyp2b13 ,expressed at much greater levels in females (R 
Kumar et al., 2017; Wiwi et al., 2004)}(J. P. Hernandez, L. C. Mota, W. Huang, et al., 
2009), are not the reason for the sexual dimorphism in obesity. It is still possible that 
some of the transcription factors that regulate Cyp2b and are predominantly expressed in 
females such as CAR, PXR, and FoxA2 (Hashita et al., 2008; J. P. Hernandez, L. C. 
Mota, W. Huang, et al., 2009; Ledda-Columbano et al., 2003; K Spruiell et al., 2014) are 
in part responsible for the murine female resistance to obesity.   
  HFD-fed Cyp2b-null females were the only mice with increased serum 
triglycerides and these mice also present with higher ALT levels, suggesting that the 
combination of a HFD and Cyp2b-knockout caused some liver damage in females. In 
contrast to males, Cyp2b-null females did not show significant perturbations in 
liver:serum ratios probably because neither serum nor liver triglycerides were perturbed 
as much in females, but also because both serum and liver triglycerides went up in HFD-
fed Cyp2b-null female mice. Ratios are often used to increase the sensitivity of data from 
two physiological systems (liver:serum; TAG:HDL) or sexually dimorphic comparison 
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(steroid metabolites)(Di Bonito et al., 2015; R Kumar et al., 2017). Therefore, we also 
examined liver triglyceride:serum FFA ratios, and found they varied significantly in 
HFD-fed Cyp2b-null female mice.  
Serum cholesterol and HDL were also significantly increased in Cyp2b-null male 
mice compared to WT male mice. Increased serum cholesterol coupled with decreased 
serum triglycerides was observed previously in diet induced obesity studies performed in 
B6 mice (Eisinger et al., 2014), and recent studies indicate that high cholesterol is 
associated with progressive NAFLD and a potential marker for NASH (Kerr & Davidson, 
2012; Walenbergh & Shiri-Sverdlov, 2015). ALT is also associated with HDL, NAFLD 
and metabolic syndrome in men, but not women (Chen, Chen, Dai, Chen, & Fang, 2008). 
Overall, multiple serum and liver lipid parameters that are associated with NAFLD and 
NASH were perturbed (Arguello, Balboa, Arrese, & Zanlungo, 2015; K. Peng, Mo, & 
Tian, 2017), indicating that Cyp2b-null male mice are progressing towards hepatic 
steatosis and NASH. However, the lack of changes in LDL and VLDL suggest that 
accompanying cardiovascular disease may not be a chronic issue (Di Bonito et al., 2015; 
Kawano & Cohen, 2013). Histopathology did not show any pathological changes 
indicative of significant liver injury, although liver lipids were increased by a HFD and 
exacerbated by Cyp2b-knockout as measured by Oil Red O. However, our research was 
performed for only 10-weeks and recent work indicates B6 mice are relatively resistant to 
fatty liver disease and take upwards of 22-weeks to develop NAFLD (Asgharpour et al., 
2016). Therefore this study was not performed for long enough to fully assess progressive 
NAFLD or NASH, but primarily obesity and early stage steatosis. Long-term (22-weeks) 
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or better yet, methionine-choline deficient dietary studies are needed to determine if the 
Cy2b-null mice may be susceptible to NASH.  
B-OHB is increased from the breakdown of fatty acids in response to starvation 
and consistent with higher WAT weight (Jastreboff et al., 2014). Taken together, WAT, 
liver triglycerides, serum cholesterol, and B-OHB levels were all increased in Cyp2b-null 
mice, primarily in males, indicating an unhealthy lipid state with increased ketosis and β-
oxidation sometimes regardless of dietary treatment. This combined with perturbations in 
transcription associated with lipid metabolism, distribution and homeostasis demonstrates 
a role for Cyp2b members in lipid metabolism and obesity.  
Several unsaturated fatty acids are metabolized by Cyp2b members including 
arachidonic acid (Bishop-Bailey, Thomson, Askari, Faulkner, & Wheeler-Jones, 2014; 
Du et al., 2005), anandamide (Sridar, Snider, & Hollenberg, 2011), and potentially 
linoleic acid (Bylund et al., 1998; Robert D. Finn et al., 2009). Some data indicates high 
affinity for fatty acids (Du et al., 2005); however, most Cyp2b-mediated metabolism 
likely occurs under high fat diet conditions or directly after a meal high in PUFA (Robert 
D. Finn et al., 2009; Sridar et al., 2011). It is interesting to consider that a Cyp2b-
mediated product of PUFA metabolism such as an epoxyecosatrienoic acid produced 
from AA or anandamide, may perform signaling functions that mediate lipid uptake, 
distribution, or metabolism in the liver, WAT, or other tissues following a diet high in 
PUFAs.  
  In summary, the data presented indicates that the hepatic Cyp2b genes are 
important in fatty acid metabolism. Cyp2b-null mice are diet-induced obese and show 
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greater susceptibility to obesity than WT mice. HFD-fed Cyp2b-null male mice present 
increased WAT mass, liver triglycerides, serum cholesterol, and B-OHB. In addition, the 
increased accumulation of liver triglycerides and decreased serum triglycerides in ND- 
and HFD-fed Cyp2b-null male mice suggests difficulty in allocating and utilizing fatty 
acids. The ND-fed Cyp2b-null male mice also showed a similar gene expression profile 
to the HFD-fed WT male mice as demonstrated by RNAseq, indicating increased lipids 
and perturbed lipid signaling regardless of diet in the Cyp2b-null mice. Taken together, 
this data indicates a role of Cyp2b in fatty acid metabolism and obesity, and therefore, it 
is certainly possible that chemical inhibition of Cyp2b members by dietary fats, 
pesticides, plasticizers, and pharmaceuticals could elicit similar effects on lipid 
metabolism and elicit obesity.  
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Supplementary Material 2.2:  Timeline of the different procedures performed 
during a 10-week treatment of 9-10 week old WT and Cyp2b-null mice with either a 
normal diet (ND; 6.2%) or a high-fat diet (HFD; 60% fat).  
 
 
 
 
 
 
 
 
Supplementary Material 2.3: Feed consumption of WT and Cyp2b-null mice during 
10-weeks of diet-induced obesity treatment. Feed consumption was measured by 
weighing the food every alternate day. Data are presented as mean calories + 
SEM.Statistical significance was determined by one-way ANOVA followed by Fisher’s 
LSD as post-hoc test (n= 8-9).‘a’ indicates WT ND are different than Cyp2b9/10/13-null 
ND, ‘b’ indicates WT ND are different than WT HFD, ‘c’ indicates Cyp2b9/10/13-null 
ND are different than Cyp2b9/10/13-null HFD, ‘d’ indicates WT HFD different than 
Cyp2b9/10/13-null HFD. 
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Supplementary Material 2.4: Differentially expressed gene list of WT HFD mice 
compared to WT ND mice. Up- and down-regulated differentially expressed genes from 
raw read counts in WT HFD male mice were determined using EdgeR (p < 0.05, FDR < 
0.1). Data published in Heintz et al. 2019, J Nutr Biochem. 
 
Supplementary Material 2.5: Shared differentially expressed gene list between 
Cyp2b-null ND and WT HFD mice compared to WT ND mice. Up- and down-
regulated differentially expressed genes from raw read counts in Cyp2b-null ND and WT 
HFD male mice were determined using EdgeR (p < 0.05, FDR < 0.1) and differentially 
expressed genes present in both treatment groups are listed. Data published in Heintz et 
al. 2019, J Nutr Biochem. 
 
Supplementary Material 2.6: Differentially expressed gene list of Cyp2b-null ND 
mice compared to WT ND mice. Up- and down-regulated differentially expressed genes 
from raw read counts in Cyp2b-null ND male mice were determined using EdgeR (p < 
0.05, FDR < 0.1). Data published in Heintz et al. 2019, J Nutr Biochem. 
 
Supplementary Material 2.7: Differentially expressed gene list of WT HFD mice 
compared to Cyp2b-null HFD mice. Up- and down-regulated differentially expressed 
genes from raw read counts in HFD-fed Cyp2b-null male mice compared to HFD-fed 
WT mice were determined using EdgeR (p < 0.05, FDR < 0.1). Data published in Heintz 
et al. 2019, J Nutr Biochem. 
 
 
Supplementary Material 2.8:  Venn Diagram showing shared differentially 
expressed genes between male and female Cyp2b-null ND mice compared to WT-
ND mice. 
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Supplementary Material 2.9: Western blots show changes in Cyp2b protein 
expression between WT and Cyp2b9/10/13-null mice. Microsomes were prepared by 
homogenizing frozen livers followed by differential centrifugation as described 
previously (Van der Hoeven & Coon, 1974). Protein concentrations were determined 
using Bradford reagent (Bio-Rad).  Immunoblots were performed using 30 μg of 
microsomal protein separated on 12% SDS-polyacrylamide gels (BioRad). Protein was 
transferred onto 0.2μm polyvinylidene difluoride (PVDF) membrane and were 
recognized using polyclonal antibodies to to Cyp2a (Invitrogen, Carlsbad, CA USA), 
Cyp3a (Chemicon International, Temecula CA USA), Cyp2b (previously developed in 
house)(J P Hernandez, L C Mota, W Huang, D D Moore, & W S Baldwin, 2009; Mota et 
al., 2010), Cyp4a (Thermofisher Scientific, Rockford IL USA). β-actin (Sigma Aldrich, 
St.Louis MO USA) was used as the reference protein.  Chemiluminescent western blot 
detection was done using alkaline phosphatase conjugated secondary antibodies, where in 
anti-mouse IgG (Immunostar, Bio-Rad) was used to visualize β-actin and anti-rabbit IgG 
(Immunostar, Bio-Rad) was used to visualize CYPs. Protein was quantified by 
densitometry (Quality One, BioRad, Hercules, CA). Relative density is shown as the 
average of two samples using -actin as the reference gene.  Data represents relative 
mean of WT compared to Cyp2b-null mice of the same gender and dietary teatment. 
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Statistical differences were determined by Student’s t-tests (n = 2) (* p < 0.05  ** p < 
0.01). 
 
Supplementary Material 2.10: GO term enrichment analysis list of up and down-
regulated genes in Cyp2b-null ND mice compared to WT ND mice. GOSeq, a GO 
term enrichment analysis program was used to adjust for gene length and expression bias 
of differentially expressed up- and down-regulated genes in Cyp2b-null ND male and 
female mice. Data published in Heintz et al. 2019, J Nutr Biochem. 
 
Supplementary Material 2.11: Lists of altered KEGG pathways between different 
treatment groups. Up- and down-regulated differentially expressed genes were 
annotated to NCBI Gene IDs using InterPro and genes with log2FC > 1.0 were uploaded 
into KEGG Mapper (http://www.genome.jp/kegg/). Data published in Heintz et al. 2019, 
J Nutr Biochem. 
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3.0 Abstract 
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease; 
however, progression to nonalcoholic steatohepatitis (NASH) is associated with most 
adverse outcomes. CYP2B metabolizes multiple xeno- and endobiotics, and male Cyp2b-
null mice are diet-induced obese (DIO) with increased NAFLD. However, the DIO study 
was not performed long enough to assess progression to NASH. Therefore, to assess the 
role of Cyp2b in fatty liver disease progression from NAFLD to NASH, we treated 
wildtype (WT) and Cyp2b-null mice with a normal diet (ND) or choline-deficient, L-
amino acid-defined high fat diet (CDAHFD) for 8 weeks and determined metabolic and 
molecular changes. CDAHFD-fed WT female mice gained more weight and had greater 
liver and white adipose tissue mass than their Cyp2b-null counterparts; males 
experienced diet-induced weight loss regardless of genotype. Serum biomarkers of liver 
injury increased in both CDAHFD-fed female and male mice; however CDAHFD-fed 
Cyp2b-null females exhibited significantly lower serum ALT, AST, and ASP 
concentrations compared to WT mice, indicating Cyp2b-null females were protected 
from liver injury. In both genders, hierarchical clustering of RNA-seq data demonstrates 
several gene ontologies responded differently in CDAHFD-fed Cyp2b-null mice 
compared to WT mice (lipid metabolism > fibrosis > inflammation). Oil Red O staining 
and direct triglycerides measurements confirmed that CDAHFD-fed Cyp2b-null females 
were protected from NAFLD. CDAHFD-fed Cyp2b-null mice showed equivocal changes 
in fibrosis with transcriptomic and serum markers suggesting less inflammation due to 
glucocorticoid-mediated repression of immune responses. In contrast to females, 
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CDAHFD-fed Cyp2b-null males had higher triglyceride levels. Results indicate that 
female Cyp2b-null mice are protected from NAFLD while male Cyp2b-null mice are 
more susceptible to NAFLD, with few significant changes in NASH development. This 
study confirms that increased NAFLD development does not necessarily lead to 
progressive NASH.  Furthermore, it indicates a role for Cyp2b in fatty liver disease that 
differs based on gender.  
 
Keywords: nonalcoholic fatty liver disease (NAFLD); corticosterone; P450; Cyp2b; 
RNAseq 
 
 
3.1 Introduction 
Liver disease often progresses from nonalcoholic fatty liver disease (NAFLD) to 
more severe diseases such as nonalcoholic steatohepatitis (NASH), fibrosis including 
cirrhosis, and liver cancer (Vernon, Baranova, & Younossi, 2011). NAFLD is the most 
common liver disease and increasing in prevalence, with 10-30% of U.S. citizens and 
25% of people worldwide diagnosed (Younossi et al., 2016). NAFLD is closely linked to 
obesity (Pallayova & Taheri, 2014) and is the result of the hepatic manifestation of the 
metabolic syndrome (Chalasani et al., 2012). NAFLD is defined as the presence of > 5% 
hepatic steatosis in the absence of other liver diseases (Younossi et al., 2016), yet less 
than 25% of patients with NAFLD develop NASH (Singh et al., 2015). In some cases the 
hepatic intracellular accumulation of lipids in fatty liver disease can develop into NASH 
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as inflammation, injury and fibrosis progress due to anti-lipotoxic protection failure 
(Singh et al., 2015). NASH is recognized as one of the primary causes of cirrhosis in 
adults and is currently the second most prominent cause for liver transplants in the United 
States (Wong et al., 2015). Studies have shown that steatosis may not affect NASH 
development (Tilg & Moschen, 2010); therefore, the pathogenesis of NASH remains 
controversial. However, fibrosis progression occurs in most patients with NASH and 
cirrhosis is the main histological feature associated with mortality of NASH patients 
(Angulo et al., 2015).  
Regardless of how these diseases progress, dietary factors are the primary source 
for both NAFLD and NASH (Tilg & Moschen, 2010). A rise in consumption of foods 
high in polyunsaturated fatty acids (PUFAs) including vegetable and soybean oil parallels 
the increase in obesity in the United States and worldwide since the 1970s (Blasbalg, 
Hibbeln, Ramsden, Majchrzak, & Rawlings, 2011). During inflammation, PUFAs found 
in hepatic membranes, are released by phospholipase A2. These free PUFAs are then 
oxidized by cyclooxygenase, lipoxygenase, or cytochrome P450s (CYPs) to form 
physiologically significant metabolites. CYP-derived epoxides include the 
epoxyeicosatrienoic acids (EETs) produced from the metabolism of arachidonic acid 
(AA) (Fer et al., 2008; Funk, 2001); the epoxyoctadecenoic acids (EpOMEs) from 
linoleic acid; the epoxyoctadecadienoic acids from α-linolenic acid; the 
epoxyeicosatetraenoic acids from eicosapentaenoic acid (EPA); and the 
epoxydocosapentaenoic acids from docosahexaenoic acid (DHA)(Bishop-Bailey, 
Thomson, Askari, Faulkner, & Wheeler-Jones, 2014; Konkel & Schunck, 2011). Some 
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PUFAs regulate CYP activity, such as DHA which binds to the retinoid X receptor 
(RXR) (Urquiza et al., 2000) and prevents constitutive androstane receptor (CAR) 
translocation to the nucleus and subsequent transcription of Cyp2b and other CAR 
biomarker proteins (C.-C. Li, Lii, Liu, Yang, & Chen, 2007). Conversely, linoleic acid 
induces Cyp2b expression via activation of CAR (Finn, Henderson, Scott, & Wolf, 
2009). 
In the liver, CAR regulates both human and murine Cyp2b genes (Hernandez, 
Mota, & Baldwin, 2009; Hoek-van den Hil et al., 2014; Wei, Zhang, Egan-Hafley, Liang, 
& Moore, 2000). Cyp2b9, Cyp2b10, and Cyp2b13 make up the primary hepatic Cyp2b 
genes in mice, and CYP2B6, the only CYP2B member in humans is highly expressed in 
the liver (Wang & Tompkins, 2008). Several studies indicate a role for Cyp2b in 
metabolizing fatty acids. Murine Cyp2b19, found in keratinocytes, metabolizes 
arachidonic acid to 11,12- and 14,15-EET that are important for a functional epidermis 
(Keeney et al., 1998).  However, human CYP2B6 does not produce significant 
arachidonic acid metabolites (Bylund, Kunz, Valmsen, & Oliw, 1998). Interestingly, 
anandamide, an arachidonic acid-derived endogenous cannabinoid, is metabolized by 
CYP2B6 into four EET metabolites (Sridar, Snider, & Hollenberg, 2011), including 5,6-
epoxyeicosatetraenoic acid ethanolamide, which has been found to be a potent agonist of 
the peripheral cannabinoid receptor, CB2 (Snider, Nast, Tesmer, & Hollenberg, 2009).  
Finn et al (Finn et al., 2009) found that loss of all hepatic CYP activity in the 
hepatic P450 oxidoreductase (POR)-null mouse model led to hepatic steatosis and the 
induction of Cyp2b10 through the activation of CAR, a putative anti-obesity receptor 
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(Gao, He, Zhai, Wada, & Xie, 2009; Hernandez, Mota, & Baldwin, 2009). The authors 
hypothesized that Cyp2b and to a lesser extent Cyp3a enzymes play a backup role in the 
metabolism and protection from the build-up of fatty acids in the liver (Finn et al., 2009). 
Additional studies show CAR’s important role in recognizing hepatic lipids via fat 
metabolism regulation (Dong et al., 2009), caloric restriction (Maglich et al., 2004), 
obesity (Maglich, Lobe, & Moore, 2009), and bile acid homeostasis (Saini et al., 2004). 
Furthermore, several studies performed in mice demonstrated that Cyp2b9 exhibited the 
highest increased expression by RNAseq following a high fat diet (HFD) (Hoek-van den 
Hil et al., 2015; Leung, Trac, Du, Natarajan, & Schones, 2016).  
In addition, RNAi-based Cyp2b-knockdown mice on an FVB/NJ background 
display increased adiposity and body weight with age as well as a decreased ability to 
eliminate PUFA-rich corn oil, primarily in males (Damiri, Holle, Yu, & Baldwin, 2012). 
In our recently published research, C57Bl/6J (B6)-Cyp2b9/10/13-null (Cyp2b-null) mice 
lacking the predominantly hepatic Cyp2b members, Cyp2b9, Cyp2b10, and Cyp2b13, are 
diet-induced obese in males with moderate increases in steatosis. Interestingly, the 
Cyp2b-null male mice developed some steatosis regardless of diet; however, they showed 
very little hepatic inflammation, which is unusual, suggesting Cyp2b-null mice may be 
protected from developing NASH (Heintz, Kumar, Rutledge, & Baldwin, 2019).  This 
study was only carried out for 10 weeks and new research indicates that B6 mice fed a 
high fructose + 42% Kcal HFD for up to 22-weeks failed to form NASH following 
NAFLD development. Therefore, the previous study was not equipped to investigate 
NASH development in Cyp2b-null mice. Based on the lack of inflammation in HFD-fed 
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Cyp2b-null mice, we predict that diet-induced NASH will increase hepatic triglycerides 
in Cyp2b-null mice. This increase in triglycerides will provide protection from liver 
inflammation and injury compared to their WT counterparts, as free fatty acids and their 
metabolites are more lipotoxic than inert triglycerides (Alkhouri, Dixon, & Feldstein, 
2009).  
We used our previously developed Cyp2b-null mouse model (Heintz et al., 2019; 
Kumar et al., 2017) to test whether a lack of Cyp2b plays a role in the progression of liver 
disease. Cyp2b-null and WT mice (n = 9) were fed either a choline-deficient, L-amino 
acid-defined, high fat diet (CDAHFD) or normal diet (ND) for 8 weeks. The CDAHFD is 
similar to a methionine-choline deficient (MCD) diet model for the determination of 
NAFLD/NASH.  However, the MCD diet exhibits severe body weight loss which makes 
long term studies difficult (Rizki et al., 2006).  CDAHFD-fed mice do not lose weight, 
but instead gradually gain weight and develop steatohepatitis and fibrosis more rapidly 
(Matsumoto et al., 2013). Both physiological and biochemical changes, including 
differential gene expression via RNA sequencing were examined in treated WT and 
Cyp2b-null mice. Results from this study show that a lack of Cyp2b causes gender-based 
differences in response to diet-induced NASH treatment.  
 
 
3.2 Materials and Methods 
3.2.1 Choline-deficient, L-amino acid-defined high-fat diet (CDAHFD):  
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Animal care and associated procedures were approved by Clemson University’s 
Institutional Animal Care and Use committee. Cyp2b9/10/13-null (Cyp2b-null) mice 
were developed using CRISPR/Cas9 technology on the C57Bl/6J (B6) background mice 
as previously described (Heintz et al., 2019; Kumar et al., 2017). Wildtype (WT) B6 mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) at 6 weeks of age 
and were acclimated for 4 weeks prior to treatment. WT and Cyp2b-null male and female 
(10 weeks old) mice were divided into groups (n=9) and fed either a normal chow diet 
(ND; Harlan, 3.1 Kcal/g: 18.6% protein, 6.2 % fat, 44.2% carbohydrates; Madison, WI 
USA) or a CDAHFD (Research Diets, 5.2 Kcal/g: 18% protein, 62% fat, 20% 
carbohydrates, 0.1% methionine; New Brunswick, NJ, USA) for 8 weeks (Matsumoto et 
al., 2013). Weight gain was monitored weekly and feed consumption was measured every 
other day. Fasting blood glucose levels were determined during weeks 4 and 6. Glucose 
tolerance tests (GTT) were performed during week 6. At the end of the study, mice were 
anesthetized and blood collected by heart puncture prior to euthanasia.  Liver, kidney, 
white adipose tissue (WAT), and brown adipose tissue (BAT) were excised and weighed. 
All tissues were immediately snap frozen with liquid nitrogen and stored at -80°C or 
placed in 10% formalin (Fisher, Fairlawn, NJ USA) for further studies. A timeline of 
procedures is provided in Supplementary Material (S3.1).  
 
3.2.2 Fasting Blood Glucose and Glucose tolerance tests:  
During weeks 4 and 6, mice were fasted for 4 hours and fasting blood glucose was 
determined using an Alphatrak 2 (AlphaTRAK, Chicago, IL USA) blood glucose meter 
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following tail bleed. During week 6, glucose tolerance was determined following an 
intraperitoneal injection of 1g/kg of their body weight of D-glucose (Sigma Ultra, St. 
Louis, MO USA) with blood glucose readings every 20 min for the first hour and every 
30 min for the second hour as described previously (Ayala et al., 2010; Heintz et al., 
2019). 
 
3.2.3 Serum biomarker panel:  
Blood samples were collected by heart puncture and incubated at room 
temperature for 30 min followed by centrifugation at 6000 rpm for 10 min. Serum from 
each sample was transferred into a fresh tube and aliquots shipped on dry ice to Baylor 
College of Medicine’s Comparative Pathology Laboratory (Houston, TX USA) for 
determination of tissuse damage serum marker concentrations including alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), 
and creatine kinase (CK), and lactate dehydrogenase (LDH).  In addition, serum glucose, 
cholesterol, triglycerides, high density lipoprotein (HDL), low density lipoprotein (LDL), 
very low density lipoprotein (VLDL), phosphorus, calcium, and direct, indirect, and total 
bilirubin were quantified.  Serum parameters were determined using a Beckman Coulter 
AU480 chemistry analyzer (Atlanta, GA, USA) and the appropriate Beckman Coulter 
biochemical kits according to the manufacturer’s instructions.  
 
3.2.4 Serum concentrations of leptin, adiponectin, corticosterone, β-hydroxybutyrate, and 
C-reactive protein:   
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Serum leptin, adiponectin and β-hydroxybutyrate concentrations were determined 
using EIA or colorimetric kits from Cayman Chemical (Ann Arbor, MI), and serum 
corticosterone and C-reactive protein (CRP) from Abcam (Cambridge, MA USA) 
according to the manufacturer’s instructions.    
 
3.2.5 Liver triglyceride, cholesterol, and hydroxyproline:  
Liver triglycerides, cholesterol and hydroxyproline were extracted and quantified 
as described previously (R. Kumar, E. J. Litoff, W. T. Boswell, & W. S. Baldwin, 2018) 
using colorimetric kits from Cayman Chemical (triglycerides only) and Abcam according 
to the manufacturer’s instructions.  
 
3.2.6 Histopathological analysis:  
During necropsy, clean liver slices were placed in 10% formalin (Fisher) or snap 
frozen in liquid nitrogen for staining. Slices placed in 10% formalin were stained with 
Hematoxylin and Eosin (H&E) or Masson’s trichrome at Colorado Histoprep (Fort 
Collins, CO USA). Slices snap frozen in liquid nitrogen were stained with Oil Red O at 
Baylor College of Medicine’s Comparative Pathology Laboratory using standard 
protocols (Dong et al., 2009). The liver lipid droplets stained by Oil Red O were 
quantified by total area of each sample imaged (400x magnification) using ImageJ Fiji 
(Schindelin et al., 2012). In Fiji, the scale bar was set to equal 0.05 mm and threshold 
color to red, with red pass selected and green/blue pass deselected. Red coverage of 
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particles was set to 130-255 and size (mm2) equals 0.00001-infinity for all images 
measured. 
 
 3.2.7 Immunoblots:  
Nuclear protein extracts were prepared by homogenizing frozen livers followed 
by differential centrifugation using a Nuclear Protein Extraction kit  (Cayman Chemical). 
Protein concentrations were determined using Bradford reagent (Bio-Rad).  Immunoblots 
were performed using 30 μg of nuclear protein separated on a 12% SDS-polyacrylamide 
gel (BioRad) and then protein was transferred onto a 0.2μm polyvinylidene difluoride 
(PVDF) membrane. Specific proteins were recognized using polyclonal antibodies to 
Proliferating Cell Nuclear Antigen (PCNA) (ThermoFisher, Waltham, MA) and β-actin 
(Sigma Aldrich, St.Louis MO USA) as the reference protein.  Chemiluminescent 
immunoblot detection was done using alkaline phosphatase conjugated secondary 
antibodies where anti-rabbit IgG (Immunostar, Bio-Rad) was used to visualize PCNA and 
anti-mouse IgG (Immunostar, Bio-Rad) was used to visualize β-actin. Protein bands were 
quantified by densitometry (Image Lab 6.0.1, BioRad, Hercules, CA). Relative density is 
shown as the average of two samples using β-actin as the reference gene. Data are 
presented as relative mean of WT ND compared to each treatment group.  
 
3.2.8 RNA sequencing (RNAseq):  
Liver samples were stored in RNAlater Stabilization Solution (Invitrogen, 
Carlsbad, CA USA) at -80°C. Total RNA was extracted from mouse livers of each 
86 
treatment group using TRIzol (Ambion, Carlsbad, CA USA) and quantified on a Qubit 
2.0 Fluorometer. RNA integrity number (RIN) was determined with an Agilent 2100 
Bioanalyzer (place) to assess RNA quality, and samples with a RIN > 8.0 were 
determined to be of high quality and used for next generation sequencing. Libraries were 
prepared using NEB Next Ultra RNA Library Prep kit. Samples were sequenced to an 
average sequencing depth of 20,000,000 read pairs with a 2x150 paired-end module using 
a NovaSeq 6000. Quality metrics were checked using FastQC on all samples sequenced, 
and Trimmomatic was used to trim low quality bases. Trimmed reads were aligned to the 
Mus musculus reference genome (GCF_000001635.25_GRCm38.p6) using GSNAP, and 
99.8% of the trimmed reads aligned. Subread feature counts software found reads that 
aligned with known genes. Raw read counts and EdgeR were used to determine 
differential gene expression (Huber et al., 2015). Series GSE137449 containing the 
RNAseq data has been uploaded to the Gene Expression Omnibus (GEO). 
 
Differential gene expression by multiple comparisons for all treatment groups was 
determined by EdgeR. Results were filtered for p- and FDR values < 0.05. Normalized 
counts from the remaining genes post-filtering were compared between groups by 
Student’s t-tests to determine significantly different (p < 0.05) expressed genes. Heatmap 
hierarchical cluster analysis by Euclidean distance using Ward’s method was performed 
with Heatmap.2 in R (https://www.r-project.org/) using significant differentially 
expressed genes with a log2FC > 1.0 between CDAHFD-fed Cyp2b-null and CDAHFD-
fed WT groups. GOSeq, a gene ontology (GO) term enrichment analysis program was 
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used to adjust for gene length and expression bias, and create GO term lists for the 
significant differentially expressed genes between CDAHFD-fed groups in female and 
male mice(Young, Wakefield, Smyth, & Oshlack, 2010). Significantly (p < 0.05) 
enriched GO terms were visualized in Revigo, which reduces enriched term redundancy 
and displays the remaining GO terms in a scatterplot (Supek, Bošnjak, Škunca, & Šmuc, 
2011). Differentially expressed genes acoss treatment groups were annotated using 
PANTHER (http://www.pantherdb.org/) and InterPro (Finn et al., 2017), and 
differentially expressed genes between CDAHFD-fed Cyp2b-null and CDAHFD-fed WT 
mice were entered into KEGG Mapper (Kanehisa, Furumichi, Tanabe, Sato, & 
Morishima, 2017) to determine and visualize biochemical pathways perturbed by diet-
induced NASH and/or a lack of Cyp2b enzymes (Heintz et al., 2019). 
 
3.2.9 Quantitative Real-time Polymerase Chain Reaction (qPCR): 
cDNA was prepared from RNA with MMLV reverse transcriptase, a dNTP 
mixture, and random hexamers (Promega Corporation, Madison WI). qPCR was used to 
quantify changes in gene expression using previously published primers (R Kumar, E J 
Litoff, W T Boswell, & W S Baldwin, 2018) and newly developed primers for genes 
involved in inflammation, fibrosis, and lipid metabolism (S3.1 Table). PCR efficiency 
was determined based on a standard curve preparedusing a sample mixture containing all 
the cDNA samples diluted at 1:1, 1:4, 1:16, 1:64, 1:256 and 1:1024 in triplicate with 
0.25X RT2 SybrGreen (Qiagen Frederick, MD USA) on a CFX 96-well Real-Time PCR 
detection system (Bio-Rad).  18S was used as the reference gene and Muller’s inverted 
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equation was used to quantify differences in gene expression (Muller, Janovjak, Miserez, 
& Dobbie, 2002; Roling, Bain, & Baldwin, 2004). 
 
3.2.10 Tests of statistical significance:  
Data are presented as mean + SEM (n = 8-9). Statistical analyses were performed 
by one-way ANOVA followed by Fisher’s LSD as the post-hoc using Graphpad Prism 
version 7 (GraphPad Software, San Diego, CA). A p-value < 0.05 was considered 
statistically significant. 
 
 
3.3 Results 
3.3.1 Changes in body mass following a CDAHFD: 
CDAHFD-fed WT female mice gained the most weight; significantly more than 
CDAHFD-fed Cyp2b-null female mice after only two weeks and this trend continued 
throughout the study.  This indicates the lack of Cyp2b enzymes had a substantial 
repressive effect on CDAHFD-mediated weight gain in females (Fig 3.1A). In contrast, 
CDAHFD-fed male mice weighed significantly less than their normal diet counterparts, 
indicating that diet was the primary modifier of weight in males, not genotype (Fig 3.1B). 
Previous research indicated one of the benefits of a CDAHFD is no weight loss 
(Matsumoto et al., 2013); nevertheless, there was little weight gain in male mice fed a 
CDAHFD (Fig 3.1B). Mice fed a CDAHFD consumed more calories compared to their 
ND counterparts; however, genotype did not effect calorie intake (S3.2). Therefore, the 
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differences in weight between CDAHFD-fed WT and CDAHFD-fed Cyp2b-null female 
mice cannot be explained by alterations in caloric uptake.  
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Figure 3.1. Changes in body weight and organ weight over the 8 weeks of diet-
induced NASH treatment. Body and select organ weights of female (A) and male (B) 
WT and Cyp2b-null mice were monitored during the 8 weeks of treatment. (C) 
Immunoblots of PCNA in female and male mice with b-actin as the reference gene. Data 
are presented as mean ± SEM. Statistical significance was determined by one-way 
ANOVA followed by Fisher’s LSD as the post-hoc test (n=9; n=2 for immunoblots). An 
‘a’ indicates ND-fed WT different than CDAHFD-fed WT, ‘b’ indicates ND-fed Cyp2b-
null different than CDAHFD-fed Cyp2b-null, ‘c’ indicates ND-fed WT different than 
ND-fed Cyp2b-null, ‘d’ indicates CDAHFD-fed WT different than CDAHFD-fed Cyp2b-
null.  
 
 
The weight gain in CDAHFD-fed WT female mice was in part attributed to 
greater liver and white adipose tissue (WAT) mass than CDAHFD-fed Cyp2b-null mice 
(Fig 3.1A). The lower liver mass in Cyp2b-null females following a CDAHFD suggests a 
protective effect of Cyp2b loss on liver proliferation or the development of fatty liver 
disease; however, liver weight decreased in relative proportion to body weight based on 
the hepatosomatic index (HSI). In contrast to females, ND-fed Cyp2b-null male mice 
accumulated more white adipose tissue than all other groups (Fig 3.1B). The increase in 
white adipose tissue in ND-fed Cyp2b-null males is consistent with previous results in 
Cyp2b-null mice (Heintz et al., 2019).  Similar to females, CDAHFD-fed Cyp2b-null 
male livers and WAT weighed less than CDAHFD-fed WT mice; however, liver weight 
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was altered in proportion to body weight (HSI) (Fig 3.1B). To determine if liver weight 
or HSI was more indicative of cell proliferation, we examined proliferative cell nuclear 
antigen (PCNA) protein levels by immunoblotting (Fig 3.1C). PCNA levels increased in 
response to a CDAHFD.  This response was significantly greater in the male CDAHFD-
fed Cyp2b-null mice than the male CDAHFD-fed WT mice, indicating that at least in 
Cyp2b-null males liver weight was likely increased due to greater proliferation.     
 
3.3.2 Serum glucose and glucose tolerance in response to a CDAHFD are gender-
dependent:   
Fasting serum glucose levels measured during weeks 4 and 6 were significantly 
decreased by the CDAHFD diet in males, but not females (Fig 3.2AB). Fasting serum 
glucose was not effected by the combination of diet and genotype in either sex. However, 
fasting serum glucose was increased in ND-fed Cyp2b-null female (25%) and male 
(32%) mice at week 6 (Fig 3.2B), consistent with previous findings (Heintz et al., 2019). 
Glucose tolerance tests (GTT) were performed to determine if Cyp2b-null mice have 
reduced ability to respond to glucose, a biomarker of metabolic disease. ND-fed Cyp2b-
null female mice were slower to clear serum glucose compared to ND-fed WT females; 
however, there were no differences attributed to diet or a combination of genotype and 
diet (Fig 3.2CD). In contrast to females, ND-fed Cyp2b-null males showed no difference 
in glucose tolerance compared to WT mice; CDAHFD-fed males exhibited a significantly 
faster response to glucose (better glucose tolerance) than ND-fed males regardless of 
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genotype (Fig 3.2CD). In general, poor glucose tolerance was genotype dependent in 
females and weight or diet dependent in males.   
 
Figure 3.2. Gender-dependent differences in serum glucose and glucose tolerance in 
response to CDAHFD. Fasting blood glucose levels were measured during weeks 4 (A) 
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and 6 (B) in female and male mice. During week 6 glucose tolerance tests were 
performed on all treatment groups (C) and glucose measured at 20, 40, 60, 90, and 120 
minutes after the glucose challenge. Results are also represented as area under the curve 
(D). Data are presented as mean serum glucose ± SEM. Statistical significance was 
determined by one-way ANOVA followed by Fisher’s LSD as the post-hoc test (n= 9). 
An ‘a’ indicates ND-fed WT different than CDAHFD-fed WT, ‘b’ indicates ND-fed 
Cyp2b-null different than CDAHFD-fed Cyp2b-null, ‘c’ indicates ND-fed WT different 
than ND-fed Cyp2b-null.  No asterisk indicates a p-value < 0.05, * indicates a p-value < 
0.01, and ** indicates a p-value < 0.0001. 
 
 
3.3.3 Serum biomarkers indicate Cyp2b-loss is protective against liver injury in females: 
Common serum biomarkers of liver injury such as ALT, AST, and ALP increased 
in female mice fed a CDAHFD; however, CDAHFD-fed Cyp2b-null females exhibited 
significantly lower serum levels of these enzymes (28%, 42%, 29% lower respectively) 
compared to their WT counterparts, indicating Cyp2b-null female mice are protected 
from diet-induced NASH (Fig 3.3A). H&E staining revealed cytoplasmic vacuolization, 
a marker of cell death (Shubin, Demidyuk, Komissarov, & Rafieva, 2016) caused by the 
CDAHFD; however, no significant differences in pathology were observed between WT 
and Cyp2b-null mice (Fig 3AB). Male mice fed a CDAHFD showed increased levels of 
serum ALT, AST, and ALP regardless of genotype (Fig 3.3B). CDAHFD-fed Cyp2b-null 
males had higher levels of creatine kinase (CK) (1.5-fold) compared to all other treatment 
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groups including their WT counterparts, suggesting that Cyp2b-null males are more 
susceptible to CDAHFD-induced damage in other tissues such as cardiac and skeletal 
muscle (Yen et al., 2017), the opposite of females (Fig 3.3B).  
 
Figure 3.3. Biomarkers of liver tissue damage in ND and CDAHFD-fed WT and 
Cyp2b-null mice. Serum ALT, AST, ALP, and CK concentrations were measured, and 
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histopathological changes were evaluated by H&E staining of liver tissues from female 
(A) and male (B) mice. Images were taken at 100x (0.2 mm) and 400x (0.05 mm) 
magnification. Data are presented as mean ± SEM. Statistical significance was 
determined by one-way ANOVA followed by Fisher’s LSD as the post-hoc test (n=5). 
An ‘a’ indicates ND-fed WT different than CDAHFD-fed WT, ‘b’ indicates ND-fed 
Cyp2b-null different than CDAHFD-fed Cyp2b-null, ‘c’ indicates ND-fed WT different 
than ND-fed Cyp2b-null, ‘d’ indicates CDAHFD-fed WT different than CDAHFD-fed 
Cyp2b-null. No asterisk indicates a p-value < 0.05, * indicates a p-value < 0.01, and ** 
indicates a p-value < 0.0001. 
 
 
3.3.4 Perturbed gene expression in Cyp2b-null mice fed a CDAHFD: 
RNA-seq was performed on liver samples from all treatment groups to further 
investigate the role of Cyp2b in the development and progression of NASH because of 
the observed changes in serum markers of liver injury in the CDAHFD-treated groups, 
especially within the relatively resistant Cyp2b-null female mice. A CDAHFD caused 
numerous changes in gene expression relative to a ND (S3.3). Analysis of the 
differentially expressed genes between CDAHFD-fed Cyp2b-null and WT groups 
(log2FC > 1.0; S3.4) by hierarchical clustering revealed numerous CDAHFD-induced 
changes in gene expression in both female and male WT mice (Fig 3.4). Several genes 
that were altered by a CDAHFD in WT mice were regulated in the opposite direction in 
CDAHFD-fed Cyp2b-null mice (Fig 3.4AB). Associated immune system genes, Cd8 
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antigen beta chain 1 (Cd8b1) and nuclear factor of activated T-cells cytoplasmic 2 
(Nfatc2), as well as the upstream cortisol synthesis calmodulin-like protein 4 (Calml4) 
gene had very low expression or down-regulation (blue) in CDAHFD-fed WT females 
but up-regulation (yellow) in Cyp2b-null counterparts (Fig 3.4A). Oppositely regulated 
genes between CDAHFD-fed WT and Cyp2b-null male mice included feeding behavior 
regulation and insulin signaling genes, hypocretin receptor 2 (Hcrtr2) and protein 
phosphatase 1 regulatory subunit 3C (Ppp1r3c), respectively. These genes had low 
expression or up-regulation (yellow) in CDAHFD-fed WT males but down-regulation 
(blue) in Cyp2b-null counterparts (Fig. 3.4B).  
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Figure 3.4. RNAseq demonstrates changes in gene expression in livers of CDAHFD-
fed Cyp2b-null mice. Heat maps showing log2-transformed, Z-score scaled RNA-seq 
expression of significant differentially expressed genes (log2FC > 1.0) between 
CDAHFD-fed Cyp2b-null and CDAHFD-fed WT groups in female (A) and male (B) 
mice. Yellow and blue color intensity indicate gene up- or down-regulation, respectively. 
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Dendrogram clustering on the y-axis groups genes by expression profile across samples. 
GO term enrichment analysis summary using Revigo (Supek et al., 2011) for up-
regulated GO terms in CDAHFD-fed Cyp2b-null female (C) and male (D) mice 
compared to CDAHFD-fed WT mice. Each scatterplot contains enriched GO terms from 
the biological process class that remain after term redundancy is reduced and are 
displayed in a two-dimensional space where semantically similar GO terms are 
positioned closer together within the plot. Each circle represents an enriched GO term; 
the cooler the color of a term, the greater significance (p < 0.05) of that term with 
measured changes in gene expression. Circle size indicates the frequency of the GO term 
in the underlying GO database, i.e. circles of more general terms are larger. 
 
 
Gene ontology (GO) enrichment analysis (S3.5) demonstrates significant (p < 
0.05) increases in terms associated with lipid metabolism and immune system regulation 
in CDAHFD-fed Cyp2b-null female mice, and increases in stimulus/stress response, cell 
communication, and signal transduction terms in CDAHFD-fed Cyp2b-null male mice 
compared to CDAHFD-fed WT mice (Fig 3.4CD). Both female and male CDAHFD-fed 
Cyp2b-null mice had down-regulated GO terms related to xenobiotic metabolism (S3.6). 
Fatty liver and NASH are known to mediate the down-regulation of detoxification 
enzymes, especially CYPs (Deol et al., 2015; H. Li, Toth, & Cherrington, 2017). Cyp2b9, 
Cyp2b10, and Cyp2b13 were all significantly down-regulated in CDAHFD-fed WT 
females; conversely, Cyp2b9 was significantly up-regulated in WT CDAHFD-fed males 
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compared to their ND-fed counterparts (S3.7). Immunoblotting confirmed that CYP2B 
protein was reduced in female but increased in male CDAHFD-fed WT mice compared 
to WT ND-fed mice (S3.8). Overall, there is substantial sexual dimorphism in gene 
expression with Cyp2b-null females showing changes in lipid metabolism, energy 
metabolism, and inflammation; Cyp2b-null males showing changes related to stress 
responses and cell signaling (Fig 3.4).   
 
3.3.5 Analysis of fibrosis, inflammation, and stress associated biomarkers in CDAHFD-
fed Cyp2b-null mice: 
Gene markers associated with fibrosis and inflammation were up-regulated in 
CDAHFD-fed WT female mice (Fig 3.5A; S3.7). When comparing CDAHFD-fed 
Cyp2b-null mice to CDAHFD-fed WT mice, expression of several fibrosis-related genes 
were slightly down-regulated or unchanged (S3.4). However, the pro-inflammatory 
interleukin-6 receptor (Il6ra) was significantly down-regulated, while other apoptotic and 
immune response genes such as immunosuppressive transforming growth factor beta 2 
(Tgfb2) (Yoshimura & Muto, 2011) and chemokine receptor 7 (Ccr7) were up-regulated 
in CDAHFD-fed Cyp2b-null female mice (S3.9). Furthermore, the tumor necrosis factor 
receptor superfamily member 18 (Tnfrsf18) also known as the glucocorticoid-induced 
TNFR-related protein and calmodulin-like 4 (Calml4), a calcium-binding messenger 
protein involved in upstream signaling of steroid hormone biosynthesis, were 
significantly up-regulated (logFC = 1.70 and logFC = 1.28, respectively) in CDAHFD-
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fed Cyp2b-null females compared to WT counterparts (Fig 3.5A), suggesting a potential 
role for glucocorticoid mediated suppression of inflammation and immune response.  
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Figure 3.5. Measured liver fibrosis and inflammatory markers in CDAHFD-treated 
Cyp2b-null female mice. Changes in the expression of fibrosis, inflammation and stress 
response-associated genes were investigated and grouped by respective biomarkers 
and/or KEGG pathways (A). LogFC values with an asterisk indicates a significant 
difference (p < 0.05) between two groups, e.g. CDAHFD-fed versus ND-fed WT mice, 
and no asterisk denotes significance by one-way ANOVA across all treatment groups. 
Histopathological changes were evaluated by Masson’s trichrome staining of female liver 
tissues (B). Images were taken at 100x (0.2 mm) and 400x (0.05 mm) magnification. 
Liver hydroxyproline (C), as well as serum C-reactive protein (D) and corticosterone (E) 
were measured in all treatment groups. Graph data are presented as mean ± SEM. 
Statistical significance was determined by one-way ANOVA followed by Fisher’s LSD 
as the post-hoc test (n=5). An ‘a’ indicates ND-fed WT different than CDAHFD-fed WT, 
‘b’ indicates ND-fed Cyp2b-null different than CDAHFD-fed Cyp2b-null, ‘c’ indicates 
ND-fed WT different than ND-fed Cyp2b-null, ‘d’ indicates CDAHFD-fed WT different 
than CDAHFD-fed Cyp2b-null. No asterisk indicates a p-value < 0.05, * indicates a p-
value < 0.01, and ** indicates a p-value < 0.0001. 
 
 
Liver histopathology along with markers of NASH were examined because of 
gene expression profile differences found between CDAHFD-fed WT and Cyp2b-null 
mice. Masson’s Trichrome confirmed the development of cytoplasmic vacuolization and 
and revealed the progresion of fibrosis from CDAHFD treatment; however, the difference 
102 
in severity was not significant between genotypes (Fig 3.5B). Liver hydroxyproline, a 
major component of collagen and marker for fibrosis development, was significantly 
increased in female CDAHFD-fed WT mice compared to ND-fed WT mice. 
Hydroxyproline concentrations were 33% lower in female CDAHFD-fed Cyp2b-null 
mice than CDAHFD-fed WT mice; however, this was not statistically significant (p = 
0.18) (Fig 3.5C). Overall, liver fibrosis was induced by a CDAHFD and some expression 
markers of liver fibrosis and inflammation were higher in female CDAHFD-fed WT mice 
than CDAHFD-fed Cyp2b-null mice; however, perturbation was often either minimal to 
moderate or not significant.    
Liver inflammation was determined by serum levels of C-reactive protein (CRP). 
CDAHFD-fed Cyp2b-null females had higher (15%) CRP concentrations over WT 
counterparts (Fig 3.5D). Corticosterone, the main glucocorticoid in rodents, was also 
measured due to induction of immune system regulation-associated GO terms and 
inflammatory markers in CDAHFD-fed Cyp2b-null females (Fig 3.4C and 3.5A). 
Corticosterone increased in CDAHFD-fed Cyp2b-null females by 2.7X compared to WT 
mice (Fig 3.5E). These results concur with the up-regulation of glucocorticoid-mediated 
KEGG pathways including Tnfrsf18 and Calml4 in CDAHFD-fed Cyp2b-null females. 
Overall, gene expression, inflammatory markers, and corticosterone levels indicate 
Cyp2b-null mice differed in their response to a CDAHFD than WT mice; however, there 
were no significant changes in fibrosis (Fig 3.5).   
CDAHFD-fed male mice show significant adverse changes compared to ND-fed 
mice, with expression markers associated with increased fibrosis and inflammation up-
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regulated in CDAHFD-fed WT male mice and greater up-regulation of fibrosis marker 
genes in CDAHFD-fed Cyp2b-null males, (Fig 3.6A; S3.4, S3.7, & S3.9) especially 
when compared to females (Fig 3.5A). Masson’s Trichrome staining also confirmed the 
development of cytoplasmic vacuolization and revealed the progression of fibrosis from 
CDAHFD treatment regardless of genotype (Fig 3.6BC). Contrary to females, 
CDAHFD-fed male mice had unexpectedly lower concentrations of CRP and 
corticosterone in CDAHFD-treated mice (Fig 3.6DE). Taken together, gene expression 
suggests only minor differences between CDAHFD-fed WT and Cyp2b-null males, and 
these changes did not manifest themselves in the histopathology or hydroxyproline 
results, indicating few to no differences between WT and Cyp2b-null male mice 
regarding susceptibility to NASH. 
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Figure 3.6. Measured liver fibrosis and inflammatory markers in CDAHFD-treated 
Cyp2b-null male mice. Changes in the expression of fibrosis, inflammation and stress 
response-associated genes were investigated and grouped by respective biomarkers 
and/or KEGG pathways (A). LogFC values with an asterisk indicates a significant 
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difference (p < 0.05) between two groups, e.g. CDAHFD-fed versus ND-fed WT mice, 
and no asterisk denotes significance by one-way ANOVA across all treatment groups. 
Histopathological changes were evaluated by H&E, and Masson’s trichrome staining of 
male liver tissues (B). Images were taken at 100x (0.2 mm) and 400x (0.05 mm) 
magnification. Liver hydroxyproline (C), as well as serum C-reactive protein (D) and 
corticosterone (E) were measured in all treatment groups. Graph data are presented as 
mean ± SEM. Statistical significance was determined by one-way ANOVA followed by 
Fisher’s LSD as the post-hoc test (n=5). An ‘a’ indicates ND-fed WT different than 
CDAHFD-fed WT, ‘b’ indicates ND-fed Cyp2b-null different than CDAHFD-fed Cyp2b-
null, ‘c’ indicates ND-fed WT different than ND-fed Cyp2b-null, ‘d’ indicates 
CDAHFD-fed WT different than CDAHFD-fed Cyp2b-null. No asterisk indicates a p-
value < 0.05, * indicates a p-value < 0.01, and ** indicates a p-value < 0.0001. 
 
 
3.3.6 Cyp2b-null mice show gender differences in CDAHFD-induced liver triglyceride 
accumulation: 
NAFLD is often a precursor to NASH and therefore differences in NAFLD were 
also investigated. GO analysis indicated an up-regulation of lipid metabolism-related 
terms in CDAHFD-fed Cyp2b-null females. In contrast, several genes associated with 
fatty acid metabolism were down-regulated in CDAHFD-fed WT female mice (Fig 3.7A; 
S3.7). Genes that reversed direction of regulation from down- to up-regulation in 
CDAHFD-fed Cyp2b-null female mice compared to CDAHFD-fed WT mice include 
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Ndufa4-mitochondrial complex associated protein (Ndufa4) and Cyp27a1, which breaks 
down cholesterol to bile acids (S3.4 & S3.9). Pathological analysis of Oil Red O staining 
established increased steatosis in CDAHFD-treated female mice, with less lipid 
accumulation in CDAHFD-fed Cyp2b-null females than CDAHFD-fed WT females (Fig 
3.7B). Total lipid area quantified by ImageJ Fiji confirmed the pathological findings 
(Schindelin et al., 2012) that CDAHFD-fed Cyp2b-null female mice had significantly 
less hepatic lipids than CDAHFD-fed WT mice (Fig 3.7C) and this was verified by total 
triglyceride concentrations measured colorimetrically (Fig 3.7D). Despite smaller 
droplets (data not shown), CDAHFD-fed Cyp2b-null mice did not appear to present with 
microsteatosis. To make sure, serum β-hydroxybutyrate levels were also measured 
because impaired mitochondrial β-oxidation can cause microvesicular steatosis 
development (Fromenty & Pessayre, 1997). Serum β-hydroxybutyrate increased in both 
CDAHFD-fed groups with no significant difference between genotypes (Fig 3.7E).  
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Figure 3.7. Steatosis and markers of steatosis in CDAHFD-fed WT and CDAHFD-
fed Cyp2b-null female mice. Changes in the expression of nonalcoholic fatty liver 
108 
disease-related genes were investigated and grouped by respective biomarkers and/or 
KEGG pathways (A). LogFC values with an asterisk indicates a significant difference (p 
< 0.05) between two groups, e.g. CDAHFD-fed versus ND-fed WT mice, and no asterisk 
denotes significance by one-way ANOVA across all treatment groups. Fatty liver 
histopathological changes were evaluated by Oil red O staining in female mice (B). 
Images were taken at 100x (0.2 mm) and 400x (0.05 mm) magnification. Total liver 
triglycerides (C) were measured in female mice to confirm Oil Red O staining results. 
Liver lipid droplets were also quantified by total area (D) using ImageJ Fiji from Oil Red 
O slides (400x). Serum levels of β-hydroxybutyrate (E), leptin (F), and adiponectin (G) 
were also determined. Graphed data are presented as mean ± SEM. Statistical 
significance was determined by one-way ANOVA followed by Fisher’s LSD as the post-
hoc test (n=5). An ‘a’ indicates ND-fed WT different than CDAHFD-fed WT, ‘b’ 
indicates ND-fed Cyp2b-null different than CDAHFD-fed Cyp2b-null, ‘c’ indicates ND-
fed WT different than ND-fed Cyp2b-null, ‘d’ indicates CDAHFD-fed WT different than 
CDAHFD-fed Cyp2b-null. No asterisk indicates a p-value < 0.05, * indicates a p-value < 
0.01, and ** indicates a p-value < 0.0001. 
 
 
There were changes in the serum lipid levels of female mice (Table 3.1A). This 
includes decreased calcium and increased serum HDL and LDH in ND-fed Cyp2b-null 
mice compared to ND-fed WT mice consistent with previous data (Heintz et al., 2019). 
CDAHFD-fed female mice had lower serum glucose and HDL compared to ND-fed 
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counterparts. However, between CDAHFD-fed genotypes, CDAHFD-fed Cyp2b-null 
mice increased HDL but decreased calcium levels. LDH was consistently increased in the 
serum of Cyp2b-null mice regardless of diet indicating skeletal or cardiac muscular tissue 
damage. Liver to serum triglyceride ratios confirm reduced accumulation of triglycerides 
in the livers of Cyp2b-null female mice regardless of diet (Table 3.1A). The metabolic 
hormones leptin and adiponectin were measured due to changes in weight, liver lipids, 
and gene expression changes. Significant differences were associated with diet and not 
genotype (Fig 3.7FG).  
 
Table 3.1. Serum biomarker levels in ND and CDAHFD-treated WT and Cyp2b-
null mice. 
A. 
 
 
 
 
 
 
 
 
Serum Panel ND-fed WT F 
ND-fed Cyp2b-
null F 
CDAHFD-fed WT 
F 
CDAHFD-fed 
Cyp2b-null F 
Calcium (mg/dL) 9.41 ± 0.15 8.02 ± 0.20c** 9.60 ± 0.14 7.72 ± 0.20d** 
Phosphorus (mg/dL) 5.68 ± 0.38 5.95 ± 0.36 6.92 ± 0.63 7.04 ± 0.35 
Glucose (mg/dL) 181.23 ± 6.72 186.42 ± 4.25 155.07 ± 12.06a 151.73 ± 5.41b* 
Triglycerides (mg/dL) 59.91 ± 9.23 53.34 ± 0.40 64.88 ± 4.30 57.97 ± 7.15 
Cholesterol (mg/dL) 71.88 ± 4.62 119.96 ± 42.45 70.57 ± 21.29 53.13 ± 2.02 
HDL (mg/dL) 46.59 ± 2.03 51.85 ± 2.28 28.26 ± 4.97a* 37.60 ± 0.82b*d 
LDL (mg/dL) 5.6 ± 0.20 8.13 ± 2.64 6.58 ± 2.19 4.28 ± 0.98 
VLDL (mg/dL) 11.98 ± 1.85 10.67 ± 1.45 12.98 ± 0.86 11.59 ± 1.43 
LDH (U/L) n.d. 260.73 ± 104.64c* n.d. 680.96 ± 96.79 b
Direct bilirubin (mg/dL) 0.024 ± 0.004 0.04 ± 0.01 0.16 ± 0.11 0.068 ± 0.01 
Indirect bilirubin (mg/dL) 0.218 ± 0.05 0.78 ± 0.58 0.56 ± 0.24 0.21 ± 0.048 
Total bilirubin (mg/dL) 0.24 ± 0.05 0.69 ± 0.47 0.71 ± 0.22 0.45 ± 0.17 
Liver:Serum Triglycerides 0.139 ± 0.03 0.065 ± 0.01c 0.192 ± 0.02 0.163 ± 0.02b* 
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B. 
 
Data are presented as mean ± SEM. Statistical significance was determined by one-way ANOVA followed 
by Fisher’s LSD as the post-hoc test (n=5).  
‘a’ indicates ND-fed WT different than CDAHFD-fed WT 
‘b’ indicates ND-fed Cyp2b-null different than CDAHFD-fed Cyp2b-null 
‘c’ indicates ND-fed WT different than ND-fed Cyp2b-null 
‘d’ indicates CDAHFD-fed WT different than CDAHFD-fed Cyp2b-null.  
No asterisk next to a ‘letter’ indicates a p-value < 0.05, * indicates a p-value < 0.01, and ** indicates a p-
value < 0.0001. n.d. = not detected 
Raw data from the serum panel and other measured endpoints are supplied in S3.6 File.   
 
 
Numerous genes associated with fatty acid metabolism were also down-regulated 
in CDAHFD-fed WT male mice compared to ND-fed counterparts, and these genes were 
further down-regulated in CDAHFD-fed Cyp2b-null male mice (Fig 3.8A; S3.4, S3.7, & 
S3.9), suggesting greater steatosis in the CDAHFD-fed Cyp2b-null male mice. These 
genes include regulators of glycogen metabolism, Ppp1r3b and Ppp1r3c, glucose 
metabolism regulator, glucose-6-phosphatase (G6pc), serum triglyceride regulator, 
angiopoietin-like protein 8 (Angptl8), and long chain fatty acid elongase 2 (Elovl2). Liver 
steatosis also increased  in CDAHFD-fed male mice, with higher liver triglyceride levels 
Serum Panel ND-fed WT M 
ND-fed Cyp2b-
null M 
CDAHFD-fed WT 
M 
CDAHFD-fed 
Cyp2b-null M 
Calcium (mg/dL) 9.82 ± 0.27 8.54 ± 0.17c* 9.26 ± 0.10 8.50 ± 0.39 
Phosphorus (mg/dL) 5.69 ± 0.34 5.76 ± 0.37 6.72 ± 0.21 7.37 ± 0.51b* 
Glucose (mg/dL) 206.87 ± 15.42 212.36 ± 7.55 124.80 ± 3.55a** 141.45 ± 9.21b* 
Triglycerides (mg/dL) 96.24 ± 5.46 66.72 ± 4.59c* 53.004 ± 4.64a** 55.15 ± 3.99 
Cholesterol (mg/dL) 96.18 ± 4.65 105.48 ± 3.69 38.26 ± 1.78a** 46.38 ± 3.078b** 
HDL (mg/dL) 69.76 ± 3.24 77.94 ± 2.25c 18.86 ± 2.33a** 29.53 ± 2.46b**d 
LDL (mg/dL) 3.53 ± 0.20 3.29 ± 0.22 6.19 ± 2.09 3.40 ± 0.56 
VLDL (mg/dL) 19.25 ± 1.09 13.34 ± 0.92c* 10.6 ± 0.93a** 11.03 ± 0.80 
LDH (U/L) n.d. 187.64 ± 23.73c** n.d. 909.80 ± 55.91bd**
Direct bilirubin (mg/dL) 0.02 ± 0.0045 0.026 ± 0.004 0.12 ± 0.0045a** 0.095 ± 0.013b**d
Indirect bilirubin (mg/dL) 0.14 ± 0.014 0.15 ± 0.0097 0.22 ± 0.015a* 0.3 ± 0.026b**d* 
Total bilirubin (mg/dL) 0.16 ± 0.012 0.18 ± 0.0073 0.34 ± 0.017a** 0.41 ± 0.032b**d 
Liver:Serum Triglycerides 0.081 ± 0.009 0.115 ± 0.007 0.244 ± 0.012a** 0.322 ± 0.034b**d
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in Cyp2b-null compared to WT mice (Fig 3.8B-D) corroborating the gene expression 
data. Serum β-hydroxybutyrate also indicates no change in ketosis in male mice similar to 
female mice (Fig 3.8E).  
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Figure 3.8. Steatosis and markers of steatosis in CDAHFD-fed WT and CDAHFD-
fed Cyp2b-null male mice. Changes in the expression of nonalcoholic fatty liver 
disease-related genes were investigated and grouped by respective biomarkers and/or 
KEGG pathways (A). LogFC values with an asterisk indicates a significant difference (p 
< 0.05) between two groups, e.g. CDAHFD-fed versus ND-fed WT mice, and no asterisk 
denotes significance by one-way ANOVA across all treatment groups. Fatty liver 
histopathological changes were evaluated by Oil red O staining in female mice (B). 
Images were taken at 100x (0.2 mm) and 400x (0.05 mm) magnification. Total liver 
triglycerides (C) were measured in male mice to confirm Oil Red O staining results. 
Liver lipid droplets were also quantified by total area (D) using ImageJ Fiji from Oil Red 
O slides (400x). Serum levels of β-hydroxybutyrate (E), leptin (F), and adiponectin (G) 
were also determined. Graph data are presented as mean ± SEM. Statistical significance 
was determined by one-way ANOVA followed by Fisher’s LSD as the post-hoc test 
(n=5). An ‘a’ indicates ND-fed WT different than CDAHFD-fed WT, ‘b’ indicates ND-
fed Cyp2b-null different than CDAHFD-fed Cyp2b-null, ‘c’ indicates ND-fed WT 
different than ND-fed Cyp2b-null, ‘d’ indicates CDAHFD-fed WT different than 
CDAHFD-fed Cyp2b-null. No asterisk indicates a p-value < 0.05, * indicates a p-value < 
0.01, and ** indicates a p-value < 0.0001. 
 
 
ND-fed Cyp2b-null male mice showed significantly lower serum calcium and 
triglycerides consistent with previous data (Heintz et al., 2019), and greater HDL and 
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LDH similar to females. Relative to CDAHFD-fed WT mice, CDAHFD-fed Cyp2b-null 
mice showed greater HDL, bilirubin, serum:triglyceride ratios, and LDH. Males showed 
similar directional changes in HDL and LDH as females; however, their 
serum:triglyceride ratios were in opposing directions, which was expected because liver 
triglycerides went down in CDAHFD-fed Cyp2b-null females and up in CDAHFD-fed 
Cyp2b-null males (Table 3.1B). Serum leptin increased 2.6-fold in ND-fed Cyp2b-null 
males compared to their WT counterparts, while leptin levels remained low in CDAHFD-
fed mice (Fig 3.8F). No differences were observed between groups for male adiponectin 
levels (Fig 3.8G). Overall, Cyp2b-null female and male mice reacted very differently to a 
CDAHFD pertaining to liver lipids, with protection from steatosis in Cyp2b-null females 
and increased steatosis in Cyp2b-null males.   
 
3.3.7 qPCR confirmation of changes in gene expression: 
qPCR was used to verify RNAseq results of genes associated with hepatic fibrosis 
(Acta2; Col1a1), inflammation (Cd68) and steroid metabolism associated with cortisol 
(Cyp17a1), insulin signaling and glucose metabolism (Ppp1r3b; G6pc), and cell 
proliferation (aldo-keto reductase 1b8, Akr1b8, ortholog of AKR1B10) in female (Fig 
3.9A) and male (Fig 3.9B) mice. All genes verified by qPCR exhibited similar directional 
trends in terms of gene expression to the RNAseq results (Fig 3.5-3.8; S3.3). Col1a1 was 
significantly different between CDAHFD-fed WT and CDAHFD-fed Cyp2b-null mice in 
both sexes, with lower Col1a1 expression in the Cyp2b-null females (Fig 3.9A) and 
higher in the Cyp2b-null males provided a CDAHFD (Fig 3.9B). Acta2 was not different 
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between CDAHFD-treated genotypes but showed similar trends in expression to Col1a1, 
suggesting increased fibrosis. Cd68 also differed by genotype in CDAHFD-fed female 
mice only, with decreased expression in CDAHFD-fed Cyp2b-null mice, suggesting 
lower inflammation and macrophage infiltration in these mice. Cyp17a1 qPCR results 
were similar to RNAseq, however, there was no statistical differences between 
CDAHFD-fed WT and Cyp2b-null mice. The insulin signaling and glucose metabolism 
genes, Ppp1r3b and G6pc trended in the same direction of the RNAseq results, with 
decreased G6pc expression in both CDAHFD-fed Cyp2b-null female and male mice 
compared to WT counterparts; however only males were significant by ANOVA. 
Females were significant by t-tests directly comparing CDAHFD-fed WT to CDAHFD-
fed Cyp2b-null mice (p = 0.04). Akr1b8 showed similar patterns in gene expression to 
RNAseq, but no differences between genotypes in CDAHFD-fed mice.  In conclusion, 
qPCR results showed exactly the same trends as RNAseq but did not always agree 
statistically.  qPCR also indicates an increase in fibrosis, inflammation, and fatty liver in 
CDAHFD-fed mice that is repressed somewhat in Cyp2b-null females.  
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Figure 3.9. qPCR confirmation of RNAseq analysis. Changes in the expression of 
genes in females (A) and males (B) involved in fibrosis, inflammation, insulin signaling, 
fatty liver, and proliferation by qPCR confirmation. Data are presented as mean ± SEM. 
Statistical significance was determined by one-way ANOVA followed by Fisher’s LSD 
as the post-hoc test (n=5). An ‘a’ indicates ND-fed WT different than CDAHFD-fed WT, 
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‘b’ indicates ND-fed Cyp2b-null different than CDAHFD-fed Cyp2b-null, ‘c’ indicates 
ND-fed WT different than ND-fed Cyp2b-null, ‘d’ indicates CDAHFD-fed WT different 
than CDAHFD-fed Cyp2b-null. No asterisk indicates a p-value < 0.05, * indicates a p-
value < 0.01, and ** indicates a p-value < 0.0001. 
 
 
3.4 Discussion   
Cyp2b-null female mice weigh less, primarily due to lower white adipose tissue 
mass, and are protected from diet-induced steatosis and to a lesser extent diet-induced 
NASH. There were few differences in fibrosis markers between CDAHFD-fed WT and 
Cyp2b-null females, however hydroxyproline levels were slighty lower in Cyp2b-null 
female mice. CDAHFD caused substantial liver injury, however Cyp2b-null females had 
significantly lower markers of liver injury including ALT, AST, and ALP compared to 
their WT counterparts. Protection from liver damage in Cyp2b-null females may occur 
due to lower immune suppression as indicated by gene expression changes in Tgfb2, 
Il6ra, and activin receptor-like kinase 1 (Acvrl1), potentially due to glucocorticoid-
mediated repression.  
In contrast, CDAHFD-fed Cyp2b-null male mice exhibit no significant changes in 
serum ALT, AST, and ALP in comparison to CDAHFD-fed WT mice indicating no 
differences in liver damage. Fibrosis was heavily induced by a CDAHFD, but there was 
also no difference between CDAHFD-fed male groups except for PCNA. Cyp2b-null 
males also have slightly greater inflammatory responses based on RNA-seq data with no 
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changes in CRP or corticosterone levels. CDAHFD-fed Cyp2b-null males also showed a 
1.5-fold increase of serum creatine kinase levels compared to all other treatment groups, 
suggesting that CDAHFD treatment causes damage to Cyp2b-null males in other tissues, 
such as cardiac or skeletal muscle, in addition to liver (Yen et al., 2017).  
Direct measurement of liver triglycerides and histopathological staining using Oil 
Red O revealed less lipid accumulation in the livers of CDAHFD-fed Cyp2b-null females 
than CDAHFD-fed WT females. Liver to serum triglyceride ratios also indicate less 
triglyceride accumulation in the livers of Cyp2b-null female mice (especially when 
treated with CDAHFD) compared to their WT counterparts. GO enrichment analysis of 
RNA-seq data demonstrated significant increases in terms associated with lipid 
metabolism in CDAHFD-fed Cyp2b-null female mice compared to CDAHFD-fed WT 
female mice. Several genes involved in fatty acid metabolism were down-regulated in 
CDAHFD-fed WT females. When comparing gene expression of CDAHFD-fed Cyp2b-
null mice to their WT counterparts, lipid metabolism genes were either minimally down-
regulated but not significantly, or reversed direction and were slightly up-regulated as 
shown in Figure 3.7.  
Conversely, male Cyp2b-null mice were not protected from development of fatty 
liver. Consistent with previous results (Heintz et al., 2019), liver steatosis increased in 
CDAHFD-fed male mice, with more triglyceride accumulation in CDAHFD-fed Cyp2b-
null males than CDAHFD-fed WT males as demonstrated by liver triglycerides and liver 
to serum triglyceride ratios. CDAHFD-fed Cyp2b-null male mice also had more down-
regulated lipid metabolism associated genes compared to female counterparts, with 
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several genes further down-regulated from CDAHFD-fed WT males, including regulators 
of glycogen and triglyceride metabolism. Based on these results, it is clear that a lack of 
hepatic Cyp2b members is not protective against fatty liver disease in male mice.  
The progression of NAFLD to NASH is characterized by inflammation, fibrosis, 
stress responses, and hepatocellular injury (Singh et al., 2015). GO terms related to 
xenobiotic metabolism were down-regulated in female and male CDAHFD-fed Cyp2b-
null mice in comparison to CDAHFD-fed WT mice, which is commonly seen in NASH 
(Deol et al., 2015; H. Li et al., 2017). Interestingly, CDAHFD decreased Cyp2b 
expression in WT females, but increased Cyp2b expression in WT males. This sexual 
dimorphism of Cyp2b gene expression in WT mice fed a CDAHFD may be associated 
with the gender differences observed in Cyp2b-null mice for other measured biomarkers. 
Markers of fibrosis and inflammation were also examined in CDAHFD-fed mice, 
however changes in these markers were relatively small. Histopathology revealed 
development of cytoplasmic vacuolization and fibrosis from CDAHFD treatment in both 
sexes, but no significant differences between genotypes. Of the major fibrotic markers 
investigated, only Tgfb1 and Tgfb2 were perturbed in CDAHFD-fed Cyp2b-null mice 
compared to CDAHFD-fed WT mice; Tgfb1 in males and Tgfb2 in females. 
Consequently, susceptibility to NASH only differed following the CDAHFD, but not by 
genotype despite minor respression of inflammatory markers and hydroxyproline in 
female mice.  
The hepatic Cyp2b members, Cyp2b9 and Cyp2b13 are highly sexually dimorphic 
(Hernandez, Mota, Huang, Moore, & Baldwin, 2009; Renaud, Cui, Khan, & Klaassen, 
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2011; Wiwi, Gupte, & Waxman, 2004), and CAR regulation of several genes including 
Cyp2b10 is also sexually dimorphic as is cell proliferation (Braeuning et al., 2006; 
Ledda-Columbano et al., 2003). Signal transducer and activator of transcription 5b 
(Stat5b) mediates growth hormone (GH)-dependent sexually dimorphic gene expression 
in the male liver (Clodfelter et al., 2006), and results indicate that the GH-STAT5b 
pathway regulates female predominant expression of Cyp2b9, as this pathway is 
suppressed by the male GH secretion profile (Holloway et al., 2007; Sakuma et al., 2004) 
through its regulation of HNF4a, CAR, and forkhead box A2 (FoxA2) (Hashita et al., 
2008; Hernandez, Mota, Huang, et al., 2009; Wiwi et al., 2004). Female predominant 
regulation of these genes is crucial in their physiological responses. For example, FoxA2 
increases fatty acid oxidation, decreases obesity, regulates Cyp2b9, and represses 
hepatocellular carcinoma only in female mice (Golson & Kaestner, 2016; Hashita et al., 
2008; Wolfrum, Asilmaz, Luca, Friedman, & Stoffel, 2004). However, it’s ability to 
regulate obesity in a sexually dimorphic manner has not been established (Bochkis, Shin, 
& Kaestner, 2013). Based on this information, it is certainly possible that the Cyp2b’s 
play a role in lipid metabolism that decreases obesity, provides protection from liver 
toxicity, but increases NAFLD in female mice because of their much higher expression, 
greater control, and production of key but as yet not completely understood oxylipins 
(Keeney et al., 1998). Most NAFLD studies using mouse models have found that disease 
is more severe in males, however sex differences differ by model and strain (Lonardo et 
al., 2019). For example, a recent study found female C57Bl/6J mice fed a high-fructose 
diet to be more susceptible to NAFLD in terms of greater hepatic inflammation and 
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decreased adiponectin in visceral adipose tisse than males, with no difference in liver 
steatosis between genders (Spruss et al., 2012).  
These gender differences are also seen in human CYP2B6, as it is also 
predominantly expressed in females although to a much lesser extent (Lamba et al., 
2003). Current studies investigating the effects of NAFLD and NASH on CYP2B6 
expression, activity and protein levels are inconclusive. A slight increase in the mRNA 
levels of CYP2B6 was found in steatotic and NASH human liver tissues, with no change 
in protein level or activity (Fisher et al., 2009). Conversely, the progression of NAFLD to 
hepatocellular carcinoma drastically decreased the estimated activity of CYP2B6 in 
hepatocellular carcinoma patients (Gao et al., 2016). To our knowledge, CYP2B6 
expression in NAFLD and NASH patients based on gender has yet to be determined; 
however, it is established that premenopausal women are protected from dysmetabolism, 
and NAFLD more often affects men (Ballestri et al., 2017).  
A previous diet-induced obesity study in our laboratory performed with a 60% 
HFD for 10-weeks increased obesity in Cyp2b-null males only (Heintz et al., 2019); 
however, WAT was increased in both genders. Liver weight was decreased in Cyp2b-null 
males regardless of diet (ND or HFD), while liver:serum triglyceride ratios increased in 
Cyp2b-null males.  Furthermore, serum cholesterol, which is associated with progressive 
NAFLD and potentially NASH (Chen, Chen, Dai, Chen, & Fang, 2008; Kerr & 
Davidson, 2012) was increased in males, but unaffected in females (Heintz et al., 2019). 
Taken together, Cyp2b-null males were susceptible to obesity and NAFLD with markers 
indicating the potential for progressive liver disease with the exception of inflammation. 
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Females showed significantly fewer effects including those on the liver. It is because of 
this lack of inflammatory markers plus increased liver triglycerides providing protection 
from free fatty acid-induced oxidative stress observed in the previous study, that we 
hypothesized less progression to NASH.  Interestingly, our hypothesis is correct although 
the manner of progression was not expected.  In Cyp2b-null females, we observed 
protection from a progressive increase in NASH biomarkers, but that was associated with 
a decrease in NAFLD following the CDAHFD.  In Cyp2b-null males, very few 
differences in NASH markers were observed while NAFLD increased; identical to the 
previous study.  This suggests that the lack of Cyp2b may increase NAFLD, especially in 
males, but is protective from progression of the disease to NASH although the data with 
males is equivocal and in females is may be due to protection from initial damage and 
NAFLD.     
  In conclusion, the data presented indicates CDAHFD-fed Cyp2b-null female mice 
are less susceptible to the development of obesity and NAFLD than WT mice, and have 
less inflammation potentially due to glucocorticoid-mediated repression of immune 
responses. Female Cyp2b-null mice fed CDAHFD had decreased concentrations of serum 
liver injury biomarkers (ALT, AST, and ALP) and less liver steatosis compared to their 
WT CDAHFD-fed counterparts. In contrast, male Cyp2b-null mice are more susceptible 
to liver damage and hepatic steatosis with no changes in fibrosis or inflammation markers 
between CDAHFD-fed WT and Cyp2b-null mice. CDAHFD-fed Cyp2b-null male mice 
had more liver triglycerides accumulation, as well as significantly higher concentrations 
of circulating creatine kinase compared to CDAHFD-fed WT males, indicating damage 
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in other tissues besides the liver. Taken together, there are marked gender-based 
differences in the role of Cyp2b in the development of NAFLD and progression to 
NASH.  
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Supplementary Material 
S3.1 Table. Primers and annealing temperatures for qPCR.  
 
  
 
 
 
 
 
 
 
 
 
 
Gene Forward Primer Reverse Primer Ta(°C) 
18s ATGGCCGTTCTTAGTTGGTG ATGCCAGAGTCTCGTTCGTT 64 
Acta2 CGAAACCACCTATAACAGCATCA GCGTTCTGGAGGGGCAAT 57 
Akr1b8 TCAGCCCACGAGGCTTCCTTC CTCCGGAGTCGCATTTGCTCGCA 66 
Cd68 CGCAGACGACAATCAACCTA AGTGGCATGGTGAAGAGATG 59 
Col1a1 GAGAGCGAGGCCTTCCCGGA GGGAGCCAGCGGGACCTTGT 66 
Cyp17a1 GATCGGTTTATGCCTGAGCG TCCGAAGGGCAAATAACTGG 61 
G6pc CGACTCGCTATCTCCAAGTGA GGGCGTTGTCCAAACAGAAT 56 
Ppp1r3b AGCCGTACAATGGACCAGAT AGTAGTAGGGCCCCAGCTTT 62.4 
132 
S3.1 Figure. Timeline of procedures performed. Procedures performed during an 8-
week treatment of 9-10 week old WT and Cyp2b-null mice with either a normal diet 
(ND; 6.2% fat) or a choline-deficient, L-amino acid-defined high fat diet (CDAHFD; 
62% fat and 0.1% methionine). 
 
 
S3.2 Figure. Feed consumption of WT and Cyp2b-null mice during 8-weeks of diet-
induced NASH treatment. Female (A) and male (B) feed consumption was measured by 
weighing the food every alternate day. Data are presented as mean calories ± SEM. 
Statistical significance was determined by one-way ANOVA followed by Fisher’s LSD 
as post-hoc test (n=9 An ‘a’ indicates ND-fed WT different than CDAHFD-fed WT, ‘b’ 
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indicates ND-fed Cyp2b-null different than CDAHFD-fed Cyp2b-null, ‘c’ indicates ND-
fed WT different than ND-fed Cyp2b-null, ‘d’ indicates CDAHFD-fed WT different than 
CDAHFD-fed Cyp2b-null.  
 
S3.3 File. List of differentially expressed genes by multiple comparisons for all 
treatment groups. Up- and down-regulated differentially expressed genes from raw read 
counts were determined by multiple comparisions in EdgeR for all treatment groups (p < 
0.05, FDR < 0.1). Data is published in Heintz et al. 2020, PLos ONE. 
 
S3.4 File. Differentially expressed gene list of CDAHFD-fed Cyp2b-null mice 
compared to CDAHFD-fed WT mice. Normalized counts of genes from the multiple 
comparisions results were compared by Student’s t tests to determine significant (p < 
0.05) differentially expressed genes between CDAHFD-fed Cyp2b-null and WT groups. 
Data is published in Heintz et al. 2020, PLos ONE. 
 
S3.5 File. GO term enrichment analysis list of up and down-regulated genes in 
CDAHFD-fed Cyp2b-null mice compared to CDAHFD-fed WT mice. GOSeq (Young 
et al., 2010), a GO term enrichment analysis program was used to adjust for gene length 
and expression bias of significant differentially expressed genes between CDAHFD-fed 
groups in female and male mice. Data is published in Heintz et al. 2020, PLos ONE. 
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S3.6 Figure. Gene ontology (GO) term enrichment analysis summary for down-
regulated GO terms in CDAHFD-fed Cyp2b-null mice. GO term enrichment analysis 
summary using Revigo (Supek et al., 2011) for significant down-regulated GO terms in 
CDAHFD-fed Cyp2b-null female (A) and male (B) mice compared to CDAHFD-fed WT 
mice. Each scatterplot contains enriched GO terms from the biological process class that 
remain after term redundancy is reduced and are displayed in a two-dimensional space 
where semantically similar GO terms are positioned closer together within the plot. Each 
circle represents an enriched GO term; the cooler the color of a term, the greater 
signficance (p < 0.05) of that term with measured changes in gene expression. Circle size 
indicates the frequency of the GO term in the underlying GO database, i.e. circles of 
more general terms are larger. 
 
S3.7 File. Differentially expressed gene list of CDAHFD-fed WT mice compared to 
ND-fed WT mice. Normalized counts of genes from the multiple comparisions results 
135 
were compared by Student’s t tests to determine significant (p < 0.05) differentially 
expressed genes between ND-fed and CDAHFD-fed WT groups. Data is published in 
Heintz et al. 2020, PLos ONE. 
 
 
 
S3.8 Figure. Immunoblots of Cyp2b protein expression between ND-fed and 
CDAHFD-fed WT and Cyp2b-null mice. Microsomes were prepared by homogenizing 
frozen livers followed by differential centrifugation as described previously (van der 
Hoeven & Coon, 1974). Protein concentrations were determined using Bradford reagent 
(Bio-Rad).  Immunoblots were performed using 30 μg of microsomal protein separated 
on 12% SDS-polyacrylamide gels (BioRad). Protein was transferred onto 0.2μm 
polyvinylidene difluoride (PVDF) membrane and were recognized using polyclonal 
antibodies to Cyp2b (previously developed in house) (Hernandez, Mota, & Baldwin, 
2009; Mota, Hernandez, & Baldwin, 2010). β-actin (Sigma Aldrich, St.Louis MO USA) 
was used as the reference protein.  Chemiluminescent immunoblot detection was done 
using alkaline phosphatase conjugated secondary antibodies, where in anti-mouse IgG 
(Immunostar, Bio-Rad) was used to visualize β-actin and anti-rabbit IgG (Immunostar, 
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Bio-Rad) was used to visualize Cyp2b. Protein was quantified by densitometry (Image 
Lab 6.0.1, BioRad, Hercules, CA). Relative density is shown as the average of two 
samples using β-actin as the reference gene. Data are presented as relative mean of WT 
ND compared to each treatment group. Statistical significance was determined by one-
way ANOVA followed by Fisher’s LSD as post-hoc test (n=2). An ‘a’ indicates WT ND 
are different than WT CDAHFD, ‘b’ indicates Cyp2b-null ND are different than Cyp2b-
null CDAHFD, ‘c’ indicates Cyp2-null ND are different than WT ND, ‘d’ indicates WT 
CDAHFD are different than Cyp2b-null CDAHFD. No asterisk indicates a p-value < 
0.05, * indicates a p-value < 0.01, and ** indicates a p-value < 0.0001. 
 
S3.9 File. List of altered KEGG pathways in CDAHFD-fed Cyp2b-null mice 
compared to CDAHFD-fed WT mice. Significant differentially expressed genes 
between CDAHFD-fed Cyp2b-null and WT groups were annotated to NCBI Gene IDs 
using InterPro and entered into KEGG Mapper (Kanehisa et al., 2017). Data is published 
in Heintz et al. 2020, PLos ONE. 
 
S3.10 Figure. Full immunoblot and gel images required by PLoS ONE. Full 
immunoblot images of PCNA, CYP2B, and b-actin.  (A) CYP2B immunoblot:  CYP2B 
is sexually dimorphic and expressed much higher in females than males (Hernandez, 
Mota, Huang, et al., 2009; Renaud et al., 2011; Wiwi et al., 2004). (B) Microsomal b-
actin as the housekeeping protein. (C) PCNA. (D) Nuclear b-actin as the housekeeping 
protein.  Left hand side of blots are often but not always stained with molecular weight 
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markers.  Blot images are from S3.8 Figure (CYP2B and b-actin) and Figure 3.1 (PCNA 
and b-actin).  Data is published in Heintz et al. 2020, PLos ONE.    
 
S3.11 File. Raw data from necropsies, glucose tolerance tests, serum and liver 
biomarkers, and qPCR.  Data is published in Heintz et al. 2020, PLos ONE. 
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4.0 Abstract 
The effects of age (9 months old), high-fat diet (4.5 months old), and the loss of 
the xeno- and endobiotic metabolizing enzymes Cyp2b9, Cyp2b10, and Cyp2b13 (Cyp2b-
null mice) on the male murine hepatic lipidome was compared. Hierarchical clustering 
and principal component analysis show that age perturbs phospholipid profiles and serum 
lipid markers the most compared to healthy, young mice; followed by a high-fat diet and 
then loss of Cyp2b. Lipid profiles from older mice followed by diet-induced obese mice 
contain greater n-6 fatty acids than normal diet (ND)-fed young mice that contain 
significantly more n-3 fatty acids. The lack of Cyp2b typically enhanced the adverse 
effects found in the older (9 mo) mice with increased liver injury, cluster of 
phospholipids, and weight gain combined with a deteriorating cholesterol profile. 
 
Keywords: VLDL, diet-induced obesity, omega-6 fatty acids, liver, serum lipids 
 
Highlights   
 In male mice, adverse outcomes such as weight gain and VLDL are more closely 
associated with age than high-fat diet or lack of Cyp2b 
 Age has a powerful effect on lipid profiles; more so than HFD or the lack of 
Cyp2b      
 Male Cyp2b-null mice show an enhancement of undesireable traits and lipid 
markers as they age 
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4.1 Introduction   
Obesity is a major risk factor for metabolic disorders such as cardiovascular 
disease, diabetes, and fatty liver disease. Data from the most recent National Health and 
Nutrition Examination Survey in 2015-2016 shows that 39.8% of adults and 18.5% of 
youth in the United States are obese (Hales, Carroll, Fryar, & Ogden, 2017). Disease 
susceptibility and overall health is greatly affected by changes to the lipidome (Murphy 
& Nicolaou, 2013; Orešič, Hänninen, & Vidal-Puig, 2008). High-fat diets, such as the 
Western diet, cause obesity and drastically alter the hepatic lipidome (Wang et al., 2017), 
and perturbed lipid profiles are associated with specific liver diseases, such as 
nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) 
(Chiappini, Desterke, Bertrand-Michel, Guettier, & Le Naour, 2016; Saito et al., 2015). 
Age also alters the phospholipid profile of mitochondria in the liver, brain, and skeletal 
tissue (Modi, Katyare, & Patel, 2008; Pollard, Ortori, Stöger, Barrett, & Chakrabarti, 
2017). Age transcended the effect of a high fat diet on alterations to the blood lipidome in 
female mice (males were not investigated) (Pati et al., 2018); however, little is known 
about changes that occur with age to the hepatic lipidome.  
Lipids provide membrane structure, energy storage, and act as signaling 
molecules that mediate lipid metabolism, inflammation, and progression of chronic 
diseases such as insulin resistance (Glass & Olefsky, 2012). For example, the 
polyunsaturated fatty acid (PUFA), linoleic acid is the endogenous ligand for HNF4α, a 
key regulator of multiple metabolic pathways (Yuan et al., 2009). Several fatty acids are 
peroxisome proliferator-activated receptor (PPAR) ligands (Feige, Gelman, Michalik, 
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Desvergne, & Wahli, 2006), and fatty acids released by lipolysis during fasting trigger 
hepatic PPARα-mediated β-oxidation while inhibiting lipogenesis through the liver X 
receptor (LXR) (Yoshikawa et al., 2003). During inflammation, PUFAs found in hepatic 
membrane phospholipids are cleaved by phospholipase A2 (Quach, Arnold, & 
Cummings, 2014). These available PUFAs are then oxidized by cyclooxygenase, 
lipoxygenase, or cytochrome P450s (CYP) to form physiologically significant 
metabolites. The CYP pathways typically metabolize PUFAs to fatty acid epoxides that 
have bioactive effects (G. Zhang, Kodani, & Hammock, 2014). CYPs including CYP1A, 
CYP1B, CYP2B, CYP2C, CYP2D, CYP2J, CYP3A, CYP4A, and CYP4F all metabolize 
PUFAs (Hankinson, 2016; Zeldin, 2001; G. Zhang et al., 2014).  
Our lab previously produced a Cyp2b9/10/13-null (Cyp2b-null) mouse model, 
lacking the primary hepatic Cyp2b members: Cyp2b9, Cyp2b10, and Cyp2b13 on a 
C57Bl/6J (B6) background (Ramiya Kumar et al., 2017) and Cyp2b-null males are diet-
induced obese (DIO) with NAFLD development (Heintz, Kumar, Rutledge, & Baldwin, 
2019). Similar lipid accumulation has also been observed in male Cyp2b-KD (RNAi-
based knockdown) mice on a FVB/NJ background as the mice aged (Damiri & Baldwin, 
2018). However, the hepatic phospholipid profile has not been investigated in Cyp2b-null 
mice. The previously referenced studies with Cyp2b-KD and Cyp2b-null mice showed 
few differences between genotypes in female mice, but significant differences in obesity 
in male mice, most likely because several strains of mice are less susceptible to obesity in 
females (Hong, Stubbins, Smith, Harvey, & Nunez, 2009; Wade, Gray, & Bartness, 
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1985). Therefore, in this study we compared the hepatic lipidome of male Cyp2b-null and 
WT mice in healthy, diet-induced obese, and older mice.  
 
4.2 Materials and Methods 
4.2.1 Treatment of experimental groups:  
Animal care procedures were approved by Clemson University’s Institutional 
Animal Care and Use committee. Cyp2b-null mice were developed using CRISPR/Cas9 
as previously described (Ramiya Kumar et al., 2017) and wildtype (WT) B6 mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME, USA) at 3 weeks of age and 
acclimated for 6 weeks prior to treatment. WT and Cyp2b-null male (9 weeks old) mice 
were divided into groups (n=9) and fed either a normal chow diet (ND; Harlan, 3.1 
Kcal/g: 18.6% protein, 6.2 % fat, 44.2% carbohydrates; Madison, WI USA) or a high-fat 
diet (HFD; Envigo TD.06414, 5.1 Kcal/g: 60.3% fat (37% saturated, 47% 
monounsaturated, 16% polyunsaturated fat), 18.4% protein, 21.3% carbohydrates; 
Madison, WI USA) for 10 weeks (Heintz et al., 2019). Mice were 4.5 months old at the 
end of the HFD study and referred to as ND-fed young or HFD-fed young; WT or 
Cyp2b-null mice. An additional experimental group of WT (Jackson) and Cyp2b-null 
male mice (n= 5) were fed a ND until they reached 9 months (termed old WT and old 
Cyp2b-null mice). At the end of the studies, mice were weighed, anesthetized, and blood 
collected by heart puncture prior to euthanasia and serum prepared. Serum biomarkers 
and liver triglycerides were measured as described (Heintz et al., 2019). Liver and 
inguinal white adipose tissue (WAT) were excised, weighed, and divided by total body 
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weight to determine the hepatosomatic index (HSI) and white adipose somatic index 
(WSI). Tissues were immediately snap frozen in liquid nitrogen and stored at -80°C.  
 
4.2.2 Targeted lipidomics and analysis:   
Phospholipid species of arachidonic (ARA; 20:4), linoleic (LA; 18:2), α-linolenic 
(ALA; 18:3) and docosahexaenoic acid (DHA; 22:6) were identified and quantified from 
the livers of mice (n=3 for young (4.5 mo) ND and HFD-fed mice; n=5 for old (9 mo.) 
mice) from each experimental group by LC-MS/MS at the Emory Integrated Lipidomics 
Core (EILC). Livers were homogenized and extracted using a modified Bligh/Dyer 
chloroform/methanol lipid extraction protocol (Bligh & Dyer, 1959)(S4.1). Recovered 
lipids were reconstituted in 1:1 v/v chloroform:methanol prior to analysis by LC/MS. 
Targeted lipidomics were conducted using Sciex AC LC system and Sciex QTrap5500 
mass spectrometer (Framingham, MA, USA). Lipids were deposited onto 
ThermoScientific Accucore C18 column (4.6 x 100mm, 2.6µm) and resolved on an 18 
minute linear gradient using the solvents and parameters recorded in detail in Suppl 
Material 4.1. PUFAs were selectively targeted in samples by performing precursor ion 
scans in the negative ion mode. The resulting scans, corresponding to the molecular 
weights are m/z 279 (LA), m/z 277 (ALA), m/z 303 (ARA), and m/z 327 (DHA). All 
peaks above signal to noise ratio of 5 were fragmented for identification. The area under 
the curve for all scans were used to compare changes in lipid distribution between 
groups. For total quantification, the area under the curve is calibrated against the area of 
an internal standard of known concentration. 
144 
 
4.2.3 Statistical analysis:  
Data are presented as mean + SEM (n = 3-5). Statistical significance was 
determined (p-value < 0.05) by unpaired Student’s t-tests when comparing two groups; 
one-way ANOVA followed by Fisher’s LSD as the post-hoc test when comparing more 
than two groups with Graphpad Prism 7.0 (Graphpad Software, San Diego, CA, USA). 
Hierarchical cluster analysis was performed on lipidomic data and visualized in heatmaps 
with MetaboAnalyst 3.6 (Xia & Wishart, 2002) to compare lipid species content across 
treatment groups. RandomForest (http://www.r-project.org/) was used to rank 
phospholipid species as a prediction of the significance of an effect each lipid species has 
on differences between treatment groups (Breiman, 2001). The tuneRF() function was 
used to determine the best number of predictors (mtry) value to get the lowest out-of-bag 
(OOB) classification error as trees are added to the forest. The number of trees to be built 
(ntree) was set to 350 for all experimental groups to achieve the lowest OOB error. The 
larger the mean decreased accuracy (MDA) value, the more important the phospholipid 
species are for the accuracy of the association between variable and response. Lipid 
species with importance scores less than or equal to zero are likely to have no predictive 
ability. Principal component analysis (PCA) was performed and a biplot drawn using the 
ggbiplot package in R to compare the relationship between multiple variables and 
treatment groups. Variables included total body weight, WSI, serum lipids, and 
phospholipid species. The factoextra R package (https://cran.r-project.org) was used to 
obtain the percent contributions of each measured variable in principle components 1-3. 
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4.3 Results and Discussion 
4.3.1 Increase in obesity due to a high-fat diet or age is exacerbated in Cyp2b-null mice:   
ND-fed old Cyp2b-null male mice weigh more than all other groups (Fig. 4.1). 
Cyp2b-null mice also weigh more than their WT counterparts after a HFD (Fig. 4.1). 
WAT weight is usually associated with the increased body mass as determined by WSI. 
Old WT mice are the only group whose body mass rises at a greater rate than the 
measured WAT or WSI. Cyp2b-null mice further exacerbate the increase in WAT/WSI 
and liver weight/HSI (Fig. 4.1). Age increases obesity similar to a HFD but with a lower 
percentage of inguinal WAT and greater liver weight, especially in Cyp2b-null mice.  
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Figure 4.1. Comparison of total body, liver and WAT weights between all treatment 
groups. Total body weight, liver weight, hepatic somatic index (HSI), WAT weight, and 
WAT somatic index (WSI) were measured for all treatment groups. Data are presented as 
mean (g) + SEM. Statistical significance was determined by one-way ANOVA multiple 
comparisons test using Fisher’s LSD as the post-hoc test (n = 5-9). ‘a’ indicates age 
difference between young (4.5 mo) and old (9 mo) mice within same genotype and diet 
group, ‘c’ indicates difference between HFD-fed young (4.5 mo) and ND-fed old (9 mo) 
mice within same genotype, ‘d’ indicates diet difference between ND-fed and HFD-fed 
mice within in same genotype and age, ‘g’ indicates genotype difference between WT 
and Cyp2b-null mice within same diet and age group. No asterisk indicates a p-value < 
0.05, * indicates a p-value < 0.01, and ** indicates a p-values < 0.0001. 
 
 
Serum cholesterol increased in old Cyp2b-null mice compared to old WT mice, 
but total cholesterol levels were highest in HFD treated groups (Fig. 4.2a). The relatively 
healthy HDL were highest following a HFD and exacerbated in Cyp2b-null mice. HDL 
significantly decreased as mice aged (Fig. 4.2a). Diets high in cis unsaturated fatty acids 
have also been found to increase HDL levels in humans in addition to serum cholesterol 
and LDL (Mensink, Zock, Kester, & Katan, 2003). Conversely, LDL, VLDL (Fig. 4.2a), 
and serum TAG (Fig. 4.2b) levels were higher in old Cyp2b-null mice compared to all 
other groups. Age clearly had an adverse impact on these parameters. Liver TAG 
increased with diet but decreased with age (Fig. 4.2b). Interestingly, ALT (Fig. 4.2c), a 
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marker of liver damage shows a spike with the combination of age and a Cyp2b-null 
genotype. Taken together, these results indicate a TAG-cholesterol profile, lower HDL, 
higher LDL and VLDL, that deteriorates with age and to a lesser degree, HFD. Often, 
this decline is greater in Cyp2b-null mice.  
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Figure 4.2. Perturbations in serum lipids, liver triglycerides, and alanine 
aminotransferase (ALT) with age, diet, and genotype. Serum cholesterol, HDL, LDL, 
and VLDL (A), serum and liver triglycerides (B), and serum ALT (C) were measured in 
all treatment groups using standard methods. Data are presented as mean + SEM. 
Statistical significance was determined by one-way ANOVA followed by Fisher’s LSD 
as the post-hoc test (n = 5-6). ‘a’ indicates age difference comparing young (4.5 mo) and 
old (9 mo) mice within the same genotype and diet group, ‘c’ indicates difference 
between HFD-fed young (4.5 mo) and ND-fed old (9 mo) mice within same genotype, ‘d’ 
indicates diet difference between ND-fed and HFD-fed mice within in same genotype and 
age, ‘g’ indicates genotype difference between WT and Cyp2b-null mice within same 
diet and age group. No asterisk indicates a p-value < 0.05, * indicates a p-value < 0.01, 
and ** indicates a p-values < 0.0001. 
 
 
4.3.2 Hepatic phospholipid data distribution and perturbations by age, diet and loss of 
Cyp2b: 
Seventy-seven total hepatic phospholipid species were identified by LC-MS/MS 
from ARA, LA, ALA, and DHA. Hierarchical clustering was performed on all 77 lipid 
species identified to evaluate the effects of age, diet, and Cyp2b-null genotype on hepatic 
lipid species content (Fig. 4.3; data in S4.2 with standard and abbreviated nomenclature). 
Age has a powerful effect on lipid profiles; more so than HFD or loss of Cyp2b based on 
the hierarchical cluster analyses (Fig. 4.3).      
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Figure 4.3. Heat map of phospholipid profiles of all treatment groups. Hierarchical 
cluster analysis heatmap of all measured phospholipid species from ND-fed WT (BL6), 
ND-fed Cyp2b-null, HFD-fed WT, HFD-fed Cyp2b-null, old WT, and old Cyp2b-null 
mice. Seventy-seven lipid species were identified from liver samples of male mice by 
LC-MS/MS from arachidonic (ARA), linoleic (LA), α-linolenic (ALA) and 
docosahexaenoic acid (DHA). 
 
 
4.3.3 Specific lipid species are associated with adverse physiological events: 
To determine associations between physiological parameters, serum lipids, and 
hepatic phospholipid profiles in the different treatment groups (genotype, age, diet) PCA 
analysis was performed (Fig. 4.4a; data in S4.3) with the top 10 parameters involved in 
differences as determined by PCA shown in Fig. 4.4b. In general, treatment groups 
segregated primarily by age and diet; genotype caused lesser differences between groups 
with age combined with genotype having a greater effect than a HFD in combination with 
genotype. ND-fed young Cyp2b-null mice were pulled towards the HFD-fed mice in the 
PCA plot, which is consistent with the increased triglycerides in this group (Fig. 4.2). 
ND-fed young mice, especially WT, were associated with greater percentage of n-3 
(ALA/DHA) fatty acid species than other groups. More importantly, no adverse 
physiological or serum parameters were associated with young ND-fed mice, concurring 
with previously data on the effects of ALA and DHA on healthy lipid homeostasis in 
humans (Amigó et al., 2020; Catapano et al., 2016) and mice (Pauter et al., 2014)(Fig. 
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4.4). HFD-fed young mice were associated with greater cholesterol, especially HDL, and 
along with older mice showed an association with WSI (Fig. 4.4). The lack of 
phospholipids in the HFD-fed mice is primarily caused by the dominance of 
phospholipids concentrations within the older mice (S4.2, S4.3). There was little to no 
separation between WT and Cyp2b-null mice following a HFD.  
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Figure 4.4. Relationship between treatment groups and measured variables. (A) 
Principal component analysis (PCA) biplot showing relationships between treatment 
groups and measured variables such as physiological parameters, serum lipids, and 
phospholipid species. Variables include serum lipids, WAT somatic index (WSI), body 
weight, and lipid species in order to associate specific biochemical parameters with 
different treatment groups (diet; age) and genotypes (WT; Cyp2b-null). (B) Top 10 
contributing variables in the PCA plot based on loading strength expressed in percent 
contribution. 
 
 
Old mice clearly had the unhealthiest profiles, strongest set of lipid species 
associations, and greatest difference between genotypes (Fig. 4.4). The effect of age also 
superseded the effect of HFD on the blood lipidome of female mice (Pati et al., 2018); 
therefore our work further demonstrates the adverse effect of age on hepatic lipid 
profiles. Age was heavily associated with more fatty acids, larger fatty acids, n-6 fatty 
acids, and higher serum VLDL and serum TAG concentrations. Increased hepatic PC 
biosynthesis, as seen in the older mice, has been proposed to stimulate the production and 
secretion of VLDL and TAG (Martínez-Uña et al., 2013). Greater dietary n-6:n-3 ratios 
have been found to increase HDL levels without suppressing atherogenesis in mice (L. 
Zhang et al., 2009). Somewhat more n-6 fatty acids showed greater association with older 
WT mice than Cyp2b-null mice. In addition, old Cyp2b-null mice were associated with 
weight and to a lesser extent WSI (Fig. 4.4). Overall, old WT and Cyp2b-null mice are 
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associated with unhealthy physiological, serum, and lipid profiles that contribute to an 
increased risk of metabolic disease and obesity (Donahue et al., 2011; Simopoulos, 
2016).  
 
4.3.4 Lipid species and outcomes associated with Cyp2b-null mice:  
To better define the phospholipid species most predictive of differences between 
Cyp2b-null and WT mice, random forest was performed (Fig. 4.5a). Very few lipid 
species were shared among the top 6 most predictive species between the different groups 
(young, old, HFD) with the exception of ARA-PC(38:4) (18:0-20:4 PC(38:4)) found in 
ND and HFD-fed young mice. LA species were common in the top 6 of ND-fed young 
and old mice; ARA species were much more common in the top 6 of HFD-fed mice when 
comparing WT and Cyp2b-null mice. Unpaired Student’s t-tests were also performed 
between genotypes and compared across groups (S4.4). One additional (DHA-38:6 
PE/78:11 CL) species in HFD-fed mice and three additional species (DHA-based 41:6-PI, 
LA-based 40:4-PA, and ALA-based 40:9 PG/86:14 CL in older mice not detected by 
random forest were found to be statistically different between genotypes (S4.4-S4.5). 
Most of the species that were different between WT and Cyp2b-null mice were decreased 
in the Cyp2b-null mice, potentially because of the absence of Cyp2b metabolism.  
A PCA biplot was used to associate different hepatic phospholipid species, serum 
parameters, and physiological outcomes with age, diet, and Cyp2b status in the mice 
(Fig. 4.5b; data S4.6 also includes a top 10 PCA contribution graph) using only the 
altered lipid species determined by random forest and Student’s t-test. This closer look at 
154 
genotypic differences confirmed that several n-3 fatty acids along with some ARA and 
LA phospholipid species are correlated with young ND-fed WT and Cyp2b-null mice; 
consistent with better health in these mice. ND-fed WT and Cyp2b-null mice show 
significantly different PCA profiles with no overlap potentially due to decreased 
metabolism; however, the ND-fed young groups are positioned next to each other within 
the plot. Interestingly, LA species make up 7 of the 10 most perturbed parameters as 
determined by PCA with ARA and WSI, a major contributor due to age and diet to age, 
making up the other contributors (S4.6).  
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Figure 4.5. Lipid species and measured variables associated with differences 
between Cyp2b-null and WT mice. (A) Random forest analysis of key lipids predictive 
of differences between Cyp2b-null and WT mice. (B) Principal component analysis 
(PCA) biplot showing relationships between treatment groups and measured variables 
such as physiological parameters, serum lipids, and phospholipid species. Variables 
include serum lipids, WAT somatic index (WSI), body weight, and lipid species in order 
to associate specific biochemical parameters with different treatment groups (diet; age) 
and genotypes (WT; Cyp2b-null). Only important or significantly perturbed lipid species 
between genotypes as determined by Student’s t-test (p < 0.05) or random forest (MDA > 
0) were included in this plot. 
 
 
HFD-fed mice show greater separation from ND-fed mice in this plot in 
comparison to Fig. 4.4, primarily due to the positioning of ND-fed Cyp2b-null mice. 
Following a HFD, there were few differences between genotypes with Cyp2b-null mice 
showing higher association with HDL (Fig. 4.2). An increase in fatty acid chain length 
was observed in HFD-fed Cyp3a-null male mice, but this was not observed in Cyp2b-null 
mice (R. Kumar, Litoff, Boswell, & Baldwin, 2018). Older mice continued to show 
differences between genotypes with a higher association with weight, WSI, and LDL in 
Cyp2b-null mice, and a greater cluster of phospholipids in the old WT mice (Fig. 4.5b). 
This is consistent with lower metabolism of some PUFA species in Cyp2b-null mice 
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(Fig. 4.2, 4.4 & 4.5), which was also observed in hepatic P450 reductase- and Cyp3a-
nullizygous mice (Finn, Henderson, Scott, & Wolf, 2009; R. Kumar et al., 2018).  
In summary, the data indicates that age > HFD > Cyp2b-null genotype 
compromises the hepatic phospholipid profile the most. ND-fed old Cyp2b-null and 
HFD-fed young mice show significant changes in several phospholipids and 
physiological parameters such as serum cholesterol and WAT compared to ND-fed 
young mice, which have significantly lower lipids and greater n-3 fatty acids. 
Interestingly, the lipid profile of ND-fed Cyp2b-null mice clustered between ND-fed WT 
mice and HFD-fed groups, consistent with their liver triglyceride concentrations. Age 
was found to increase total and LDL-cholesterol in both humans and rodents (Ericsson, 
Berglund, FrostegÅrd, Einarsson, & Angelin, 1997; Parini, Angelin, & Rudling, 1999). 
Total body and liver weight, serum LDL, VLDL, TAG, and ALT levels are all 
significantly higher in old Cyp2b-null mice compared to their WT counterparts as well as 
several featured groups. The combination of age and lack of Cyp2b is more harmful than 
age alone, as it resulted in dyslipidemia and liver injury. Overall, aging and a HFD are 
associated with weight gain, WAT, LDL, VLDL, and a relative increase in n-6 species 
compared to n-3 species. This profile is further exacerbated in old Cyp2b-null mice, 
suggesting accelerated aging or metabolic disease symptoms with the lack of Cyp2b in 
male mice.    
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Supplementary Material: 
S4.1. Detailed methods of detection of phospholipids by LC-MS/MS. 
 
S4.2. Lipidomic data from all treatment groups. Seventy-seven lipid species were 
identified from liver samples of male mice by LC-MS/MS from arachidonic (ARA), 
linoleic (LA), α-linolenic (ALA) and docosahexaenoic acid (DHA). Treatment groups are 
ND-fed young (4.5 mo), ND-fed old (9 mo), and young mice fed a HFD for 10 weeks. 
All data is in relative percent. 
 
S4.3. Data used to make Figure 4 principal component analysis (PCA) biplot.  
 
S4.4. Phospholipids identified as important by both t-tests and random forest 
between WT and Cyp2b-null mice. (A) Lipids that are statistically different by 
Student's t-tests between Cyp2b-null and WT mice in the different age and diet groups. 
(B) Important or significantly perturbed phospholipid species in Cyp2b-null mice 
compared to WT mice identified by both random forest analysis and Student’s t-tests in 
young (4.5 mo) ND-fed, young (4.5 mo) HFD-fed, and old (9 mo) mice.  
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S4.5. Important perturbed hepatic phospholipid species in Cyp2b-null mice within 
each group. (A) Venn diagram of important lipid species between Cyp2b-null and WT 
mice of each featured group based on random forest analysis (MDA > 0). (B) Venn 
diagram of significantly increased (red) or decreased (blue) lipid species in Cyp2b-null 
mice of each featured group as determined by Student’s t-tests (p < 0.05).  
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S4.6. Data used to make principal component analysis (PCA) biplot for Figure 4.5b. 
PCA contribution graph below containing the top 10 contributing variables of the PCA 
plot based on loading strength expressed in percent contribution. The factoextra R 
package (https://cran.r-project.org) was used to obtain the percent contributions of each 
measured variable in principle components 1-3. 
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CHAPTER FIVE 
HUMAN CYP2B6 IS AN ANTI-OBESITY ENZYME THAT METABOLIZES 
POLYUNSATURATED FATTY ACIDS TO IMPORTANT OXYLIPIN 
METABOLITES IN THE 9- AND 13- POSITIONS 
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5.0 Abstract 
Multiple factors in addition to over consumption lead to obesity and non-alcoholic 
fatty liver disease (NAFLD) in the United States and worldwide. CYP2B metabolizes 
numerous xeno- and endobiotic compounds, and male Cyp2b-null mice are diet-induced 
obese with increased white adipose tissue and steatosis. However, it has yet to be 
determined whether human CYP2B6 is anti-obesogenic and a putative mechanism. 
CYP2B6 containing baculosomes were used to determine endogenous inhibitors of 
CYP2B6. Several polyunsaturated fatty acids (PUFAs) including arachidonic acid, 
linoleic acid, DHA, and -linolenic acid (ALA) were inhibitors with IC50’s below 
10M. LC-MS/MS revealed that CYP2B6 metabolizes PUFAs, with a greater than 20-
fold preference for metabolism of ALA to 9-HOTrE and to a lesser extent 13-HOTrE. To 
further study the role of CYP2B6 in vivo, humanized-CYP2B6-transgenic (hCYP2B6-
Tg) and Cyp2b-null mice were fed a 60% high-fat diet for 16 weeks. Compared to 
Cyp2b-null mice, hCYP2B6-Tg mice reduced weight gain and metabolic disease as 
measured by glucose tolerance tests, however hCYP2B6-Tg male mice increased liver 
triglycerides. Serum and liver oxylipin metabolite concentrations generally increased in 
male hCYP2B6-Tg mice, while only serum oxylipins increased in female hCYP2B6-Tg 
mice. RNA-seq data also demonstrated sexually dimorphic changes in gene expression, 
as Cyp2b10/CYP2B6 was induced in male, but not female, hCYP2B6-Tg mice. Overall, 
our data indicates that CYP2B6 is an anti-obesity enzyme, but to a lesser extent than 
murine Cyp2b. Therefore, the inhibition of CYP2B6 by xenobiotics or dietary fats can 
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exacerbate obesity and metabolic disease through disrupted metabolism of key lipid 
metabolites.  
 
Keywords: -linolenic acid (ALA), diet-induced obesity, oxylipin, Cyp2b-null, 
CYP2B6, non-alcoholic fatty liver disease (NAFLD)  
 
Highlights 
 Human CYP2B6 partially reverses diet-induced obesity observed in Cyp2b-null mice 
 Unlike WT mice, effects are strongest in hCYP2B6-Tg female mice 
 CYP2B6 increases steatosis, which was not expected, but also reduces metabolic 
disease 
 CYP2B6 primarily metabolizes α-linolenic acid to 9-HOTrE and 13-HOTrE in vitro 
 However, in vivo CYP2B6 metabolizes several PUFAs in the 9- and 13- positions 
 
 
5.1 Introduction 
Obesity, in addition to insulin resistance and dyslipidemia, are the most important 
risk factors for development of nonalcoholic fatty liver disease (NAFLD) (Masuoka & 
Chalasani, 2013). The prevalence of obesity is increasing in the United States, and the 
most recent 2017-2018 National Health and Nutrition Examination Survey recorded 
42.4% of adults are obese (Hales, Carroll, Fryar, & Ogden, 2020). The constitutive 
androstane receptor (CAR) has been identified as an anti-obesity transcription factor, as 
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its activation in leptin-deficient mice induced cytochrome P450 2b10 (Cyp2b10) and 
subsequently improved hepatic glucose and fatty acid metabolism (Dong et al., 2009). 
Additionally, a loss of hepatic CYP activity in hepatic P450 oxidoreductase (POR)-null 
mice led to steatosis and the induction of Cyp2b primarily through CAR activation (Finn, 
Henderson, Scott, & Wolf, 2009), indicating a role for CAR in recognizing and Cyp2b in 
metabolizing hepatic lipids. Furthermore, forkhead box protein A2 (Foxa2) regulates 
lipid metabolism and ketogenesis genes in mice including Cyp2b9 (Hashita et al., 2008; 
Wolfrum, Asilmaz, Luca, Friedman, & Stoffel, 2004), and three recent studies found 
Cyp2b9 exhibited the highest increase in gene expression following a HFD in mice 
(Heintz, Kumar, Rutledge, & Baldwin, 2019; Hoek-van den Hil et al., 2015; Leung, Trac, 
Du, Natarajan, & Schones, 2016). Our previously generated Cyp2b9/10/13-null (Cyp2b-
null) mice are diet-induced obese (DIO) with increased NAFLD in males (Heintz et al., 
2019). Similarly, age-dependent lipid accumulation was observed in RNAi-mediated 
Cyp2b-knockdown male mice (Damiri & Baldwin, 2018). These findings implicate 
Cyp2b’s role in hepatic fatty acid metabolism and obesity. 
In the liver, CAR followed by pregnane X receptor (PXR) are the primary 
regulators of human and murine Cyp2b genes (Hernandez, Mota, & Baldwin, 2009; P. 
Wei, Zhang, Egan-Hafley, Liang, & Moore, 2000). CYP2B6 is the only hepatic CYP2B 
isoform in humans; Cyp2b9, Cyp2b10, and Cyp2b13 are the dominant hepatic Cyp2b 
genes in mice. CYP2B members are also regulated by the glucocorticoid receptor (GR) 
and transcription factors FOXA2, hepatocyte nuclear factor 4α (HNF4α), and 
CCAAT/enhancer-binding protein α (C/EBPα) in humans (Benet, Lahoz, Guzmán, 
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Castell, & Jover, 2010; Dvorak et al., 2003; Hongbing & Masahiko, 2003; L. Li, Li, 
Heyward, & Wang, 2016) and rodents (Audet-Walsh & Anderson, 2009; Hashita et al., 
2008; Wiwi, Gupte, & Waxman, 2004). Growth hormone-mediated regulation of these 
transcription factors results in the female predominant expression of murine Cyp2b 
(Hernandez, Mota, Huang, Moore, & Baldwin, 2009; Renaud, Cui, Khan, & Klaassen, 
2011; Wiwi et al., 2004). Although there is large interindividual variation in human 
hepatic CYP2B6 expression, it is also primarily female expressed, but to a much lesser 
degree compared to rodents (Lamba et al., 2003). It is hypothesized that changes in the 
expression of transcription factors such as FOXA2 by fluctuations of steroids and 
hormones may contribute to the large interindividual variations of CYP2B6 expression in 
human populations (L. Li et al., 2016).  
Human CYP2B6 has broad substrate specificity, playing a role in the metabolism 
of numerous xeno- and endobiotic compounds (Zanger & Klein, 2013). The substrate 
selectivity of CYP2B6 includes over 60 clinical drugs such as artemisinin, propofol, 
ketamine, ifosfamide, nevirapine, efavirenz, mephobarbital, bupropion, and tamoxifen 
(Mo et al., 2009), as well as many important environmental toxicants including 
chlorpyrifos (Tang et al., 2001), carbaryl (Hodgson & Rose, 2007), parathion 
(Foxenberg, McGarrigle, Knaak, Kostyniak, & Olson, 2007), triclosan (Wu et al., 2017), 
perfluorocarboxylic acids (Abe et al., 2017), and the insect repellant N,N-diethyl-m-
toluamide (DEET) (Hodgson & Rose, 2007). Endogenous compounds such as steroids, 
bile acids, and fatty acids are also metabolized by CYP2B6 (Mo et al., 2009; Nebert & 
Russell, 2002).  
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Polyunsaturated fatty acids (PUFAs) may regulate Cyp2b transcription and act as 
Cyp2b substrates. For example, the omega-6 fatty acid, linoleic acid (LA), activates CAR 
and induces Cyp2b10 (Finn et al., 2009). The omega-3 fatty acid, docosahexaenoic acid 
(DHA) inhibits CAR translocation and subsequently inhibits Cyp2b transcription (C.-C. 
Li, Lii, Liu, Yang, & Chen, 2007). Arachidonic acid is metabolized by Cyp2b19 (mouse) 
and Cyp2b12 (rat) in keratinocytes, as well as Cyp2b1/2 in rat hepatic microsomes to 
anti-inflammatory epoxyeicosatrienoic acids (EETs) (Capdevila et al., 1990; Du et al., 
2005; Keeney, Skinner, Wei, Friedberg, & Waterman, 1998). Human CYP2B6 also 
appears to play a role in the epoxidation of anandamide, an arachidonic acid-derived 
endogenous cannabinoid to bioactive hydroxyeicosatetraenoic acid (HETE) and EET 
metabolites (Sridar, Snider, & Hollenberg, 2011), such as 5,6-EET-ethanolamide, a 
potent agonist of the peripheral cannabinoid receptor, CB2 (Snider, Nast, Tesmer, & 
Hollenberg, 2009). However, the role of human CYP2B6 in the metabolism of most 
PUFAs is not well-characterized or completely untested.  
Murine Cyp2b enzymes are anti-obesogenic in males. Cyp2b-null mice are diet-
induced obese with an increase in NAFLD, white adipose tissue, serum cholesterol, 
leptin, and β-hydroxybutyrate. Furthermore, Cyp2b-null males fed a normal diet show 
increased liver triglycerides and a gene expression profile similar to WT mice fed a HFD, 
indicating progression to NAFLD even without a high-fat diet (Heintz et al., 2019). In 
contrast, female weight gain was not significantly different, nor was NAFLD; however, 
the lack of Cyp2b in female mice was moderately protective from methionine and 
choline-deficient diet-induced non-alcoholic steatosis (NASH) (Heintz, McRee, Kumar, 
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& Baldwin, 2020). However, the role of CYP2B6 as an anti-obesity gene has not been 
assessed. The purpose of this research is to determine the role of CYP2B6 in PUFA 
metabolism and test whether CYP2B6 is an anti-obesity enzyme by comparing diet-
induced obesity (DIO) between Cyp2b-null mice and our newly produced humanized 
CYP2B6 mice to determine if CYP2B6 can reverse obesity and NAFLD in Cyp2b-null 
mice. PUFA metabolites of CYP2B6 were identified in vitro from CYP2B6 containing 
baculosomes by LC-MS/MS and in vivo from serum and liver following high-fat diet 
treatment. Physiological (body, tissue weights, glucose tolerance), biochemical 
(cholesterol, serum and liver lipids, PUFA metabolites), and transcriptomic (RNAseq) 
changes were measured. Results indicate human CYP2B6 primarily metabolizes PUFAs 
in the 9- and 13- positions and partially reverses diet-induced obesity observed in Cyp2b-
null mice, but with unexpected sexually dimorphic effects.  
 
 
5.2 Materials and Methods 
5.2.1 CYP2B6 inhibition:  
The Vivid CYP2B6 Blue Screening kit with CYP2B6-containing baculosomes 
was obtained from ThermoFisher (Waltham, MA, USA) and used to screen for potent 
PUFA inhibitors of CYP2B6. Decreased fluorescence due to chemical inhibition was 
quantified on a Gen5 microplate reader (Synergy H1 Hybrid Reader, BioTek, Winooski, 
Vermont, USA) at 415/460 nm excitation/emission at 30-second intervals for 30 minutes 
in kinetic assay mode in accordance with manufacturer’s protocol. IC50 values were 
172 
determined as described previously using GraphPad Prism 7.0 (Graphpad Software, San 
Diego, CA, USA) (Baldwin & Roling, 2009; Schmidt, Sengupta, Saski, Noorai, & 
Baldwin, 2017). Briefly, chemical concentrations were log10 transformed, sigmoidal 
concentration-response curves were fit with a variable slope model with least squares 
ordinary fit. Confidence intervals were produced assuming asymmetrical distribution as 
recommended by GraphPad. 
 
5.2.2 CYP2B6 fatty acid substrates:  
CYP2B6 containing and control baculosomesTM (Thermo Fisher) were incubated 
with 25 µM arachidonic acid (AA), linoleic acid (LA), α-linolenic acid (ALA), or 
docosahexaenoic acid (DHA) (n = 3) for two hours in VIVIDTM P450 reaction buffer and 
the NADPH-regeneration system (Thermo Fisher). Following incubation, samples were 
stored at -80°C and shipped on dry ice to the Emory Integrated Lipidomics Core (EILC). 
Oxidized lipids were selectively extracted from the samples by solid phase extraction 
because of their low concentrations in comparison to other high abundance lipid species. 
This was done by depositing homogenized samples into a C18 solid phase extraction 
cassette, rinsing with hexane to remove nonpolar lipid species, and eluting with methyl 
formate. The recovered lipids were analyzed via LC-MS/MS in a multiple reaction 
monitoring (MRM) based method that selectively targets oxylipins using an AB SCIEX 
QTrap5500 enhanced high performance hybrid triple quadrupole/linear ion trap 
LC/MS/MS with a mass range of m/z 5 to 1250 in triple quadrupole mode and 5-1000 in 
LIT mode. The LC/MS/MS is paired with an ExionLC AC HPLC/UHPLC system with 
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an ExionLC column oven and autosampler along with a computer workstation running 
LipidView software (AB SCIEX) (Naudin et al., 2020; Tillman et al., 2020). The 
concentration of the intracellular oxylipins were calibrated against external standards. 
 
5.2.3 High-fat diet treatment of Cyp2b-null mice and hCYP2B6-Tg: 
CYP2A13/CYP2B6/CYP2F1-transgenic mice from Dr. Qing Yu and Dr. Xinxin 
Ding’s laboratory’s containing a bacterial artificial chromosome (BAC) of 210 kb from 
human chr19 containing CYP2A13, CYP2B6, and CYP2F1 genes (Y. Wei et al., 2012) 
were bred to Cyp2b9/10/13-null (Cyp2b-null) mice from our laboratory that lack the 
primarily hepatic murine Cyp2b members, Cyp2b9, Cyp2b10, and Cyp2b13 (Ramiya 
Kumar et al., 2017) to produce humanized CYP2B6-transgenic (hCYP2B6-Tg) mice 
lacking the hepatic murine Cyp2b members. These mice also express CYP2A13, which is 
primarily expressed in the nasal mucosa and lung and CYP2F1, which is primarily 
expressed in the lung (Y. Wei et al., 2012). Cyp2b-null and hCYP2B6-Tg female and 
male mice (10 weeks old; n=8 per gender) were fed a high-fat diet (HFD; Envigo 
TD.06414, 5.1 Kcal/g: 60.3% fat (37% saturated, 47% monounsaturated, 16% 
polyunsaturated fat), 18.4% protein, 21.3% carbohydrates; Madison, WI USA) for 16 
weeks. Weight gain was monitored weekly and feed consumption was measured every 
other day. Glucose tolerance tests (GTT) were performed during week 13. At the end of 
the study, mice were anesthetized and blood collected by heart puncture prior to 
euthanasia. Liver, kidney, inguinal white adipose tissue (WAT), brown adipose tissue 
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(BAT), and testes were excised and weighed. All tissues were immediately snap frozen 
with liquid nitrogen and stored at -80°C. 
 
5.2.4 Fasting blood glucose and glucose tolerance tests:  
Mice were fasted for 4.5 hours and fasting blood glucose was determined using an 
Alphatrak 2 (AlphaTRAK, Chicago, IL USA) blood glucose meter following tail bleed 
on week 13. Then glucose tolerance was determined following an intraperitoneal 
injection of 1g/kg D-glucose (Sigma Ultra, St. Louis, MO USA) with blood glucose 
readings from tail bleeds every 20 min for the first hour and every 30 min for the second 
hour as described previously (Ayala et al., 2010; Heintz et al., 2019). Results are 
recorded over the time and as area under the curve (AUC). Data are presented as mean 
blood glucose levels ± SEM. Statistical significance was determined by unpaired 
Student's t-tests using GraphPad Prism 7.0. 
 
5.2.5 Serum biomarker panel:  
Blood samples were collected by heart puncture and incubated at room 
temperature for 30 min followed by centrifugation at 6000 rpm for 10 min. Serum from 
each sample was transferred into a fresh tube and aliquots shipped on dry ice to Baylor 
College of Medicine’s Comparative Pathology Laboratory (Houston, TX USA) for 
determination of serum biomarker concentrations including alanine aminotransferase 
(ALT), cholesterol, triglycerides (TAG), high density lipoprotein (HDL), low density 
lipoprotein (LDL), and very low density lipoprotein (VLDL). Serum parameters were 
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determined using a Beckman Coulter AU480 chemistry analyzer (Atlanta, GA, USA) and 
the appropriate Beckman Coulter biochemical kits according to the manufacturer’s 
instructions. 
 
5.2.6 Liver triglycerides:  
Liver triglycerides were extracted and quantified as described previously (R. 
Kumar, Litoff, Boswell, & Baldwin, 2018) using colorimetric kits from Cayman 
Chemical (Ann Arbor, MI). In addition, visual confirmation was performed with Oil Red 
O. During necropsy, clean liver slices were snap frozen in liquid nitrogen and stained 
with Oil Red O at Baylor College of Medicine’s Comparative Pathology Laboratory 
using standard protocols (Dong et al., 2009). 
 
5.2.7 Lipidomic analysis of polyunsaturated fatty acids (PUFA) metabolites:  
Serum and liver samples were shipped on dry ice to EILC for lipidomic analysis 
of lipid metabolites from AA, LA, ALA, DHA, and eicosapentaenoic acid (EPA). 
Oxidized lipids were selectively extracted from samples by solid phase extraction 
following ELIC methods (Naudin et al., 2020). 
Random forest analyses by MetaboAnalyst 3.6 (Xia & Wishart, 2002) were 
performed on lipidomic data to rank PUFA metabolite species as a prediction of how 
large of an effect each species has between genotype (Breiman, 2001). The mtry 
parameter was set to 7, and the number of trees to be built was set to 500 for each 
analysis to achieve the lowest out-of-bag (OOB) error. The larger the mean decreased 
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accuracy (MDA) value, the more important the lipid metabolites are for the accuracy of 
the association between variable and response. Lipid metabolites with importance scores 
less than or equal to zero are likely to have no predictive ability. Statistical significance 
between genotypes was also determined by unpaired Student's t-tests using GraphPad 
Prism 7.0. Data are presented as mean concentration ± SEM. 
 
5.2.8 RNA sequencing (RNAseq):  
Liver samples were stored in RNAlater Stabilization Solution (Invitrogen, 
Carlsbad, CA USA) at -80°C. Total RNA was extracted from mouse livers of each 
treatment group using TRIzol (Ambion, Carlsbad, CA USA) and quantified on a Qubit 
2.0 Fluorometer. RNA integrity number (RIN) was determined with an Agilent 2100 
Bioanalyzer (place) to assess RNA quality, and samples with a RIN > 8.0 were 
determined to be of high quality and used for next generation sequencing. Libraries were 
prepared using NEB Next Ultra RNA Library Prep kit. Samples were sequenced to an 
average sequencing depth of 20,000,000 read pairs with a 2x150 paired-end module using 
a NovaSeq 6000. Quality metrics were checked using FastQC on all samples sequenced, 
and Trimmomatic was used to trim low quality bases. Trimmed reads were aligned to the 
Mus musculus reference genome (GCF_000001635.25_GRCm38.p6) using GSNAP, and 
100% of the trimmed reads aligned. Subread feature counts software found reads that 
aligned with known genes. Raw read counts and EdgeR were used to determine 
differential gene expression (Huber et al., 2015). Series GSE148460 containing the 
RNAseq data has been uploaded to the Gene Expression Omnibus (GEO).  
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DAVID (Huang da, Sherman, & Lempicki, 2009a, 2009b) functional annotation 
tool was used to perform the analysis of enriched gene ontology (GO) terms from 
differentially expressed gene lists for female and male mice (adjusted p-value < 0.05). 
Chord plots were generated in R using GOplot (Wencke, Sánchez-Cabo, & Ricote, 2015) 
to display the relationship between enriched GO terms and differentially expressed genes. 
Hierarchical cluster analysis was performed on variables including total body weight, 
WSI, serum lipids, oxylipin species from liver and serum, and differentially expressed 
genes (logFC > 1.0 or < 1.0) and visualized in heatmaps with MetaboAnalyst 3.6 (Xia & 
Wishart, 2002) to compare measured variables between genotypes.  
 
 
5.3 Results 
5.3.1 Inhibition of CYP2B6 by endogenous compounds: 
Various fatty acids and other endobiotic chemicals (10 μM) were screened to 
measure inhibition of CYP2B6 activity in CYP2B6 containing baculosomes (Fig. 5.1A), 
as we hypothesized many inhibitors would also be substrates. Most of the endobiotic 
compounds examined significantly reduced CYP2B6 activity, however, AA and DHA 
decreased CYP2B6 activity the most, by 78% and 89.6%, respectively. Concentration-
dependent response curves from CYP2B6 containing baculosomes incubated with fatty 
acids, bile acids, or steroids were determined to further investigate the inhibition of 
CYP2B6 by PUFAs in comparison to other endobiotics and the plasticizer, nonylphenol, 
as a positive control (Acevedo et al., 2005). In concurrence with the CYP2B6 screening 
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results, AA and DHA had the lowest IC50s (1.04 μM and 2.69 μM, respectively) 
compared to other LA (9.19 μM) and ALA (9.53 μM) measured (Fig. 5.1B). However, 
even the strongest endogenous inhibitors have 5X times less affinity to CYP2B6 than the 
known xenobiotic inhibitor, nonylphenol (Acevedo et al., 2005). Most bile acids and 
steroids measured had much higher IC50s than the PUFAs, apart from lithocholic acid 
(IC50 = 2.47 μM) (Fig. 5.1B). Based on the low IC50 values for AA and DHA, it is 
expected that these PUFAs are effective inhibitors and potential substrates for CYP2B6; 
at least following a HFD or a diet high in those respective PUFAs. 
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Figure 5.1. Endogenous inhibitors of CYP2B6. (A) Percent activity of CYP2B6 
containing baculosomes treated with 10 μM of various fatty acids and endobiotic 
inhibitors. (B) Concentration-response curves of CYP2B6 containing baculosomes 
treated with fatty acids, bile acids, steroids, or nonylphenol (positive control). Data are 
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presented as mean ± SEM. Statistical significance was determined by unpaired Student’s 
t-tests of each inhibitor treatment compared to untreated (n=4-6). * indicates p-value 
<0.05; ** indicates p-value <0.01; *** indicates p-value <0.001; **** indicates p-value 
<0.0001.  
 
 
5.3.2 Preferential metabolism of ALA to 9-HOTrE by CYP2B6-containing baculosomes:  
Oxylipins of AA, LA, DHA, and ALA produced by CYP2B6 were measured by 
LC-MS/MS to further investigate the role of CYP2B6 in PUFA metabolism. Considering 
their IC50s, surprisingly few AA, LA and DHA metabolites were formed (Fig. 5.2). 
Instead, the n-3 PUFA, ALA, was the most prominently metabolized PUFA with 
metabolite concentrations almost 20X greater than other PUFA metabolites. 9-hydroxy-
10E,12Z,15Z-octadecatrienoic acid (HOTrE) and 13-HOTrE were the primary oxylipins 
produced. Such high concentrations suggest that CYP2B6 has a specific PUFA substrate 
and products, potentially as key signaling molecules. Interestingly, in addition to ALA, 
other n-3 and n-6 based oxylipins were also primarily metabolized at the 9 or 13 position, 
indicating that CYP2B6 preferentially metabolizes PUFAs in these positions.  
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Figure 5.2. PUFA metabolites of CYP2B6. LC-MS/MS was used to measure 
production of oxylipid metabolites formed by CYP2B6 containing baculosomes 
compared to control baculosomes incubated with 25 μM arachidonic acid, linoleic acid, 
docosahexaenoic acid, and α-linolenic acid (n=3). 
 
 
5.3.3 Humanized-CYP2B6-Tg mice have increased glucose sensitivity and decreased 
body mass following 16 weeks of HFD treatment: 
Female hCYP2B6-Tg mice gained significantly less weight than Cyp2b-null 
counterparts after 16 weeks of HFD treatment. Changes in body mass were similar until 
about week 11 and continued to separate by genotype for the duration of the study (Fig. 
5.3A). In contrast, male hCYP2B6-Tg mice showed no significant differences in body 
mass gain compared to Cyp2b-null mice over 16 weeks of HFD treatment; although male 
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hCYP2B6-Tg mice tended to gain a little less weight than their Cyp2b-null counterparts 
during the second half of the study (Fig. 5.3A). Both genotypes in female and male mice 
consumed similar amounts of calories throughout the duration of the 16-week HFD study 
(Suppl. Material 5.1; S5.1); therefore, caloric consumption does not explain the 
differences in body mass. The reduced weight gain in hCYP2B6-Tg female mice may be 
partly attributed to lower tissue weights as inguinal WAT was decreased 27% although 
not significantly; only kidney weights were significantly decreased (Table 5.1). No 
differences were observed in tissue weights between Cyp2b-null and hCYP2B6-Tg male 
mice (Table 5.1).  
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Figure 5.3. Genotypic differences in body weight gain and glucose sensitivity during 
16 weeks of high-fat diet treatment. (A) Change in body weight gain over 16 weeks of 
HFD treatment. (B) Glucose tolerance tests (GTT) performed during week 13 on Cyp2b-
null and hCYP2B6-Tg female and male mice. Results are represented as area under the 
curve. Data are presented as mean ± SEM. Statistical significance was determined by 
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unpaired Student’s t-tests (n=7-8). * indicates a p-value < 0.05 and ** indicates a p-value 
< 0.01. 
 
Table 5.1. Comparison of tissue weights between Cyp2b-null and hCYP2B6-Tg 
female (A) and male (B) mice fed a HFD for 16 weeks. 
A. 
 
B. 
 
Data are presented as mean (g) + SEM. Statistical significance was determined by 
unpaired Student’s t-tests (n=7-8). * indicates a p-value < 0.05, ** indicates a p-value < 
0.01, and *** indicates a p-values < 0.0001. 
 
 
GTTs were performed to determine if HFD-fed hCYP2B6-Tg mice respond better 
than HFD-fed Cyp2b-null mice to a glucose challenge, a biomarker of metabolic disease. 
Female hCYP2B6-Tg mice performed slightly better than Cyp2b-null counterparts, but 
only at the last time point, suggesting that this may be an outlier. However, male 
hCYP2B6-Tg mice exhibited a significantly faster response to a glucose challenge than 
Cyp2b-null males even though there was no change in weight between the genotypes 
Tissue Weights Cyp2b-null F hCYP2B6-Tg F 
Total Body 29.63 + 1.40 27.05 + 1.21 
Liver 1.02 + 0.03 0.99 + 0.04 
Kidney 0.33 + 0.01 0.29 + 0.01* 
WAT 2.25 + 0.33 1.65 + 0.31 
BAT 0.13 + 0.02 0.12 + 0.01 
 
Tissue Weights Cyp2b-null M hCYP2B6-Tg M 
Total Body 38.81 + 1.99 38.93 + 1.66 
Liver 1.40 + 0.13 1.51 + 0.07 
Kidney 0.48 + 0.04 0.52 + 0.02 
WAT 3.41 + 0.07 3.52 + 0.33 
BAT 0.31 + 0.03 0.29 + 0.07 
Testes 0.33 + 0.03 0.38 + 0.03 
 
185 
(Fig. 5.3B), suggesting some other physiological perturbation is protecting hCYP2B6-Tg 
mice from metabolic disease relative to Cyp2b-null mice. 
 
5.3.4 Hepatic and serum lipids in HFD-fed hCYP2B6-Tg mice: 
Differences in hepatic lipid accumulation between Cyp2b-null and hCYP2B6-Tg 
mice were examined to determine if the presence of hCYP2B6 provided protection from 
NAFLD as do murine Cyp2b members in male mice (Finn et al., 2009; Heintz et al., 
2019). Male but not female hCYP2B6-Tg mice showed increased hepatic triglycerides 
compared to Cyp2b-null mice, (Fig. 5.4a); the opposite of what was predicted and 
observed in Cyp2b-null compared to WT (B6) male mice (Heintz et al., 2019). 
Histological analysis of Oil Red O staining was performed to confirm the chemical 
analysis of lipid accumulation in the liver; however, although steatosis increased as a 
result of HFD treatment, differences observed between genotypes were relatively small 
and not significant (Fig. 5.4b). There were also no significant differences in serum lipids 
between Cyp2b-null and hCYP2B6-Tg mice (Table 5.2). Overall, the increase of inert 
liver triglycerides in hCYP2B6-Tg mice may be protective based on increased glucose 
sensitivity although other measured physiological and biochemical parameters are 
equivocal.  
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Figure 5.4. Comparison of steatosis markers in hCYP2B6-Tg and Cyp2b-null mice. 
(A) Total liver triglycerides were measured in Cyp2b-null and hCYP2B6-Tg female and 
male mice. Data are presented as mean + SEM. Statistical significance was determined 
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by unpaired Student’s t-tests (n=5). * indicates a p-value < 0.05. (B) Fatty liver 
histopathological changes were evaluated by Oil red O staining in female and male mice. 
Images were taken at 100x (0.2 mm) and 400x (0.05 mm) magnification. 
 
 
Table 5.2. Comparison of serum biomarkers between Cyp2b-null and hCYP2B6-Tg 
female (A) and male (B) mice fed a HFD for 16 weeks. 
A. 
 
B. 
 
Data are presented as mean (g) + SEM. Statistical significance was determined by 
unpaired Student’s t-tests (n=5). 
 
 
5.3.5 Hepatic and serum oxylipin metabolites produced in HFD-fed hCYP2B6-Tg mice: 
Concentrations of serum and hepatic lipid metabolites from LA, AA, ALA, DHA, 
and EPA were compared between HFD-fed Cyp2b-null and hCYP2B6-Tg mice to 
identify lipid metabolites metabolized by human CYP2B6 in vivo. The oxylipin species 
most predictive of differences between Cyp2b-null and hCYP2B6-Tg mice in serum or 
Serum Biomarkers Cyp2b-null F hCYP2B6-Tg F 
ALT 21.76 + 2.02 18.81 + 1.14 
Triglycerides 87.53 + 15.68 71.33 + 12.36 
HDL 74.37 + 2.88 75.26 + 1.78 
LDL  6.75 + 0.46 7.59 + 0.29 
VLDL  17.51 + 3.14 14.27 + 2.47 
Cholesterol 133.24 + 7.44 127.82 + 4.05 
 
 1 Serum Biomarkers Cyp2b-null M hCYP2B6-Tg M 
ALT 40.02 + 15.89 30.65 + 7.51 
Triglycerides 88.06 + 9.61 79.25 + 7.31 
HDL 100.76 + 3.03 98.70 + 1.76 
LDL  10.90 + 0.76 10.97 + 0.76 
VLDL  17.61 + 1.92 15.85 + 1.46 
Cholesterol 213.71 + 6.18 200.52 + 6.56 
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liver tissue are primarily AA and LA-species as determined by random forest analysis 
(Fig. 5.5).  
 
Figure 5.5. Random forest analysis of lipid metabolites by tissue type in female and 
male mice. Important lipid metabolites identified by random forest analysis between 
Cyp2b-null and hCYP2B6-Tg mice in serum or liver tissue. 
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The anti-inflammatory signaling molecule, AA 14,15-EET was ranked the most 
predictive lipid metabolite in hepatic tissue in female and male hCYP2B6-Tg mice (Fig. 
5.5). Interestingly, AA 14,15-EET was the only statistically different oxylipin by 
unpaired Student’s t-tests between Cyp2b-null and hCYP2B6-Tg female mice in serum, 
and there were no significant changes in oxylipin concentrations between HFD-fed 
Cyp2b-null and hCYP2B6-Tg mice in the liver. While individual hepatic oxylipin 
differences were small or not significant, the total average concentration of oxylipins in 
the liver significantly increased in male hCYP2B6-Tg mice (Table 5.3).    
 
Table 5.3. Total average of oxylipin metabolites measured in liver and serum of 
HFD-fed Cyp2b-null and hCYP2B6-Tg mice. 
 
Data are presented as mean (ng/μL) + SEM. Statistical significance was determined by 
unpaired Student’s t-tests (n=5). * indicates a p-value < 0.05. 
 
 
Hepatic pro-inflammatory response metabolites, LA 9--hydroxyoctadecadienoic 
acid (LA 9-HODE) (females) and AA 12-hydroxyeicosatetraenoic acid (AA 12-HETE) 
(males), followed by LA 13-HODE derivative, 13-keto-9Z,11E-octadecadienoic acid (LA 
13-KODE), were identified as the most predictive lipid metabolites in serum of female 
and male mice (Fig. 5.5). With the exception of AA 12-HETE, these metabolites and 
 Serum Liver 
 Cyp2b-null hCYP2B6-Tg Cyp2b-null hCYP2B6-Tg 
Females 
0.002521 ± 
0.0005892 
0.003214 ± 
0.0007361 
0.007582 ± 
0.001603 
0.004072 ± 
0.000926 
Males 
0.002238 ± 
0.0005311 
0.005842 ± 
0.002113 
0.002008 ± 
0.0004811 
0.004106 ± 
0.0008813* 
 
190 
others were also different by Student’s t-tests (Table 5.4). LA 9,10-dihydroxyoctadec-12-
enoic acid (DiHOME) a hydrolase metabolite of 9,10-epoxy-12Z-octadecenoic acid 
(EpOME), LA 9-HODE and LA 13-KODE, as well as AA 14,15-epoxyeicosatrienoic 
acid (AA 14,15-EET) and ALA isoprostane all increased in the serum of female 
hCYP2B6-Tg mice (Table 5.4A). These PUFA metabolites also increased in the serum 
of male hCYP2B6-Tg mice but not significantly. The only lipid metabolite to 
significantly increase in the presence of CYP2B6 in the serum of male mice was AA 
thromboxane B2 (TXB2) (Table 5.4B). Total average oxylipin concentrations in serum 
samples increased, but not significantly, in both female and male hCYP2B6-Tg mice 
compared to Cyp2b-null mice (Table 5.3).   
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Table 5.4. Measured serum and liver lipid metabolite concentrations in Cyp2b-null 
and hCYP2B6-Tg female (A) and male (B) mice fed a HFD for 16 weeks. 
A. 
 
 
 
 
 
 
 
 
 
 Serum Liver 
Oxylipin Species Cyp2b-null hCYP2B6-Tg Cyp2b-null hCYP2B6-Tg 
AA 14,15-EET 
3.444E-06 ± 
2.11E-06 
2.909E-05 ± 
2.946E-06** 
0.0008699 ± 
0.0004062 
0.0003727 ± 
0.000219 
AA 11,12-EET 
0.001911 ± 
0.0003876 
0.002914 ± 
0.001033 
0.007769 ± 
0.002561 
0.003422 ± 
0.001977 
AA 9-HETE 
0.008382 ± 
0.005741 
0.007522 ± 
0.003799 
0.01077 ± 
0.005417 
0.006018 ± 
0.002752 
AA 12-HETE 
0.0004833 ± 
9.685E-05 
0.001130 ± 
0.0003599 
0.002732 ± 
0.0008528 
0.001756 ± 
0.001041 
AA 11,12-DHET 
0.01543 ± 
0.003179 
0.02971 ± 
0.006977 
0.02317 ± 
0.009411 
0.01133 ± 
0.00699 
AA PGE2 
0.0047044 ± 
0.001773 
0 ± 0* 
0.0002838 ± 
0.0002838 
0 ± 0 
AA PGF2a 
0.003416 ± 
0.0008837 
0.005472 ± 
0.001738 
0.04234 ± 
0.02609 
0.02244 ± 
0.01324 
AA TXB2 
6.141E-05 ± 
2.902E-05 
0.0001025 ± 
4.572E-05 
0.001356 ± 
0.000447 
0.0006450 ± 
0.0004188 
LA 9-HODE 
0.001124 ± 
0.0001462 
0.004251 ± 
0.0009221* 
0.03462 ± 0.0141 
0.01603 ± 
0.009448 
LA 9-HpODE 
0.02914 ± 
0.002886 
0.02957 ± 
0.004296 
0.03637 ± 
0.01197 
0.03278 ± 
0.004932 
LA 13-KODE 
0.0003835 ± 
6.357E-05 
0.001051 ± 
0.0001858** 
0.007301 ± 
0.00389 
0.002536 ± 
0.001444 
LA 9,10-DiHOME 
9.894E-05 ± 
4.307E-05 
0.000345 ± 
8.309E-05* 
0.002194 ± 
0.0008728 
0.0008417 ± 
0.0005167 
EPA Resolvin 
0.002928 ± 
0.0001994 
0.004320 ± 
0.0006148 
0.0007463 ± 
0.0004635 
0.0003922 ± 
0.0002707 
ALA 9-HOTrE 0 ± 0 
0.0001253 ± 
0.0001253 
0.0006108 ± 
0.0002531 
0.0002325 ± 
0.0002325 
ALA Isoprostane 0 ± 0 
0.0002449 ± 
6.423E-05** 
0.008005 ± 
0.003746 
0.003327 ± 
0.001886 
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B. 
 
Data are presented as mean (ng/μL) + SEM. Statistical significance was determined by 
unpaired Student’s t-tests (n=5). * indicates a p-value < 0.05 and ** indicates a p-value < 
0.01. 
 
 
5.3.6 Gene expression differences between HFD-fed Cyp2b-null and hCYP2B6-Tg mice: 
RNAseq was performed on liver samples to examine the effect of CYP2B6 on 
global hepatic gene expression compared to Cyp2b-null mice during HFD treatment 
 Serum Liver 
Oxylipin Species Cyp2b-null hCYP2B6-Tg Cyp2b-null hCYP2B6-Tg 
AA 14,15-EET 
1.281E-05 ± 
4.445E-06 
3.707E-05 ± 
2.216E-05 
8.732E-05 ± 
2.825E-05 
0.0003897 ± 
0.0002161 
AA 11,12-EET 
0.002183 ± 
0.0006091 
0.006343 ± 
0.003742 
0.0009780 ± 
0.0003435 
0.004964 ± 
0.002834 
AA 9-HETE 
0.003868 ± 
0.001342 
0.01030 ± 
0.003904 
0.006016 ± 
0.001504 
0.01118 ± 
0.003558 
AA 12-HETE 
0.0004491 ± 
0.0001189 
0.002130 ± 
0.001214 
0.0006437 ± 
0.000258 
0.002592 ± 
0.001547 
AA 11,12-DHET 
0.01763 ± 
0.00509 
0.04130 ± 
0.02508 
0.002351 ± 
0.001458 
0.01177 ± 
0.006342 
AA PGE2 
0.002081 ± 
0.0008876 
0.002618 ± 
0.001158 
0.0004154 ± 
0.0004154 
0 ± 0 
AA PGF2a 
0.001286 ± 
0.0008909 
0.007236 ± 
0.003804 
0.005866 ± 
0.002478 
0.02343 ± 
0.01314 
AA TXB2 0 ± 0 
0.0001574 ± 
5.767E-05* 
0.0002758 ± 
0.0001044 
0.00140 ± 
0.0008361 
LA 9-HODE 
0.001534 ± 
0.0005044 
0.004277 ± 
0.00226 
0.004474 ± 
0.001505 
0.01805 ± 
0.01013 
LA 9-HpODE 
0.02545 ± 
0.002158 
0.02385 ± 
0.007709 
0.02616 ± 
0.00340 
0.02363 ± 
0.004619 
LA 13-KODE 
0.0005594 ± 
0.0001023 
0.001398 ± 
0.0008135 
0.0006725 ± 
0.0001771 
0.002463 ± 
0.001289 
LA 9,10-DiHOME 
9.070E-05 ± 
4.131E-05 
0.0002486 ± 
0.0001336 
0.0003869 ± 
0.000138 
0.001156 ± 
0.0006744 
EPA Resolvin 
0.003274 ± 
0.000697 
0.003091 ± 
0.0008124 
0 ± 0 0 ± 0 
ALA 9-HOTrE 0 ± 0 0 ± 0 0 ± 0 
0.0004337 ± 
0.000286 
ALA Isoprostane 
0.0001335 ± 
5.946E-05 
0.0003280 ± 
0.000126 
0.0008786 ± 
0.000269 
0.003881 ± 
0.002122 
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(S5.2).  Gene ontology (GO) enrichment chord plots were used to display the relationship 
between differentially expressed genes and enriched biological process GO terms (S5.3). 
Several circadian rhythm-associated genes were up-regulated in HFD-fed hCYP2B6-Tg 
mice compared to Cyp2b-null mice (Fig. 5.6). Circadian regulation plays an important 
role in liver metabolism and metabolic disease (Shi et al., 2019). Female and to a lesser 
extent, male hCYP2B6-Tg mice had several perturbed protein processing and 
phosphorylation associated genes. Previous RNAseq data generated in our lab determined 
Cyp2b-null mice have increased endoplasmic reticulum stress compared to wild-type 
mice (Heintz et al., 2019). Consistent with these results, female and to a lesser extent, 
male hCYP2B6-Tg mice had several perturbed protein processing and phosphorylation 
associated genes compared to Cyp2b-null mice. In addition, female hCYP2B6-Tg mice 
had several down-regulated genes involved in lipid synthesis, notably Angptl8, a critical 
modulator of serum triglyceride levels (Luo & Peng, 2018) (Fig. 5.6). Interestingly in 
males, Cyp2b10 was the second highest induced gene (logFC=6.19) in HFD-fed 
hCYP2B6-Tg compared to Cyp2b-null mice (S5.2). Cyp2b10 is the murine ortholog to 
human CYP2B6 and 74% identical. Based on alignment program settings and sequencing 
variation (i.e. number of SNPs), CYP2B reads were aligned to Cyp2b10 on the reference 
genome (S5.4). Furthermore, the epidermal growth factor receptor (Egfr) was down-
regulated (logFC = -1.34) in male hCYP2B6-Tg mice compared to Cyp2b-null mice. The 
down-regulation of EGFR provides a mechanism for the activation of CAR and 
subsequent induction of Cyp2b10/CYP2B6 (Mutoh et al., 2013). Conversely, Cyp2b10 
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was not differentially expressed in females, probably because Egfr was up-regulated 
(logFC = 0.77) in female hCYP2B6-Tg mice. 
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Figure 5.6. Chord plots displaying relationships between RNAseq gene expression 
data and gene ontology. Chord plots were used to display the relationship between 
enriched GO terms and differential gene expression data in female (A) and male (B) 
mice. 
 
 
To determine associations between physiological parameters, serum lipids, serum 
and liver oxylipin species, and differentially expressed genes between HFD-fed Cyp2b-
null and hCYP2B6-Tg mice, hierarchical cluster analysis was performed using the top 50 
measured variables from female and male mice (Fig. 5.7). There was clear separation by 
genotype in females, with hierarchical clustering showing that in addition to differentially 
expressed genes, serum-associated variables make up the most distinguishing factors 
between genotypes in female mice (Fig. 5.7A). HFD-fed hCYP2B6-Tg female mice were 
associated with an increase in several serum oxylipins, LDL, and HDL as well as more 
differentially expressed genes than Cyp2b-null females. Fewer serum parameters, TAG, 
VLDL, and two AA serum oxylipin species (AA-TBX2; AA-PGE2) (role in 
inflammation) were increased in HFD-fed Cyp2b-null female mice (Fig. 5.7A).  
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Figure 5.7. Hierarchical cluster analysis comparing measured variables between 
HFD-fed hCYP2B6-Tg and Cyp2b-null mice. Hierarchical cluster analysis determining 
the top 50 measured variables associated with HFD-fed Cyp2b-null or hCYP2B6-Tg 
female (A) or male (B) mice visualized in heatmaps. Variables include serum lipids, 
WAT somatic index (WSI), body weight, serum and liver oxylipin species, and 
differentially expressed genes (logFC >1.0 or <1.0). 
 
 
Samples also clustered by genotype in male mice, but with more variability than 
females (Fig. 5.7B). Interestingly, HFD-fed Cyp2b-null males were associated with an 
increase in serum cholesterol and HDL and only one liver oxylipin metabolite. 
Conversely, hCYP2B6-Tg counterparts were correlated with an increase in WSI, LDL, 
and numerous serum and liver oxylipin species (Fig. 5.7B). In addition, an increase in 
circadian rhythm-related genes in hCYP2B6-Tg mice was a prominent differentiating 
factor between genotype clusters in both female and male mice (Fig. 5.7).   
 
 
5.4 Discussion 
Female hCYP2B6-Tg mice gained less weight than Cyp2b-null counterparts after 
16 weeks of HFD treatment. The difference in weight was not as great and the duration of 
the study was longer than previously conducted when comparing Cyp2b-null and WT 
mice (Heintz et al., 2019). This suggests that human CYP2B6 is an anti-obesity enzyme, 
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but not with the efficacy of the murine Cyp2b enzymes. In addition, the sexual dimorphic 
effects of human CYP2B6 and murine Cyp2b’s were flipped, as Cyp2b-null male mice 
weighed much more than WT mice (Heintz et al., 2019), but it was Cyp2b-null female 
mice that weighed more than hCYP2B6-Tg mice (Fig. 5.3).  
In addition to body weight, hCYP2B6-Tg females also decreased WAT mass 
27%, but not significantly, when compared to Cyp2b-null mice. While 27% is not 
statistically significant, a 27% drop in WAT mass is biologically impressive. Genes that 
play a role in adipocyte lipid accumulation, Angptl8 (Y. Zhang et al., 2016), and 
differentiation (Slc16a1) (Petersen et al., 2017) were concurrently down-regulated in 
hCYP2B6-Tg female mice, as well as acyl-coA synthetase short chain family member 2 
(Acss2), which has been found to promote the systemic storage of fats under HFD 
conditions in mice (Huang et al., 2018). Additionally, previous studies have found serum 
TAG, VLDL and Angptl8 expression to be positively correlated in humans and mice 
(Chung et al., 2016; R. Zhang, 2012). These variables were also increased and grouped 
together by hierarchical cluster analysis in HFD-fed Cyp2b-null female mice. Female 
RNAseq results also indicate disruption of circadian rhythm genes, which often regulate 
lipid distribution (S. Liu et al., 2013) as well as effects on lipid 
metabolism/cholesterol/bile acid pathways (Insig2) (Yabe, Komuro, Liang, Goldstein, & 
Brown, 2003) and energy utilization (Sgk1) (Lang & Voelkl, 2013).  
Concentrations of specific oxylipin metabolites were significantly increased in the 
serum of hCYP2B6-Tg females, which corresponds well with their signaling role and 
obesity-associated effects observed in the physiological and transcriptomic results of 
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HFD-fed hCYP2B6-Tg female mice. These altered oxylipin species do not share one 
specific role, as AA-14,15-EET is anti-inflammatory (Jiang et al., 2014), while LA-9-
HODE and 13-KODE are agonists of the pain receptor, transient receptor potential 
vanilloid 1 (TRPV1) and likely inflammatory (Patwardhan, Scotland, Akopian, & 
Hargreaves, 2009). Furthermore, hierarchical cluster analysis showed changes in AA-
14,15-EET are associated with genes involved in proliferation (Ccno, Frs3, Junb) 
(Passegué, Jochum, Behrens, Ricci, & Wagner, 2002; Valencia et al., 2011; Villa et al., 
2017) and LA-9-HODE and 13-KODE, which are closely associated with each other, are 
associated with genes involved in insulin signaling (Irs2, Clec2h) (Hines et al., 2011). 
Changes between HFD-fed hCYP2B6-Tg and Cyp2b-null female mice suggest CYP2B6 
affected lipid distribution from the liver to other tissues.  
In contrast to females, there was no change in weight between genotypes in HFD-
fed male mice, although male hCYP2B6-Tg mice exhibited increased glucose sensitivity 
and higher liver triglyceride levels compared to Cyp2b-null males. High fat diets often 
cause a shift from normal triglyceride synthesis to bioactive lipid intermediates that can 
induce endoplasmic reticulum (ER) stress and cause lipotoxicity (Fuchs & Sanyal, 2012); 
however, lipotoxic ER stress was not observed in male hCYP2B6-Tg mice. We suspect 
that the increase in inert hepatic triglycerides provided lipotoxic protection from other 
fatty acid-derived species (Cusi, 2009; Jou, Choi, & Diehl, 2008). Additionally, the 
downregulation of Egfr in male hCYP2B6-Tg provides a mechanism for the up-
regulation of Cyp2b10 (Mutoh et al., 2013) and potentially explains the physiological and 
200 
lipid metabolism differences between male and female hCYP2B6-Tg mice, as Egfr was 
up-regulated in females.  
Differences between male hCYP2B6-Tg and Cyp2b-null mice were 
predominantly liver-based effects. In addition to increased liver triglyceride accumulation 
and glucose sensitivity, HFD-fed hCYP2B6-Tg males also increased total average 
concentrations of hepatic oxylipin species compared to Cyp2b-null counterparts. 
Increased levels of oxylipin metabolites of ALA and LA have been previously associated 
with soybean oil-induced fatty liver and obesity in mice (Deol et al., 2017). Additionally, 
similar to females, hCYP2B6-Tg male mice also experienced perturbations in circadian 
rhythm-associated genes that are important mediators of hepatic lipid homeostasis (Shi et 
al., 2019). 
In humans, excess intrahepatic fat and visceral adipose tissue (VAT) have been 
associated with perturbed glucose and lipid metabolism. VAT is highly lipolytic and 
increases levels of free fatty acids in the liver, causing enhanced gluconeogenesis and 
hepatic insulin resistance (Bugianesi, McCullough, & Marchesini, 2005). Additionally, it 
has been shown that adults and children with NAFLD have impaired glucose tolerance in 
equal proportions to the degree of steatosis (Bedogni et al., 2012; Gastaldelli et al., 2007). 
In this study HFD-fed hCYP2B6-Tg male mice simultaneously increased hepatic 
triglycerides and glucose uptake compared to Cyp2b-null mice, which is unusual but not 
unprecedented (Xu et al., 2005) as other studies have shown that NAFLD can be 
protective (Raubenheimer, Nyirenda, & Walker, 2006). Differences are also potentially 
due to the differing roles of human versus murine CYP2B, as CAR activation in murine 
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models inhibits gluconeogenesis, lipogenesis and fatty acid synthesis, but in human 
hepatocytes CAR was only found to inhibit gluconeogenesis (Lynch et al., 2014), and 
RNAseq suggests the potential for CAR activation based on decreased Egfr and Cyp7a1, 
and increased CYP2B6/Cyp2b10 (Fig. 5.6) (Mutoh et al., 2013). Interestingly, decreased 
Egfr and Cyp7a1 were associated with decreased serum cholesterol and HDL (Fig. 5.7) 
Furthermore, AA-14,15-EET and other CYP-derived EETs (Gangadhariah et al., 2017) 
contribute positively to insulin sensitivity. Taken together, there appears to be several 
pieces of evidence that suggest a role positive role for CYP2B6 in glucose tolerance.  
Although AA and DHA had the lowest IC50 values compared to the other PUFAs 
measured by concentration-dependent response curves, ALA was the predominant 
substrate metabolized by CYP2B6 in vitro followed by LA and AA when adequate 
substrate was provided. CYP2B6 oxylipin metabolites were produced in the 9- and 13- 
positions at high concentrations, especially 9-HOTrE followed by 13-HOTrE. The 
oxylipin 13-HOTrE is known for its role in suppression of inflammation (N. Kumar et al., 
2016; Schulze-Tanzil et al., 2002), and although the biological effect of the previously 
determined lipoxygenase product 9-HOTrE (M. Liu et al., 2013) is not established, it is 
predicted to share a similar anti-inflammatory role (J. Zhang et al., 2017). Conversely, 
important or significantly altered PUFA metabolites from liver and serum samples of 
HFD-fed hCYP2B6-Tg mice suggests CYP2B6 primarily metabolizes the n-6 PUFAs, 
LA and AA in vivo, in the 9- and 13- positions. This change in substrate preference is 
most likely attributed to the available concentrations of the different PUFAs and their 
affinity for CYP2B6 (Fig. 5.1). The HFD provided has nearly10X more n-6 than n-3 
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PUFAs as the main source of PUFAs in the HFD treatment was soybean oil, which is 
approximately 55% LA and only 7% ALA (Clemente & Cahoon, 2009). In addition, 
ALA had a much lower affinity to CYP2B6 compared to AA according to concentration-
dependent response curve results, indicating more ALA would need to be present for 
metabolism to occur.  
In conclusion, the data presented indicates CYP2B6 is an anti-obesity enzyme, 
but to a lesser degree than murine Cyp2b enzymes. CYP2B6 metabolizes PUFAs in vitro 
and in vivo preferentially in the 9- and 13- positions on LA and ALA and produces 
several important anti-inflammatory mediators of metabolic disease, as well as some 
inflammatory oxylipins. In addition, HFD-fed hCYP2B6-Tg male and female mice were 
less susceptible to development of metabolic disease compared to Cyp2b-null mice 
through different mechanisms as female mice showed reduced body weight and males 
increased glucose sensitivity. Overall, this study provides putative mechanisms by which 
CYP2B6 acts as an anti-obesity/anti-metabolic disease enzyme and suggests how 
chemical inhibition or polymorphic loss of CYP2B6 could increase diet-induced obesity 
and metabolic disease through reduced production of important oxylipins and changes in 
circadian-mediated regulation of lipid metabolism and distribution.   
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Supplementary File 5.1. Feed consumption of Cyp2b-null and hCYP2B6-Tg mice 
during 16-weeks of high-fat diet treatment. Female and male feed consumption was 
measured by weighing the food every alternate day. Data are presented as mean calories 
± SEM. Statistical significance was determined by unpaired Student’s t-tests (n=8). * 
indicates a p-value < 0.05.  
 
Supplementary File 5.2. Differentially expressed gene lists of female and male HFD-
fed hCYP2B6-Tg mice compared to HFD-fed Cyp2b-null mice. 
 
Supplementary File 5.3. GO term enrichment analysis list of up and down-regulated 
genes in female and male HFD-fed hCYP2B6-Tg mice compared to HFD-fed 
Cyp2b-null mice. 
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Supplementary File 5.4. CYP2B6 alignment to Cyp2b10 on mouse reference 
genome. Alignment of male hCYP2B6-Tg bam files to mouse reference genome using 
IGV viewer (Robinson et al., 2011). The high number single nucleotide polymorphisms 
(SNPs) within the exon regions of Cyp2b10 is provides evidence of the human CYP2B6 
misalignment to mouse Cyp2b10. 
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CHAPTER SIX 
DISCUSSION 
 
The purpose of this research was to determine the role of CYP2B in unsaturated 
fatty acid metabolism, obesity and nonalcoholic fatty liver disease (NAFLD). Our 
previously generated Cyp2b-null mouse model (R. Kumar et al., 2017) was used to 
continue to study the role of Cyp2b in NAFLD and progression to nonalcoholic 
steatohepatitis (NASH), as well as changes to the hepatic lipidome. In addition, CYP2B6 
containing baculosomes and a newly generated humanized-CYP2B6-Tg mouse model 
were also used to determine the metabolic role of human CYP2B6 in vitro and in vivo, 
respectively. 
Cyp2b-null male, but not female, mice are diet-induced obese, with increased 
accumulation of liver triglycerides and decreased serum triglycerides in both normal diet 
(ND)- and high fat diet (HFD)-fed Cyp2b-null male mice (Data by R. Kumar). The 
purpose of Aim 1 was to identify differentially expressed genes involved in energy and 
fatty acid metabolism in HFD-fed Cyp2b-null mice by RNA sequencing (RNAseq). 
Analysis of global hepatic gene expression using hierarchical clustering showed that ND-
fed Cyp2b-null male mice share a similar hepatic gene expression profile to HFD-fed WT 
male mice, as samples from these groups clustered together. Venn diagrams confirmed 
that these two experimental groups share over 40% of each group's total number of 
differentially expressed genes, indicating that the Cyp2b-null genotype causes effects 
similar to that of a HFD-treatment potentially due to increased liver triglycerides in the 
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ND-fed Cyp2b-null male mice. In addition, shared GO terms, and similarly perturbed 
KEGG pathways also present evidence that ND-fed Cyp2b-null male mice have similar 
gene expression changes to HFD-fed WT mice, clearly indicating perturbations in lipid 
utilization and metabolism. 
Conversely, significantly fewer genes were altered in female mice. Hierarchical 
clustering showed samples grouped by diet and not genotype. These gene expression 
results demonstrate the lack of response to the Cyp2b knockout and to a lesser extent, 
HFD, in female mice compared to male mice, similar to the physiological results from 
this study (Data by R. Kumar). Pre-menopausal female mice are generally considered 
partially resistant to obesity (Hong, Stubbins, Smith, Harvey, & Nunez, 2009; Spruiell et 
al., 2014). This resistance was also observed in our study and indicates that the sexually 
dimorphic Cyp2b9 and Cyp2b13 enzymes (Hernandez, Mota, Huang, Moore, & Baldwin, 
2009; Wiwi, Gupte, & Waxman, 2004) are not the reason for the sexual dimorphism in 
obesity. However, the transcription factors that regulate Cyp2b including CAR, PXR, and 
FoxA2 may be partially responsible for the murine female resistance to obesity; as these 
transcription factors are important in lipid metabolism regulation and predominantly 
female expressed (Hashita et al., 2008; Hernandez et al., 2009; Ledda-Columbano et al., 
2003; Spruiell et al., 2014). 
The key findings from Aim 1 show perturbed lipid signaling regardless of diet in 
Cyp2b-null mice, supporting that hepatic murine Cyp2b genes are important in fatty acid 
metabolism and obesity. Although Cyp2b-null mice showed greater triglyceride 
accumulation and increased NAFLD, they showed very little hepatic inflammation, 
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suggesting Cyp2b-null mice may be protected from developing NASH. The purpose of 
Aim 2 was to determine whether a lack of Cyp2b worsens or remediates the pathological 
effects of NASH.  
After 8 weeks of choline-deficient, L-amino acid-defined high fat diet 
(CDAHFD) treatment, female Cyp2b-null mice had lower white adipose tissue and liver 
mass, as well as a lower total body weight than their CDAHFD-fed WT counterparts. 
CDAHFD-fed Cyp2b-null females also exhibited significantly decreased levels of serum 
markers of liver injury including ALT, AST, and ALP and liver triglycerides compared to 
WT mice. Increased levels of liver inflammation marker, C-reactive protein, 
corticosterone, the main glucocorticoid in rodents, and transcriptomic up-regulation of 
glucocorticoid-mediated KEGG pathway genes including Tnfrsf18 and Calml4 and 
immunosuppressive gene Tgfb2 (Yoshimura & Muto, 2011) in Cyp2b-null females, 
suggest protection from liver damage is due to glucocorticoid-mediated repression of 
immune responses, resulting in less inflammation.  
In contrast, CDAHFD-fed male mice experienced diet-induced weight loss and 
increased serum markers of liver injury regardless of genotype. CDAHFD-fed Cyp2b-
null males had increased serum creatine kinase levels by a 1.5-fold compared to all other 
groups, suggesting that CDAHFD treatment caused damage to Cyp2b-null males in other 
tissues, such as cardiac or skeletal muscle, in addition to liver (Yen et al., 2017). Liver 
steatosis also increased in CDAHFD-fed male mice, with higher liver triglyceride levels 
in Cyp2b-null compared to WT mice. In addition, numerous genes associated with fatty 
acid metabolism were down-regulated in CDAHFD-fed WT male mice compared to ND-
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fed counterparts, and these genes were further down-regulated in CDAHFD-fed Cyp2b-
null male mice, suggesting greater steatosis in the CDAHFD-fed Cyp2b-null male mice, 
which concurred with hepatic triglyceride levels. Although fibrosis was heavily induced 
by CDAHFD treatment in both sexes, there were few differences in fibrosis markers 
between CDAHFD-fed genotypes, except for slightly lower hydroxyproline levels in the 
livers of Cyp2b-null female mice. 
These results show that Cyp2b-null female mice are protected from diet-induced 
steatosis and to a lesser extent diet-induced NASH. In Cyp2b-null males, very few 
differences in NASH markers were observed while NAFLD increased, corroborating 
with results in Aim 1. These studies indicate a role for Cyp2b in fatty liver disease that 
differs based on gender, probably due to the highly sexually dimorphic nature of murine 
hepatic Cyp2b members (Hernandez et al., 2009; Ledda-Columbano et al., 2003; Renaud, 
Cui, Khan, & Klaassen, 2011; Wiwi et al., 2004). Overall, results from Aim 2 confirm 
that increased NAFLD development does not necessarily lead to progressive NASH. 
Often NASH patients have little or no liver steatosis, in fact, only 10-20% of patients 
with NAFLD progress to NASH primarily due to failure of antilipotoxic protection (Tilg 
& Moschen, 2010).  
Previous observations have indicated that Cyp2b-KD mice developed age-onset 
obesity in males with a significant lesser effect in females (Damiri & Baldwin, 2018). In 
addition, Cyp2b-null male mice are more susceptible to obesity than WT mice when fed a 
HFD as determined in Aim 1. The hepatic phospholipid profile has not been investigated 
in Cyp2b-null mice. The purpose of Aim 3 was to determine changes in the hepatic 
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phospholipid profile of healthy, obese and old Cyp2b-null male mice. Phospholipid 
species were identified and quantified from the livers of male Cyp2b-null and WT young 
(4.5 mo) ND and HFD-fed mice and old (9 mo) mice by LC-MS/MS.  
 Age had the strongest effect on the hepatic phospholipid profile, followed by a 
HFD and then a loss of Cyp2b in male mice. The effect of age also superseded the effect 
of HFD on the blood lipidome of female mice (9). Principle component analysis (PCA) 
showed lipid profiles from ND-fed young mice, especially WT, were associated with 
more n-3 fatty acids, including α-linolenic acid (ALA) and docosahexaenoic acid (DHA) 
which help to maintain healthy lipid homeostasis in both humans (Amigó et al., 2020; 
Catapano et al., 2016) and mice (Pauter et al., 2014). Interestingly, the lipid profile from 
ND-fed Cyp2b-null mice was situated between ND-fed WT and HFD-fed groups on the 
PCA plot, concurring with triglyceride levels and findings from Aim 1. Age increased 
total and LDL-cholesterol, as previously found in both humans and rodents (18, 19), and 
these biomarkers were further exacerbated in old Cyp2b-null mice. In addition, total body 
and liver weight, serum VLDL, TAG, and ALT levels were all significantly higher in old 
Cyp2b-null mice compared to WT counterparts as well as all other featured groups. PCA 
results conclude old WT and Cyp2b-null mice are associated with unhealthy 
physiological, serum, and lipid profiles that contribute to an increased risk of metabolic 
disease and obesity (31, 32). The combination of age and a lack of Cyp2b enhanced 
adverse effects, as it resulted in dyslipidemia and liver injury in old Cyp2b-null mice. 
These findings suggest accelerated aging and metabolic disease in Cyp2b-null mice. 
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The purpose of Aim 4 was to investigate the role of human CYP2B6 in 
polyunsaturated fatty acid (PUFA) metabolism in vitro and in vivo. Using CYP2B6 
containing baculosomes, several PUFAs including arachidonic acid (AA), linoleic acid 
(LA), DHA, and ALA were identified as endogenous inhibitors of human CYP2B6 with 
IC50’s below 10μM. However, these endogenous inhibitors have 10-15x’s less affinity to 
CYP2B6 compared to known xenobiotic inhibitors of CYP2B6, such as nonylphenol 
(Hernandez et al., 2007). In addition, these PUFAs are also metabolized by CYP2B6, 
with a greater than 20-fold preference for the metabolism of α-linolenic acid to 9-HOTrE 
and to a lesser extent 13-HOTrE. This high concentration of a lipid metabolite suggests 
the potential for 9-HOTrE as an important signaling molecule.  
When investigating the role of CYP2B6 in vivo during a 16-week HFD treatment, 
hCYP2B6-Tg mice, females and to a lesser extent males, reduced weight gain. However, 
male mice increased liver triglycerides compared to HFD-fed Cyp2b-null mice. This lipid 
accumulation in the liver is suspected to be protective against metabolic disease (at least 
initially) in hCYP2B6-Tg mice based on glucose sensitivity, as an increase in inert 
hepatic triglycerides can provide lipotoxic protection from other fatty acid-derived 
species (Cusi, 2009; Jou, Choi, & Diehl, 2008). Unexpectedly, lipidomic analysis of 
serum and liver samples revealed that most significantly altered PUFA metabolites in 
either tissue were LA or AA oxylipin metabolites, also primarily in the 9- and 13- 
positions. These results are most likely attributed to the high-fat diet which had a much 
greater ratio of n-6 to n-3 PUFAs available for metabolism as the main source of PUFAs 
in the diet was soybean oil (Clemente & Cahoon, 2009).  
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Differential gene expression revealed several up-regulated circadian rhythm-
associated genes in HFD-fed hCYP2B6-Tg mice compared to Cyp2b-null mice. 
Circadian genes are important regulators of hepatic lipid homeostasis (Shi et al., 2019) 
and lipid distribution (Liu et al., 2013). The epidermal growth factor receptor (Egfr) was 
down-regulated in male HFD-fed hCYP2B6-Tg mice compared to Cyp2b-null mice. The 
down-regulation of EGFR provides a mechanism for the activation of CAR and 
subsequent induction of Cyp2b10/CYP2B6 (Mutoh et al., 2013). Conversely, Cyp2b10 
was not differentially expressed in females, as Egfr was up-regulated in female 
hCYP2B6-Tg mice, potentially explaining the physiological and lipid metabolism 
differences between male and female hCYP2B6-Tg mice.  
Overall, human CYP2B6 is an anti-obesity enzyme that metabolizes PUFAs but is 
not as effective as murine Cyp2b9 or Cyp2b10 in reversing diet-induced obesity (Aim 1). 
With advancements in detection methods, the number of endo- and xenobiotic substrates 
of CYP2B6 is increasing (Wang & Tompkins, 2008), including over 60 clinical drugs 
(Mo et al., 2009), numerous environmental toxicants (Hodgson & Rose, 2007), as well as 
steroids, bile acids and fatty acids (Mo et al., 2009). Findings from Aim 4 define a 
mechanism by which chemical inhibition of CYP2B6 can increase diet-induced obesity 
and metabolic disorders through reduced production of important oxylipins and changes 
in circadian-mediated regulation of lipid metabolism and distribution.    
Future studies 
 Based on the findings from Aim 4, CYP2B6 metabolizes PUFAs into lipid 
metabolites that are important mediators of pro- and anti-inflammation such as LA-9-
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HODE and 13-KODE (in vivo), and ALA-13-HOTrE (in vitro) (N. Kumar et al., 2016; 
Warner et al., 2017). Future research examining the roles of ALA, LA, and AA CYP2B6 
metabolites as signaling molecules, especially in 9- and 13- positions, should be further 
investigated in vitro (initially) using cells from a variety of tissues including liver, 
adipose, and skeletal muscle. Lipid metabolites are endogenous ligands of several cell-
surface and nuclear receptors, such as peroxisome proliferator-activated receptors 
(PPARs), which are present in many cell types and act as moderators of systemic and 
cellular metabolic functions in different tissues (Wahli & Michalik, 2012). Results from 
this work could potentially identify key signaling metabolites that are important in 
treating metabolic diseases. 
 In addition, our hCYP2B6-Tg mouse model can be used to study interactions 
between chemical inhibitors of CYP2B6 and HFD treatment. Perfluorooctanesulfonic 
acid (PFOS) is an anthropogenic fluorosurfactant and a persistent organic pollutant found 
worldwide. Exposure to PFOS disrupts normal hepatic lipid metabolism and causes 
steatosis in animal models (Das et al., 2017; Wan et al., 2012). Furthermore, fatty liver 
induces Cyp2b in PFOS-exposed models (Dong et al., 2016). Initial in vitro studies 
conducted in our lab have determined PFOS is an inhibitor of CYP2B6. Research is 
currently underway to test whether Cyp2b-null or hCYP2B6-Tg mice are more sensitive 
to NAFLD following exposure to PFOS. 
Conclusion 
Over one third of adults are considered overweight worldwide and 13% are obese 
(WHO, 2020). Furthermore, global prevalence of NAFLD is about 25%, with the 
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prevalence of obesity in over 50% and 81% of NAFLD and NASH patients, respectively 
(Younossi et al., 2016). As rates of obesity and diabetes increase worldwide, it is 
predicted that NAFLD will also become even more prevalent. Findings from this work 
support the importance of considering exposure to environmental toxicants as a 
contributing factor to the development of obesity and fatty liver disease. The inhibition of 
key detoxification enzymes, such as CYP2B6, by pesticides, pharmaceuticals, or dietary 
fats may perturb lipid homeostasis and metabolism based on studies using our Cyp2b-null 
and hCYP2B6-Tg mouse models. 
This research also enforces the value of investigating gender differences in 
metabolic and liver disease studies (Durazzo et al., 2014; Ohta et al., 2014). Our results 
differed by gender, most likely due to the sexually dimorphic expression of murine 
Cyp2b members in both of our mouse models. Human CYP2B6 expression is also 
sexually dimorphic, as it is predominantly expressed in females (Lamba et al., 2003). 
Although the exact role of CYP2B6 in NAFLD and NASH has yet to be determined 
(Fisher et al., 2009; Gao et al., 2016), CYP2B6 polymorphisms also need to be 
considered in terms of susceptibility to fatty liver disease, as CYP2B6 is one of the most 
polymorphic CYP genes in humans (Zanger & Klein, 2013).  
In addition, there are numerous interspecies similarities and differences with 
regards to species-specific CYP isoform composition, expression and catalytic activities 
(Martignoni, Groothuis, & de Kanter, 2006). Our work established a significant 
difference in the role of fatty acid metabolism between murine Cyp2b and human 
CYP2B6, as murine Cyp2b decreases, while human CYP2B6 increases lipid 
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accumulation in the liver. Additionally, we have also determined using both in vitro and 
in vivo models that PUFAs, especially LA, and ALA, are metabolized preferentially in 
the 9- and 13- positions by CYP2B6. These results as well as others previously discussed, 
validate our recently established hCYP2B6-Tg mouse model as a relevant tool for 
studying functions of CYP2B6 in human liver. 
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